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Introduction: Atherothrombotic disease is the leading aetiology of mortality in the 
Western countries. Its main cause is not hypercholesterolemia but the Metabolic 
Syndrome (MetS). In the last three decades MetS evolved from a quintet 
(hyperglycaemia, hypertension, hypertriglyceridemia, low HDL and waist) to become an 
octet named Cardiometabolic Syndrome (CMS), where the triad, consisting of 
inflammation/metaflammation, oxidative stress (OS) and endothelial dysfunction (ED) is 
essential to understand its impact at the vascular level. Insulin resistance (IR) is 
located at the heart of both syndromes. From the inflammatory point of view, the most 
used marker has been the CRP with the inconvenience of being highly unspecific.  
Finding new markers has become the researchers‟ goal for the last years. The present 
work confirms that the C3 convertase in plasma can be useful as a marker and 
possibly as a pathogenic factor, which if confirmed, would postulate C3 as a target of 
future preventive strategies.  
Objectives: Assess the behaviour of C3 convertase, key enzyme that controls the 
complement cascade in relation to MetS, CMS including ED, IR and cardiovascular 
(CV) risk in a population referred to cardiometabolic secondary care.  
Methodology: An observational retrospective cross-sectional study was performed on 
a random cohort of adult individuals from Madrid. Specific cardiometabolic factors were 
measured as part of the clinical routine of the Cardiometabolic Unit. CV risk was 
calculated by REGICOR formula. IR was estimated by HOMA-IR formula in a non-
exogenous insulin replacement group. Subjects were stratified by C3 complement 
quartiles to assess the distribution of the cardiometabolic markers. Multivariable 
regression analysis was applied to identify predictors of C3 variability.  
Results: A total of n=374 subjects were selected (53.60±14.80 yr. old, 44.9% females), 
where 65% were hypertensive, 42% hyperglycaemic and 35% MetS. C3 complement 
levels were associated with: 1. MetS: MetS diagnosis, each single MetS criterion, 
proportional number of MetS criteria and new MetS criteria (p<0.001). 2. CMS: 
inflammation (CPR, fibrinogen, p<0.001) and metaflammation (Adiponectin, IL-6, 
p≤0.05), ED (TPA, PAI-1, VCAM, p≤0.050) and OS showed tendency (TBARS, 
p=0.084). 3. IR: HOMA (p<0.001). 4. CV risk: factors and CV risk (p<0.001). All of 
these correlations were independent of age and gender. Most of the previous variables 
were also correlated with C3 quartiles. Hypertriglyceridemia had the highest impact on 
C3 differing from clinical guidelines according to multivariate analysis (p<0.001). 
Conclusions: In relation with the MetS quintet, C3 resulted a strong predictor of each 
criteria, C3 was proportional to number of MetS criteria and described a possible 
arbitrary threshold between two and three criteria suggesting earlier CV prevention 
through equal risk.  In relation to the CMS octet, C3 also predicted strongly 
inflammation/metaflamation, ED and showed tendency with OS. In this order, 
hypertriglyceridemia, CRP, HTA, waist, HOMA and hyperglycaemia resulted predictors 
of the 34% of C3 complement variability by multivariate analysis. The association with 
HOMA may influence the results of this study but can not explain all the correlations. 
This study suggested that simultaneous evaluation of CRP and C3 would increase the 
intrinsic reliability of CRP as required in precise Cardiometabolic Medicine.  
 
UNESCO International Nomenclature: 3207.04 Cardio-vascular pathology, 3207.02 
Atherosclerosis, 3201.01 Clinical Pathology. 
 
Keywords: C3 complement, C3 convertase, atherotrhombosis, MetS, IR, CV risk, 
CRP, ED, inflammation, atherosclerosis, fibrinogen, OS, REGICOR, HOMA, multi-





UNESCO International Nomenclature / Áreas de Clasificación de la UNESCO  
 Áreas Clasificación de la UNESCO UNESCO International Nomenclature 
3207.04 Patología Cardiovascular Cardio-vascular pathology 
3207.02 Aterosclerosis Atherosclerosis 






























































Ankle-Brachial pressure Index 
American Heart Association 
Action for Health in Diabetes 
Acquired Immune Deficiency Syndrome 
Arterial Intima Thickness 
Acute Myocardial Infarction 
Adult Treatment Panel III 
Body Mass Index 
Blood Pressure 
C3 Complement 
Centers for Disease Control and Prevention,  
Coronary Heart Disease 
Cardio-metabolic Syndrome 




Dietary Approach to Stop Hypertension 
Diastolic Blood Pressures 
Diabetes Mellitus 
Deoxyribonucleic Acid 
Endothelium and Cardiometabolic Medicine 
Unit 
Endothelial Progenitor Cells 
European Cardiovascular Society 
Endothelial Dysfunction 
Ethylenediaminetetraacetic acid 
Enzyme-Linked Immunosorbent Assay 
Endothelial Nitric-oxide Synthase  
Endoplasmic Reticulum 
Endoplasmic Reticulum Stress 
European Society of Cardiology 
Food & Drug Administration 
Flow Mediated Dilatation 
Frequently Sampled IV Glucose Tolerance 
Test  
Good Clinical Practice 
Glomerular Filtration Rate 
Hitachi Automatic Analyser 
High Blood Pressure (hypertension) 
Homocysteine 
High Density Lipoprotein 
Human Immunodeficiency Virus 
Homeostatic Model Assessment 
Heart Rate 
Horseradish Peroxidase 
Intercellular Adhesion Molecule 
International Committee on Harmonization 
Insulin-like Growth factor 1  
Impaired glucose tolerance  
Interleukin-6 Interleukin-10 
Chemistry Analyzer developed by DPC 
International Diabetes Federation 


























































Insulin tolerance test 
Intravenous Glucose tolerance test  
Latent Autoinmune Diabetes of Adults 
Low Density Lipoprotein 
Lipoprotein-a 
Lipopolysaccharides (Endotoxin) 
Mean Arterial Pressure 
Mannose-binding Lectin  




Nicotinamide Adenine Dinucleotide 
Phosphate 
National Cholesterol Education Program 
Non-exogenous insulin replacement 
National Health and Nutrition Examination 
Survey  
National Heart Lung and Blood Institute  
Oral Glucose Tolerance Test 
Nitric Oxide 
Auto inflate Blood Pressure (Mod705 CP®) 
Oxidative Stress 
Plasminogen Activator Inhibitor  
Peripheral Arterial Tone 
Personal Medical History 
Measure of the acidity or alkalinity 
Quantitative insulin sensitivity check index 
Population Register of Cardiac Disease 
Reactive Hyperemia Index 
Ribonucleic Acid 
Reactive Oxygen Species 
S-Adenosyl-L-homocisteine 
Systolic Blood Pressures 
Standard Desviation 
Smooth Muscle Cell 
Computer Statistical Program 
Diabetes Mellitus type 1 
Diabetes Mellitus type 2 
Total Antioxidant Capacity 
Total Antioxidant Capacity of plasma 
Thiobarbituric Acid 
Thiobarbituric  Acid Reactive Substances 
Triglycerides 
3,3’,5,5’-Tetramethylbenzidine 
Tumor Necrosis Factor alpha 
Tissue Plasminogen Activator (PLAT) 
Urokinase  
Unfolded Protein Response 
Vascular Cell Adhesion Protein 1 





List of figures 



















































Comparison of leading causes of deaths. 
Clinical phases of coronary atherosclerosis 
Atherosclerosis is a chronic low-grade inflammatory process started in the endothelium. 
Overview of the complement activation pathways. 
History evolution of the Metabolic Syndrome (MetS) concept.  
Cardiometabolic pathologies where adiponectin levels decrease result in pro-inflammatory 
signalling and exacerbation of disease. 
Study design inclusion and exclusion criteria’s flow chart for the baseline population sample. 
Summary of the nephelometry procedure to measure C3 complement concentrations by 
ELISA 
Pictogram of the adiponectin concentration measurement procedure by ELISA method. 
Summary of the laboratory technical procedure steps to measure TNF-α concentration, 
modified from DCP Labs manual. 
Summary of the TBARS measurement method by nephelometric assay. 
Stages of Homocystein measurement. 
Example of REGICOR cardiovascular color-coded charts in non-diabetic and diabetic men 
divided into smokers and non-smokers. 
Search strategy algorithm. 
Study timeline graph from data collection to submission. 
Bar graph shows the stratification of our population by number of ATP-III metabolic 
syndrome (MetS) criteria met per patient. 
Median graphs: Almost linear correlation between C3 complement level means and the 
number of C3 criteria met. 
Median graphs. The C3 complement plasma concentrations per number of MetS criteria . 
Correlation between CRP and C3 complement measurements. 
Scatter plot shows the relationship between HOMA, insulin resistance, and C3 complement 
plasma concentrations. 
Scatter plot between fasting glucose measurements and C3 complement levels. 
Scatter diagram between age and C3 complement concentrations in blood. 
Correlation between C3 levels and increasing obesity degrees 
Scatter plot between A1c(%) measurements and C3 complement (mg/dl) concentrations. 
Graph displaying the means of C3 per tobacco consumption status.  
Graph displaying the means of age per tobacco consumption status. 
Uric acid levels and C3 
Scattered plot with regression line of ferritin concentrations and C3 levels  
Graph showing Lp(a) and C3 complement values. 
Scattered plot representing the correlation between C3 levels in plasma and cardiovascular 
risk percentages in 10 years calculated by REGICOR. 
Representation of C3 mean concentrations per cardiovascular risk level (low, moderate, high) 
according to REGICOR formula 
Representation of C3 mean concentrations per cardiovascular risk levels (low and moderate- 
high) calculated according to REGICOR formula. 
The graph represents the negative association between adiponectin leveles and C3 quartiles. 
Mean values of Il-10 according to C3 complement cuartiles. 
Means of PAI-1 concentrations per quartile of C3. 
Representation of the means of TPA and quartiles of C3. 
Borderline association between C3 complement and TBARS values. 
Histogram of C3 complement concentrations and normal distribution curve. 
Bar chart representing the tendency incrementing the mean fasting glucose levels per C3 
complement quartiles. 




























































Listed metabolic syndrome (MetS) criteria differentiated by each health organization 
standards.  
Cut off points for waist circumference according to ethnicity, gender and health 
organization. 
Biochemistry parameters measured at the hospital general laboratory, units and 
methodology. 
Biochemistry parameters measured at the ECMU laboratory on clinical routinely basis, 
units and used methods. 
Gender distribution of the study sample population. 
Summary of baseline characteristics of the study sample population. 
Summary of the proportions of metabolic conditions presented in the patients’ personal 
medical history (PMH). 
Percentages of subjects classified in healthy, incomplete and complete MetS according to 
the number of MetS criteria met per patient. 
Percentages distribution of ATP-III metabolic syndrome criteria in the study population. 
Distribution of the population per number of MetS criteria met per patient. 
C3 complement concentrations’ means per presence or absence of MetS criterion. 
Independence assessment for several non-modifiable and modifiable glucose-metabolism 
variables. 
Summary of HOMA variable descriptive statistics in non-exogenous insulin replacement 
(NEIR) group. 
Distribution of C3 values according to gender. 
Distribution of C3 according to the degree of obesity. 
Summary of significant associations between presence of cardiovascular risk factors and   
levels of C3 complement. 
Correlation between smoking consumption and C3 complement concentrations. 
Differences in C3 complement concentrations according to the presence or absence of 
hyperuricemia, hyperferritinemia and high-Lp(a). 
Distribution of C3 concentrations according to cardiovascular risk REGICOR levels. 
C3 concentrations and cardiovascular risk levels calculated by REGICOR formula. 
Distribution of the adiponectin values across the C3 complement quartiles. 
Distribution of Interleukin-10 levels among across C3 quartiles. 
Descriptive distribution of the PAI-1 means between C3 quartiles. 
Distribution of the TPA mean values per C3 quartiles. 
Homogenous distribution of the sample population among the quartiles of C3 complement 
concentrations. 
C3 distribution by percentiles, representing the quartiles cut-off points. 
Homogenous gender distribution per quartile according to the number of subjects and 
percentages. 
Display of the age distribution in the sample population across the C3 quartiles. 
Description of the haemodynamic and anthropometric variables distribution along the C3 
complement levels quartiles. 
Distribution of the percentage of number of metabolic criteria met per C3 quartile. 
Differences in Cardiovascular risk measured by REGICOR formula among the C3 quartile 
groups. 
Distribution of the sample population values of fasting glucose, glycosylate haemoglobin 
and insulin resistance (calculated with HOMA formula) per C3 complement quartiles. 
Distribution of the means lipid profile parameters among the C3 complement quartiles. 
Description of the distribution of levels of inflammation and coagulation markers in the 
sample population divided by C3 complement concentration levels. 
Cross-tabulations between c3 quartiles and presence of hyperuricemia or 
hyperferritinemia. 






















Cross-tabulation between hypertension, HBP MetS criteria and C3 complement quartiles. 
The distribution of population with low HDLc diagnosed by plasma concentrations and by 
MetS criteria among the C3 complement quartiles. 
Distribution of the sample population classified by presence/absence of hyperglycaemia 
and C3 complement quartiles. 
The distribution of the hypertrygliceridemic and non-hypertrigliceridemic populations by 
C3 quartiles. 
Cross-tabulation distribution of BMI and central obesity across the C3 complement 
quartiles. 
Cross-tabulation distribution of gender, presence of MetS and cardiovascular risk among 
C3 quartiles. 
Association between smoking status classifications (smoker/non-smoker vs. smoker/ex-
smoker/non-smoker) and C3 levels. 
Multivariate model for C3 complement population description. 
Initial analysis of the maximum model variables. 
























Cardiovascular diseases (CVDs) are the primary aetiology of morbidity and mortality 
in the world. An estimated 17.3 million people died from CVDs in 2008, representing 
30% of world mortality, being the main cause of death. By 2030, more than 23 million 
people will die annually from CVDs. According to WHO data collected in 2013, 2.8 
million deaths are caused every year by obesity and being overweight, being the fifth 
leading risk for global deaths [1]. Moreover, overweight and obesity account for 44% of 
the diabetes burden, 23% of the coronary heart disease and between 7% and 41% of 
certain types of cancer. 
Even though over 80% of CVD deaths take place in low and middle-income countries, 
we have to keep in mind that the CVDs retain ultimate responsibility for 41% of the total 
mortality in western countries [2]. CVDs entail more than 2 million deaths per year in 
the European Union. One of every eight European men and one of every 17 European 
women will die before 65 years of age due to cardiovascular reasons. They are also 
the main cause of invalidity and decreased quality of life. 
 
 
Fig. 1.1 Modified from comparison of leading causes of deaths, Global, 2000 and 2012, 
health statistics and information systems, World Health Organization. 
It is known worldwide that most CVDs can be prevented by acting on the classical 
cardiovascular risk factors. These risk factors are mainly divided into three principal 
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groups such as behavioural, metabolic and other risk factors. Human behaviour is 
related to tobacco use, physical inactivity, alcohol abuse and unhealthy diet (rich in fat, 
sugar, calories and salt). The metabolic group agglomerates overweight and raised 
blood pressure, hyperglycaemia and hyperlipidaemia. Finally, the third heterogenic 
group conglomerates genetic disposition, psychological factors, age, gender and other 
risk factors such as hyperuricemia, hyperhomocysteinemia, hyperferritinemia, raised 
CRP, many others which we will study [3]. 
Medical professionals cannot forget that the governmental institutions, health 
organizations and also our professional duty is to promote, prevent and control the 
already known risk factors. Nevertheless, our duty as healthcare professionals and 
researchers has to advance a step further, pointing out the primary prevention and 
unknown risk factors such as C3 convertase.  
The underlying pathologies of CVDs are mainly atherosclerosis or atherothrombotic 
disease, and at great distance rheumatic heart diseases, congenital heart diseases, 
disorders of the heart muscle, electrical conduction system of the heart and heart valve 
diseases [3, 4]. 
The leading pathogenic role is played by atherosclerosis, which develops over the 
years and is usually advanced by the time symptoms occur, generally in middle age. 
Acute coronary and cerebrovascular events frequently occur suddenly, and are often 
fatal before medical care can be given. Modification of risk factors has been shown to 
reduce mortality and morbidity in people with diagnosed or undiagnosed cardiovascular 
disease[5].  
Atherosclerosis has moved from being considered a deposit and degenerative disease 
to be understood as a chronic inflammatory disease, which will develop an acute 
clinical event as a result of atheromatous plaque‟s disruption [4, 6]. Nowadays, the 
atheroma formation with superimposed thrombosis represents the underlying 
pathophysiological process in the development of cerebrovascular diseases, deep 
venous and pulmonary thrombosis and acute coronary syndromes (ACS), namely 
unstable angina, acute myocardial infarction and sudden death, arising due to partial or 
complete occlusion of the artery [7].  Atheroma formation can begin in infancy and 
progresses over decades until eventual weakening of the cap results in a plaque which 
is vulnerable to rupture and thrombosis [8]. On the other hand, there is mounting 
evidence to support a central role for inflammatory processes in the pathogenesis of 
CVDs, and similar inflammatory processes are also related to the pathogenesis of type 
two diabetes mellitus (T2DM), supporting the common soil hypothesis.  
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The inflammation does not start alone; it belongs to a triad with oxidative stress and 
endothelial dysfunction instead. The outcome of the chronic damage may trigger 
atheroma rupture and thromboembolic occlusion [9]. Therefore, the latest researching 
pathways are directed towards the inflammatory, oxidative stress and endothelial 
dysfunction biomarkers as the first step in the atheroma formation chain. The 
endothelium has emerged as the key regulator of vascular homeostasis. In that, it has 
not merely a barrier function but also acts as an active signal transducer for circulating 
influences that modify the vessel wall phenotype [10]. Alteration in endothelial function 
precedes the development of morphological atherosclerotic changes and can also 
contribute to lesion development and later clinical complications.  
The biomarkers will play a crucial role in the diagnosis monitoring and treatment of the 
early as well as late stages of the CVDs development. These markers would represent 
the key factors to predict the cardiometabolic risk inherited to a person from his 
childhood, allowing us to develop a real primary prevention [11]. Elevation in markers 
of inflammation predicts outcomes of patients with acute coronary syndromes, 
independently of myocardial damage. their diagnostic role in basal conditions have not 
been sufficiently studied. Low-grade chronic inflammation, as indicated by levels of the 
inflammatory marker C-reactive protein (CRP), prospectively defines risk of 
atherosclerotic complications, but CRP is not an specific marker, condition that reduces 
its value in the clinical practice. 
Therefore, the aim of this thesis will be the correlation between C3 convertase as key 
component of the intricate inflammatory cascade complement pathways, endothelial 
damage, reticulum and metabolic stress and cardiovascular risk. Nowadays, the 
secondary prevention with our current treatments such as statins or diuretics reduces 
the probabilities of CVDs when the arterial damage was already initiated. Then the 
question should be what if we could tackle this risk in early steps. 
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2. Knowledge review 
 
2.1. Atherosclerosis as low-grade inflammatory process 
Atherosclerosis has moved from being considered a deposit degenerative disease to 
be understood as a chronic inflammatory disease which complications lead to acute 
clinical episodes when the atherosclerotic plaques are disrupted or become occlusive 
[12]. 
Firstly, we should differentiate between two key concepts, arteriosclerosis and 
atherosclerosis. Both processes jointly participate in the cardiovascular disease 
development. 
Arteriosclerosis corresponds to a diffuse process characterised by a progressive loss of 
elasticity and increment of the arterial wall stiffness thereof. Therefore, arteriosclerosis 
is a generalized age-related process, which is presented as a diffuse thickening of the 
endothelial and medial layers of the arteries.  
Atherosclerosis is a focal process of atheroma deposit localised in certain territories, 
such as proximal and distal thirds of the coronary arteries and carotid arteries 
bifurcation.  
The formation of atherosclerotic plaque or atheromatous disease was first defined by 
Marchand in the early nineteenth century as an arterial lesion characterised by sclerotic 
fibrous tissue enveloping a central soft atheroma. This term remains as the cornerstone 
of the CVD but has evolved to a multifactorial background.  The atheroma‟s basic 
components are lipid deposit and cellular and collagen progressive proliferation. 
The atherogenic process starts at early age. The turnover of lipoproteins in and out of 
the subendothelium is a normal physiological process. But the generation of lipids‟ 
deposits is conditioned by the inflow of these lipoproteins and their resistance to 
oxidative modifications involve a change in their biological behaviour. The modified 
low-density lipoproteins (LDLs), especially oxidized, are cytotoxic and harmful to the 
endothelium, chemotactic for monocytes and also inhibit macrophages‟ migration. 
Oxidized LDLc induce the expression of tumour necrosis factor α (TNF-α) or interleukin 
1 (IL-1), which favour the endothelial expression of adhesion endothelial molecules 
[13].
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Monocytes phagocytise these modified LDLc becoming foam cells. If the circulating 
lipoprotein level exceeds the phagocytic capacity of monocytes, macrophages exert a 
chemotactic function on monocytes and smooth muscle cells of the arterial wall which 
become macrophages. 
The lysis of these lipid-laden cells releases cholesterol crystals and catalytic enzymes 
contained in cell debris to the cellular interspace, triggering a local inflammatory 
process. This early precursor stage of the atheromatous plaque stage can be observed 
from the childhood as fatty streaks. The atheroma may be macroscopically visible at 
the end of puberty. 
Due to the perpetuation of the pathogenetic mechanism outlined above a defensive 
endothelial wall mechanism through connective tissue reaction stabilises the plaque 
and generates a fibroathenoma. Rokitansy in 1852 postulated his inlayed theory where 
the initial mechanism was the fibrotic and thickening intima reaction which was 
secondarily loaded with lipid content. However, for Virchow (1856), the lipid infiltration 
determined the plaque formation. Both theories considered the endothelium as a 
passive agent of an undergoing fibrotic process. It was needed a century to reach the 
integration of both theories and consider atherogenesis as an inflammatory response to 
a endothelial aggression by Ross [14], where mechanical, chemical, biological and 
immunological stimuli develop endothelial dysfunction and damage. Endothelial injury 
triggers a response of monocyte infiltration, alters the endothelial antithrombotic ability, 
fibrinolytic properties and even vasomotor response.  
These facts facilitate the platelet aggregation. Fuster [15] classified the endothelial 
damage into three stages: 
 Stage I: functional but not morphological damage due to local changes in the 
blood flow (flexure areas, hypertension, arterial branches) or inside the wall 
itself (ischemia vasa vasorum). When these lesions remain the release of 
proteolytic enzymes, free radicals, etc. the endothelial damage leads to stage 
two. 
 Stage II: endothelial denudation with intimal damage keeping intact the internal 
elastic lamina. In this phase platelet aggregation and fibrin deposit, secondary 
to activation of the coagulation cascade, may lead to thrombosis [5]. 
 Stage III: intima and media layers are involved Inflammation is considered the 
key regulatory process and predisposes to thrombogenesis. There is an early 
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involvement of both monocytes and macrophages during atherogenesis. These 
inflammatory monocytes express high levels of beta transforming growth factor 
(TGF-β), tumour necrosis factor (TNF), interleukin (IL-1) and angiogenic 
mediators, such as vascular endothelial growth factor (VEGF). Mast cells 
produce various mediators such as histamine, leukotrienes, chymase, trytasa, 
interleukin-6 (IL-6),  interferon gamma (IFN-γ) and are involved in adaptive 
immunity. Successive evidence attribute them a key regulatory role in 
inflammation, immunity, atherosclerosis and its complications[7].  
Multiple factors contribute to the pathogenesis of atherosclerosis, including endothelial 
dysfunction, dyslipidemia, inflammatory, and immunologic factors, plaque rupture and 
smoking. In particular, endothelial dysfunction is induced by oxidized low density 
lipoprotein (LDLc), can be considered as a final common pathway [19] and is felt to be 
caused principally by loss of endothelium-derived nitric oxide [18]. This starting point of 
endothelial damage generated by inflammation processes triggers the atheroma 
formation process.  
 
 
2.2. Atheroma formation from healthy endothelium and  
progression to CVD 
 
Fatty streaks represent the first step of the atheroma formation.  The histologists 
describe it as focal thickening of the intima with accumulation of lipid-laden 
macrophages (foam cells), which constitute the hallmark of the early atheroma, and 
extracellular matrix[16]. Hematopoietic stem cells migrate, and proliferate populating 
the intima [17]. Lipids accumulate both intracellular land extracellular deposits 
producing the fatty streak binding and trapping low density lipoprotein and T 
lymphocytes. [10]. The smooth muscle cells accumulated within the deep layer of the 
fatty streak are susceptible to apoptosis, which is associated with further macrophage 
accumulation. Their vesicles can calcify into chronic atherosclerotic plaques [11]. A 
dense cap of collagen will cover a lipid core and micro-vessels will supply oxygen and 
nutrients forming the atheroma‟s own microvasculature network (vasa vasorum). The 
atheroma will extend from the adventitia through the media and into the thickened 
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intima [13]. These thin vessels are prone to disruption, haemorrhage and progression 
of the coronary atherosclerosis [14,15].  
We described below a comprehensive modified classification based on morphologic 
descriptions of the coronary atheroma formation and progression and symptoms 
(fig.2.). This modified clasification combines the American Heart Association (AHA) 




Comprehensive atheroma formation classification: 
a. Early lesions:  
Nonatherosclerotic intimal lesions: Absent Thrombosis. Reversible lesions. 
Asymptomatic. 
 Type I: Intimal thickening, fatty dot: Normal accumulation of smooth muscle 
cells (SMCs) in the intima in the absence of lipid or macrophage foam cells. 
This lesion is only visible under microscopy.  
 
 Type II: Intimal xanthoma or fatty streak: Superficial (luminal) accumulation of 
foam cells without a necrotic core or fibrous cap; based on animal and human 
data, such lesions usually regress. Yellowish lesion which is macroscopically 
visible. Foaming cells are seen arranged in rows and accompanied by SMC and 
T lymphocytes. Extracellular lipid deposits are only visible with electronic 
microscope. 99% of children between 2 and 15 years old have these lesions at 
aortic level. 
 
 Type III: preatheroma. Pathologic intimal thickening: SMC-rich plaque with 
proteoglycan matrix and focal accumulation of extracellular lipid. The deposit of 
extracellular lipids or "core" is visible with a conventional microscope. This 
deposit interrupts the ordered arrangement of the foam cells and displace the 
SMC of the intima. There is no decrease in vessel lumen because collagen 
formation, thrombosis and bruising do not occur in the plaque. 
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b. Advanced lesions 
 
 
b.1. Progressive atherosclerotic lesions: Absent thrombosis or thrombus mostly 
mural and infrequently occlusive. From this phase the lesions are potentially 
symptomatic but normally silent. 
  
 Type IV. Atheroma: is developed from the third decade of life. The blood lumen 
may start diminishing. There is a lipid nucleus constituted by an initially 
delimited accumulation of extracellular lipids at the intima level, which evolves 
to disorganized nucleus by eccentric thickening. SMC are displaced by this lipid 
accumulation. A layer of peptidoglycans (PG) separates this nucleus and the 
intimal endothelial cells filtered by macrophages, lymphocytes and SMC. At the 
same time, some capillaries emerge surrounding the lipid nucleus and some 
foam cells and SMC start apoptosis . This atheroma can evolve to a thin fibrous 
cap atheroma: a thin, fibrous cap (< 65 µm) infiltrated by macrophages and 
lymphocytes with rare or absence of SMCs and a relatively large underlying 
necrotic core; intraplaque haemorrhage/fibrin may be present.  
 
 Type V: Fibrous cap atheroma: When the layer of PG is substituted by fibrous 
tissue such as collagen it results in type V lesion. In the fibrous atheroma we 
find a well-formed fibrous layer that covers the lipid nucleus, composed 
basically by collagen. This collagen is synthesized by the SMC in response to 
the disorganization of the intima and replaces the matrix of proteoglycans. It 
occurs from the fourth decade onwards. This lesion is susceptible to necrosis 
fissure and thrombosis and also presents a stenosis of the arterial lumen to a 
greater or lesser degree: 
 
 Early necrosis: focal macrophage infiltration into areas of lipid pools with 
an overlying fibrous cap.  
 
 Late necrosis: loss of matrix and extensive cellular debris with an 
overlying fibrous cap. 
 
The lipid nucleus will continue generating capillaries, favouring micro-
haemorrhages. At the tunica media level of the artery wall, an increase in 
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macrophages, lymphocytes and lipid deposit weakens the arterial wall and 
facilitates the appearance of aneurysms. 
 
b.2. Lesions with acute thrombi: Symptomatic. 
 
 Type VI: complicated atheroma. The type IV and V lesions are susceptible to 
fissures and thrombosis through its weaker areas resulting in type VI lesion with 
luminal thrombosis or no communication of thrombus with necrotic core. 
 
o Plaque rupture: Fibroatheroma with fibrous cap disruption. The luminal 
thrombus communicates with the underlying necrotic core producing 
occlusive or nonocclusive thrombus. 
 
o Plaque erosion: Plaque composition, as above plus no communication of 
the thrombus with the necrotic core. It can occur on a plaque substrate 
of pathologic intimal thickening or fibroatheroma. Usually nonocclusive 
thrombus. 
 
o Although thrombosis in general will be favoured by disruption of plaques, 
in other cases they will occur without previous ruptures, favoured by 
predisposing personal factors. Some identified fibrinolysis inhibitor 
factors are diabetes, smoking status, increased fibrinogen or high levels 
of Lp (a). 
 
 Type VII: Calcified nodule atheroma: Eruptive (shedding) of calcified nodules 
with an underlying fibrocalcific plaque with minimal or absence of necrosis. 
Usually resulting in nonocclusive thrombus. 
 
b.3. Lesions with healed thrombi: absent thrombosis. 
 
 Type VIII: Fibrotic plaque (without calcification): Collagen-rich plaque with 
significant luminal stenosis. These lesions may contain large areas of 
calcification with few inflammatory cells and minimal or absence of necrosis and 
represent healed erosions or ruptures 
 
 Type VIII calcified: Fibrocalcified plaque (+/- necrotic core) 





Fig. 2.1: Clinical phases of coronary atherosclerosis modified from Fuster: Phase 1 
(types I to III of Stary): consists of a small plate, which progresses very slowly. It is 
common in subjects younger than 30 years of age and is usually asymptomatic. 
Phase2 (types IV and V of Stary): characterized by atheroma rich in extracellular lipids, 
and capable of producing an asymptomatic stenosis. Phases 3 and 4 (type VI of Stary) 
make unpredictable the course of atherosclerosis and they occur with rupture of the 
plate that is accompanied by a mural thrombus. Phase III symptoms comprise angina 
unstable angina, infarction or sudden death. Phase 5 (type VII and VIII Stary) vessel 
occlusion occurs without rupture of the plaque. This type of lesion produces a third of 
the coronary occlusions and is morphologically accompanied by a greater myocytes 
proliferation. 
 
Atheroma formation associates coronary artery remodelling with abnormal arterial 
physiology and development of clinical symptoms [16]. Positive remodelling is linked to 
unstable plaques in patients presenting with unstable angina; meanwhile, negative 
remodelling is associated with obstructive plaques in patients with stable angina [17].  




2.3. Endothelium’s role in vascular pathology 
2.3.1. Endothelial complexity 
 
Healthy endothelium has been described as an unicellular layer of endothelial cells 
(ECs), which coats the blood vessels (arterial and venous), lymph vessels, heart 
chambers, corpora cavernosa and eye anterior chamber. It comprises an area over a 
1000 square metres (6 tennis courts), it weighs about 4 kg, being regarded as the 
greatest virtual organ of our body, which regulates the flow of 7200 litres of blood a day 
and the cells are oriented in the direction of the blood flow [19]. The endothelium is a 
unique structure. Twenty years ago was seen as a passive coating which facilitated the 
passage of cells and molecules into the surrounding tissues. In the past two decades 
the EC has been studied in the umbilical cord, synovial villi, foreskin, placenta, breast 
and abdominal adipose tissue. This layers maintains vascular tone and organs blood 
perfusion, maintains vascular patency, regulates hemostasis balancing thrombosis and 
clotting, is a barrier for toxics, controls inflammation and regulates angiogenesis. 
As an organ of enormous complexity, the endothelium is involved in embryogenesis, 
histogenesis, organogenesis, wound healing, angiogenesis, tumorigenesis and 
metastasis. The endothelial tissue also plays a vital role in host defence and is involved 
in the organization of thirteen barriers: I alveolar-capillary, placenta, liver, glomerular, 
blood-brain, blood-nerve, blood-cerebrospinal fluid, blood-ocular (blood-retinal and 
blood-aqueous), hematic-testicular, hematic-splenic, hematic-thymic and 
hematopoietic. The endothelium is the inner skin of the human body. It is considered a 
paraneurona belonging to the diffuse neuroendocrine system. The EC plays an 
important role in the regulation of capillary‟s permeability, lipoprotein's metabolism and 
tissue's aging. Actively involved in immunological reactions (systemic lupus 
erythematous, scleroderma, Raynaud's phenomenon, psoriasis, preeclampsia, 
Kawasaki disease, asthma event), inflammatory (rheumatoid arthritis), tumour growth 
and metastatic process. Furthermore EC synthesises neuropeptides, 
neurotransmitters, cytokines, growth factors, adhesion molecules and membrane 
receptors. It also expresses autocrine, paracrine and endocrine functions[20]. 
One of the most striking features of the endothelial lining is its ability to keep the blood 
soluble even in prolonged contact with the vessel wall, as well as their participation in 
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clot formation. The molecular mechanism of the hemocompatibility of normal 
endothelium is given by the expression of thrombomodulin, and plasminogen activators 
of type heparan sulfate glycosaminoglycans may interact with antithrombin III, all 
produced by the endothelium. But at the same time is able to synthesize endothelium 
stabilizing molecules of the blood clot and cause thrombosis to synthesize plasminogen 
activator inhibitor (PAI - 1), tissue factor, interleukin-1 and alpha tumour necrosis factor. 
All these cytokines are synthesized by the endothelium. As well as being a 
multifunctional organ, the endothelium is also defined as compartmentalized and 
specialized organ depending on the anatomical region where is located [21].  
 
The endothelial lining has vasoconstrictor and vasodilator, procoagulant and 
anticoagulant, pro-and anti-inflammatory functions. It also promotes and inhibits cell 
growth and promotes and stops the process of angiogenesis. In addition, the 
endothelium actively participates in the inflammatory response and immune 
phenomenon. The endothelium, with circadian behaviour, early morning is different, 
increases the synthesis of PAI - 1 and decreases fibrinolytic activity, which is consistent 
with increased sympathetic activity and increased platelet aggregation. Therefore, it is 
suspected that this is the reason why cardiovascular and stroke are more common 
early in the morning.   
The endothelial cells are rich in lipids (cholesterol, phospholipids, sphingolipids) 
proteins (caveolin, actin PCK) and enzymes (nitric oxide synthases).  Zawadzki and 
Furchogtt suggested that ECs secreted substance with vasorelaxant properties and an 
intense investigation that led to the identification of the endothelium-derived relaxing 
factor started, nowadays known as nitric oxide (NO). NO is considered the epitome of 
healthy endothelium, from the metabolic conversion of L-arginine to L-citrulline. NO has 
vasodilatory effectsand is a physiologic inhibitor of smooth muscle growth and 
promotes apoptosis with an unclear role in relation to angiogenesis[22]. Other 
vasoactive substances released by the endothelial prostacyclin, bradykinin, angiotensin 
II and endothelin. The factors released by endothelial cells will be crucial in the 
regulation of vascular tone.  
A proper balance between the vasoconstrictor factors released by the endothelium 
(angiotensin II and endothelin), and vasodilators (prostacyclin, bradykinin and NO) 
allow the maintenance of normal vascular tone, which under physiological conditions is 
slightly vasodilator. NO is a paracrine mediator, different than angiotensin and 
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antidiuretics [23]. NO is a molecular gas with an extremely short half-life, unstable out 
of the system and difficult to measure. 
The normal endothelium does not generally support binding of white blood cells. 
However, with an atherogenic diet, early patches of endothelial cells start to express on 
their surface selective adhesion molecules which will bind leukocytes. The VCAM-1 
(vascular cell adhesion protein 1) precisely attracts monocytes and T lymphocytes 
found in the early human nascent atheroma [24] The usual loci for atheroma formation 
are located at branch points in arteries, where the endothelial cells experiment the not 
laminar flow‟s aggression. This aggression reduces the production of nitric oxide (NO), 
natural anti-inflammatory molecule with vasodilator properties and increases the 
production of intercellular adhesion molecules (ICAM-1) and proteoglycans. These 
mechanisms promotes multiplied by 4 the promotion of early atheromatous lesions 
attracting inflammatory cells which will perpetuate the inflammatory response.  
Inflammatory processes are involved in the promotion, evolution and also contribute to 
precipitate the acute thrombotic complications of the atheromatous plaque. The 
macrophages produce proteolytic enzymes which will degrade the collagen support 
and procoagulant tissue factors which will trigger thrombosis response [25] as already 
described, inflammation contributes across the spectrum of cardiovascular disease, 
including the earliest steps in atherogenesis.  
To date, elevated levels of several inflammatory mediators among apparently healthy 
men and women have proven to have predictive value for future vascular events. In 
particular, prospective epidemiological studies have found increased vascular risk in 
association with increased basal levels of cytokines such as IL-6 and TNF-α  [12], cell 
adhesion molecules such as soluble ICAM-1, P selectin, and E selectin and 
downstream acute-phase reactants such as CRP, fibrinogen, and serum amyloid [13].  
 Several traditional cardiovascular risk factors track with these inflammatory 
biomarkers, in particular, central obesity and body mass index due to adipocytes can 
produce inflammatory cytokines, and a common underlying disorder of innate immunity 
may well link obesity, accelerated atherosclerosis, and insulin resistance. In support of 
this hypothesis, very recent observations show that elevated levels of both IL-6 and 
CRP associate not only with the subsequent development of atherosclerosis, but also 
with the development of type II diabetes, even among individuals with no current 
evidence of insulin resistance [26]. During the last decades the CRP (C reactive 
proteína) appeared like the most promising inflammatory biomarker [27]. 




Fig. 2.2: Atherosclerosis is a chronic low-grade inflammatory process started in the 
endothelium. The atherosclerosis formation is triggered and chromicised maintaining 
endothelial damage by constant toxics such as tobacco, HBP, hyperlipidaemia or 
hyperglycaemia among others and subsequently initiating the inflammation cascade. 
Modified from “Ethnicity, Metabolism and Vascular Function: From Biology to Culture” 
Caballero E. 2008.  
 
But these already classic inflammatory biomarkers are not the sole new molecules 
which can predict and measure the cardiovascular events and their evolution. There 
are multiple soluble immune effector molecules found in arterial lesions, such as 
antibodies and complement proteins. Complement activation, either by the antibody-
dependent classical pathway or the alternative or lectin pathways, generates 
proinflammatory mediators. A good example of them, are C3a and C5a, which activate 
endothelium and enhance leukocyte recruitment to inflammatory sites. The 
complement cascade is involved in the stimulation and regulation of antibody 
responses. In particular, the CD19/ CD21 receptor complex on B cells links the 
complement system to the activation of B cells [13]. 
Patients with atherosclerotic disease produce antibodies specific to atheroma antigens. 
These antigens groups include oxidized low-density lipoproteins, and heat shock 
protein.  The complement system is involved in both the inductive and effector phases 
of humoral immune responses. Due to this dual mechanism by which these antibodies  
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influence atherogenesis, the process complexity is not clearly explained. However, 
several studies demonstrate that complement is involved in modulating atherogenesis 
[28]. Furthermore, antibody-independent activation of complement in arterial lesions 
may contribute to the inflammatory process of atherosclerosis and several studies 
provide evidence that complement activation is involved in atherogenesis. Besides this, 
components of the complement system are frequently found in human atheromas [29]. 
C3 and C4 deposition in arterial lesions has also been demonstrated [30]. Additionally, 
RNA analysis studies indicate that complement genes are expressed locally within the 
plaques [20]. 
In relation to this fact, the complement system, found by J Bordet in the 19th century, 
represents one of the most important figures of the inflammation cascade. The 
complement cascade acts as a protein functional system. These proteins are 
synthesized by hepatocytes, tissue macrophages, blood monocytes, and epithelial cells 
of the genitourinal tract and gastrointestinal tract. In the bloodstream, they develop an 
amplified self-regulated enzymatic response during the inflammatory process. This 
process includes several functions such as opsonization (enhancing phagocytosis of 
antigens), chemotaxis  (attracting macrophages and neutrophils), cell lysis  (rupturing 
membranes of foreign cells), and agglutination (clustering and binding of pathogens 
together). All of these are basic steps in the formation and rupture of the atheroma 
plaque.  
 
2.3.2. Endothelial dysfunction (ED)  
ED represents the inability of the small arterioles to vasodilate when necessary, leading 
to microvascular dysfunction and possible myocardial ischemia. The NO-mediation is 
compromised due to reduced production and favoured consumption. Beyond this main 
action, ED also promotes leukocyte and platelets activation and adhesion, increases 
the permeability of the arterial wall, favouring the protein oxidation, cell proliferation and 
atherosclerosis[31].  
Besides NO, other markers of ED are circulating progenitor cells (CPCs), 
atherosclerosis, hyperlipidemia, DM, smoking habit, ischemia and aging among others. 
EPCs are regenerative cells that are rarely found in blood in healthy individuals. EPCs 
are reported to participate in neovascularization after stroke, remodelling ischemic 
cardiac tissue and correlated to microvascular peripheral endothelial function [32, 33]. 
On top of EPCs and NO, atherosclerosis is also involved in impaired vasodilation, 
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augmented vasoconstriction through serotonin upregulation and microvascular 
dysfunction. DM, as well as tobacco, contributes to ED increasing oxidative stress. 
Additionally, hyperlipidemia reduces flow response to acetylcholine and hypertension 
reduced relaxation mediated by the endothelium [34, 35]. 
 
2.3.3 Evaluation of the endothelial function  
The endothelium has emerged as the key regulator of vascular homeostasis, 
damaged endothelial function precedes the development of morphological 
atherosclerotic changes. Endothelial function can be evaluated directly or indirectly. 
All the direct testing techniques involve the microvascular response to endothelial-
dependent stimuli such as reactive hyperhemia or vasoactive substances. 
Unfortunately endothelial function testing, using direct or indirect methods, is not 
routinely used in everyday clinical practice. 
Direct testing is infrequent in the clinical studies due to its invasive nature involving 
biochemical and cellular integrity via coronary angiography. The coronary 
microvascular response to acetylcholine or adenosine is tested by blood flow 
measurement via intracoronary Doppler[36]. A healthy endothelium results in 
vasodilation and ED in vasoconstriction as observe in angina[37]. Besides 
angiography, an impedance plethysmography test measures forearm blood flow but 
also requires the direct intravascular administration of vascular agonists.  
Due to the invasive character of the direct ED measurements, the assessment of the 
endothelium function in this study was indirect via cytokines as endothelial dysfunction 
markers, such as vascular adhesion molecule-1 (VCAM-1) and plasminogen activator 
inhibitor-1 (PAI-1). 
Most cardiovascular risk factors activate molecular machinery in the endothelium that 
results in expression of chemokines, cytokines, and adhesion molecules, like VCAM-1 
and PAI-1. 
Vascular cell adhesion molecule 1 (VCAM-1):  
VCAM-1 mediates the adhesion of lymphocytes, monocytes, eosinophils, and 
basophils to vascular endothelial wall after endothelial cells are activated by pro-
inflammatory cytokines such as TNF-α and IL-6, leading to vascular inflammation and 
atherosclerosis [38].  Mediators of endothelial dysfunction, such as 
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hypercholesterolemia, smoking, or oxidative stress, enhance endothelial cell activation, 
measured by VCAM-1 levels, leading to increased vasoconstriction, smooth muscle 
proliferation, platelet aggregation, leukocyte adhesion and LDLc oxidation[38].  
VCAM-1 has been associated independently of traditional cardiovascular risk factors 
and inflammatory markers with common carotid artery intima–media thickness and 
endothelial dysfunction[39]. An alternative method to assess endothelial function, more 
accurate than the measurement of instable NO gas, involved the measurement of 
biomarkers of endothelial activation and dysfunction (VCAM-1). Elevated circulating 
levels of adhesion molecules have been associated with cardiovascular risk factors and 
predict atherosclerosis and cardiovascular events [40]. 
Plasminogen activator inhibitor-1 (PAI-1): 
PAI-1 is the principal inhibitor of tissue-type and urokinase-type plasminogen 
activators, which convert plasminogen to plasmin. PAI-1 stimulates cell migration by 
binding to the low-density lipoprotein receptor-related protein. Then, fibrinolysis is 
regulated by PAI-1 which prevents the escape of this potentially destructive protease 
system. Increased PAI-1 levels predispose patients to the formation of atherosclerotic 
plaques prone to rupture with a high lipid-to-vascular smooth muscle cells ratio as a 
result of decreased cell migration.  
Overexpression of PAI-1 has been linked to endothelial dysfunction, metabolic 
syndrome and cardiovascular disease [41]. PAI-1 has been also implicated in adipose 
tissue development, control of insulin signalling in adipocyte, atherothrombosis, 
diabetogenesis and insulin resistance [42]. The PAI-1 production has been positively 
associated to oxidative stress, TNF-α, cortisol and IL-6 levels, disturbances of the 
renin-angiotensin and insulin glycolipid control systems[43, 44]. 
 
 
2.4. Inflammatory cascade: complement system interaction 
with pro-inflammatory factors 
The fundamental role of the inflammatory cascade in the pathogenesis of CVDs has 
been globally recognised. Inflammation contributes to the development and 
progression of atherosclerotic lesion formation, plaque rupture and thrombosis [45]. 
The most consistently studied and demonstrated factor in relation to prediction of CVDs 
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development has been the CRP [46, 47]. CRP levels can be induced by a wide variety 
of stimuli, including acute and chronic infection and are elevated in various 
inflammatory diseases such as rheumatologic pathologies as demonstrated in several 
studies and meta-analysis[48]. The lack of specificity related to CRP encourages the 
authors to expand the research to other inflammatory markers and provide us with 
supporting evidence of the functional role for the complement activation in the 
pathogenesis of CVDs through pleiotropic effects on endothelial and hematopoietic cell 
function and haemostasis[49]. 
Inflammatory response is part of a complex biological mechanism activated by harmful 
stimuli involving immune cells, blood vessels and molecular mediators. Chronic 
inflammation leads to progressive simultaneous destruction and healing processes of 
the affected tissue. A chronic inflammatory disorder may lead to a variety of diseases, 
such as atherosclerosis, allergic reactions as asthma, immune system disorders and 
rheumatologic diseases among others. 
Inflammation is currently viewed as a complex pathophysiologic process that engages 
hundreds of mediators and different cell types and tissues and can be initiated by any 
stimulus causing cell injury. This complex cascade is triggered by a variety of stimuli: 
 Inflammatory mediators (bacterial/viral/fungal sources, endotoxins, cytokines, 
histamine, oxidized products, complement fragments, etc.) 
 Depletion of anti-inflammatory mediators (nitric oxide, IL-10, glucocorticoids, 
albumin, etc.) 
 Fluid stress, transients of gas pressure or temperature, etc. 
The intricacy of this inflammatory cascade involves multiple steps as follow: 
 Early Cell Responses: ion exchange, depolymerisation, degranulation, release 
of inflammatory mediators, strengthening endothelial permeability and 
upregulation of adhesion molecules. 
 Tissue Degradation: neutrophil entrapment into vessels, transvascular 
migration, platelet aggregation and thrombosis, red cell aggregation, protease 
release, oxygen free radical formation, apoptosis and organ dysfunction. 
 Initial Repair: downregulation of anti-inflammatory genes, upregulation of pro-
inflammatory genes (cytokines), monocyte and T-Lymphocyte infiltration. 
 Repair: release of growth factors, connective tissue growth, revascularization. 
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The complement system is actively involved in the inflammation cascade in a 
multifaceted way regulating actively various steps of the inflammatory response, 
including changes in vascular flow and calibre, the increase in vascular permeability, 
extravasation of leukocytes, and chemotaxis. Complement components are activated in 
plasma. Complement may regulate other inflammatory mediators or be associated with 
a direct action on target cells and can independently participate in the regulation of 
inflammation, in either the presence or absence of an infection [50]. 
Three biochemical pathways activate the complement system: the classical 
complement pathway, the alternative complement pathway, and the lectin pathway. 
These three activation pathways converge at the formation of the C3 convertase which 
cleave C3, the central effector protein of the complement cascade, to C3a and C3b.  
The classical complement pathway typically requires for activation antigen-antibody 
complexes (immune complexes) generating a specific immune response, whereas the 
alternative and mannose-binding lectin pathways can be activated by C3 hydrolysis or 
antigens without the presence of antibodies (non-specific immune response). The 
activation of the alternative pathway via generation of hydroxilated C3 surges and a 
surveillance mechanism enabling rapid responses to invading pathogens or modified 
self-cells. Lectin and alternative pathways also constitute the amplification loop for 
complement activation [51].  
The classical pathway is activated by the interaction antibody-antigen to cells surface 
mediated by the C1 binding and subsequent cleavage of C4 and C2. On the surface of 
the active cell a serine protease, namely C3 convertase, will synthetize an 
anaphylotoxin, C3a, which will promote opsonisation. This response will also 
beamplified by C3 convertase generating further C3b [52]. The MBL pathway is similar 
to the classical pathway, albeit antibodies are substituted by lectin proteins[53]. 
Conversely, the alternative pathway owns the ability to initiate the complement 
cascade without requiring contact with proteins. The thioester bond of C3 produces a 
significant quantity of self-activated C3 which binds B factor. C3 convertase will also 
cleavage C3 amplifying the response. The C3b proteins produced by the classical 
pathway will generate a positive feedback loop to form C3 convertase [54].  
The three pathways of activation generate homologous variants of the protease C3-
convertase. In all of them, C3-convertase cleaves and activates component C3, 
creating C3a and C3b, and causing a cascade of further cleavage and activation 
events[55].  
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C3 complement plays a central role in the activation of the complement system. Its 
processing by C3 convertase is the central reaction in both classical and alternative 
complement pathways. C3 convertase belongs to the family of serine proteases as a 
part of complement system which eventuate in opsonisation of particles, release of 
inflammatory peptides, C5 convertase formation and cell lysis. C3 convertase is mainly 
synthetized in the liver, in smaller proportion in the adipose tissue and it is present 




Fig.2.3. Overview of the complement activation pathways, modified from Kuby et al.’s 
algorithm, Inmunology 2003.The three pathways of complement activation: classical, 
lectin (mannose-binding lectin (MBL)) and alternative converge at formation of the C3 
convertase products. C3b acts as an opsonintargeting C3b surfaces for phagocytosis. 
C3a and C5a act as anaphylotoxins, promote chemotaxis and the degranulation of 
mast cells.  
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 The smaller fragment called C3a is released and stimulates inflammation through the 
chemo-attractant activity. C3b fragment, becomes covalently attached to the cell 
surface or to the antibody molecules through the thioester domain at the site of 
complement activation. Derived from proteolytic degradation of complement C3, C3a 
anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of 
smooth muscle, increases vascular permeability and causes histamine release from 
mast cells and basophilic leukocytes. It also interacts with adipogenic proteins that 
stimulate triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat 
storage and playing a role in postprandial TG clearance. 
After cleavage and binding to cell surface, the C3b fragment is ready to bind a plasma 
protein called Factor B. The Factor B (a zymogen) is cleaved by a plasma serine 
protease Factor D releasing a small fragment called Ba and generating a larger 
fragment called Bb that remains attached to C3b. Thus, the alternative pathway C3 
convertase is formed and is able to cleave C3 now [56]. On the other hand, during the 
classical or lectin pathways, the C3 convertase contains different proteins of 
complement system – C4b and C2a. The cleavage of C4 and C2 is mediated by serine 
proteases - C1 complex in classical pathway and Mannose-binding lectin-associated 
serine proteases in lectin pathway. C4 is homologous to C3, and C4b contains an 
internal thioester bond, similar to that in C3b, that forms covalent amide or ester 
linkages with the antigen-antibody complex or with the adjacent surface of a cell to 
which is antibody bound. C2 is cleaved by C1s to a smaller fragment called C2b and 
larger fragment called C2a that binds to C4b. The fragments C4a and C2b are released 
[57].  
C3 convertase exists in two forms (C3bBb and C4bC2a) but both of them cleave C3, 
central molecule of complement system  (hence the name "C3-convertase").  C3b 
binds to the surface of pathogens, leading to greater internalization by phagocytic 
cells by opsonization. C3a is the precursor of an important cytokine (adipokine) 
named ASP and is usually rapidly cleaved by carboxypeptidase B. C3a and C5a 
have anaphylatoxin activity, directly triggering degranulation of mast cells as well as 
increasing vascular permeability and smooth muscle contraction.  
This accelerated spiral has its own regulatory systems, thus C3-convertase can be 
inhibited by Decay accelerating factor (DAF), which is bound to erythrocyte plasma 
membranes via a glycophosphatidilinositol anchor and blocks the membrane attack 
complex [58]. C3 convertases are unstable, their average half-life lasts 10 to 20 
minutes. C3 convertases are deactivated spontaneously or their dissociation is 
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facilitated by the regulators of complement activation proteins, such as decay 
acceleration factor (DAF), complement receptor 1 (CR1), C4b-binding protein and 
Factor H. C3 convertase assembling is suppressed by the proteolytic cleavage of C3b 
(and C4b), mediated by Factor I in the presence of membrane cofactor protein (MCP, 
CD46), C4b-binding protein, CR1 or a plasma-glycoprotein Factor H.  
These negative control processes are essential for the protection of self-tissue [59]. On 
the contrary, C3 convertase cleaves C3 producing C3b, which can form an additional 
C3 convertase. This positive-feedback effect is a unique feature of the alternative 
pathway of complement and results in the deposition of large numbers of C3b 
molecules on the surface of activating particles [60] Properdin (Factor P) is the only 
known positive regulator of complement activation that stabilizes the alternative 
pathway convertases (C3bBb).  
The complement deficiency would result in increased susceptibility to infection and to 
complement-tissue damaged. Deficiency of C3 and C4 have been linked to 
glomerulonephritis sue to an increased deposit of immune complexes in the glomerula 
[61]. Dysregulations in the alternative complement cascade have demonstrated an 
accelerated development of atherosclerosis and thrombosis and point to the potential 
role for complement C3 in CVDs [62, 63]. As an example, some studies have 
demonstrated that elevated levels of C3 at the time of an acute ischaemic event have 
been associated with worse outcomes and predict restenosis following 
endarterectomy[64]. 
Already defined atherosclerosis as a chronic low-grade inflammatory disease 
comprises the action of T-Lymphocytes, mast cells and macrophages at the early 
lesions. A healthy endothelium maintains vascular tone, flow and patency, inhibits cell 
adhesion and suppresses activation of the coagulation cascade via the secretion of 
multiple molecules such as nitric oxide (NO), endothelin I and prostacyclin [20].  
The atherosclerosis developing process will start via endothelial cell activation towards 
to an inflammatory, vasoconstrictive and thrombotic phenotype. This atherogenic 
endothelial cell phenotype increases the expression of cellular adhesion molecules, 
namely vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 
(ICAM-1), E-selectin and P-selectin. These adhesion molecules promote binding of 
inflammatory cells to the activated endothelium and support their migration into the 
arterial intima magnifying the inflammatory response within the arterial wall [65]. C5a 
and C5b interact with endothelial cells regulating these cellular adhesion molecules, 
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therefore, contribute to endothelial activation and leukocyte infiltration into the wall[49, 
66]. 
The activation of the alternative complement cascade also shows pathophysiological 
relevance in its role as rise giver to fibrin clots of denser structure. C3 has been 
identified as a clot component which bounds to fibrin with high affinity supporting a 
functional relationship between elevated C3 and prolonged fibrinolysis[67].  
Cross-talks among complement, coagulation cascades and atherosclerosis therefore 
occurs at multiple levels to coordinate haemostatic and immune response. The C3 
seems to play a central role in the complement system and its regulation is exerted by 
a complex mechanism composed by its own intrinsic decay, stabilization by properdin, 
disassembly by glycoprotein B1H, inactivation by C3b inactivator and protection by 
activators from the alternative pathway. Consequently, C3 convertase plays the 
junction point role of the three complements pathways and its study as an inflammatory 
biomarker and acute phase reactant seems the logic approach in the cardiovascular 
pathogenesis environment [68].  
There is rising interest in identifying new inflammatory risk factors for cardiovascular 
disease, to improve our understanding of the cardiovascular events development 
biology and to account for the cases of heart disease that cannot be explained by 
known risk factors.  
Investigation of the newly adopted risk factors frequently involves the study of 
circulating biomarkers. In recent years, a spirited debate has arisen regarding the 
validity and usefulness of these new measures. A careful assessment of the evidence 
suggests that most newer biomarkers are not ready for routine clinical use in the 
primary prevention setting. The traditional risk factors perform quite well with regard to 
the prediction of future cardiovascular risk. Inadequate recognition and control of the 
„classic‟ risk factors continues to account for a large number of avoidable 
cardiovascular events. At the same time, new insights into disease mechanisms should 
lead to the development of novel preventive therapies, regardless of how well 
biomarkers themselves perform in risk stratification. Furthermore, new developed 
technologies allow the profiling of large panels of genes, transcripts, proteins, or small 
molecules and facilitate the discovery of newer biomarkers capable of providing both 
mechanistic insight and true prognostic utility, and here C3 convertase plays a main 
role again. 
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Our research team has not been the first one which paid attention to this protein. In 
1987 Muscari et al noticed the humoral immunity changes in patients with coronary 
ischemia [69] and later when continuing their studies he described for the first time the 
possible predictive value related to coronary disease [28]. Five years later the same 
team linked the C3 protein levels to insulinemia in patients with personal history of 
atheroeslerosis [29]. Another Italian team paid attention to the relation of the C3 with 
the hypertension [70]. Lately, other authors correlate C3 serum levels with the central 
obesity and smoking habit [71].  Several researches during the last 3 decades are 
intensifying the fence attack towards the final target and seeding the possible relations 
of the C3 convertase levels with the diverse cardiometabolic risk factors. Most of the 
classical cardiovascular risk factors are included in the metabolic syndrome (MetS) 
entity. Subsequently, most studies reveal a tendency pointing out the C3 convertase as 




2.4.1. C-reactive protein as first inflammatory marker linked to 
metabolic syndrome 
Circulating levels of several inflammatory biomarkers have been studied to assess their 
value in predicting CVD. The best characterized and standardized biomarker of 
inflammation is C-reactive protein (CRP). The largest study to date that examined the 
association between inflammation and the MetS was the NHANES III study [72]. 
CRP was described as an inflammatory protein produced by hepatocyte and activated 
monocyte under the influence of cytokines such as interleukin (IL) -6 and tumour 
necrosis factor-alpha [73], being acute phase reactant in stress situations. Clinical 
evidence since the 1990s has demonstrated the relationship between inflammatory 
process, atherogenesis, plaque rupture and cardiovascular event. The elevation of 
serum concentrations of acute phase reactants, such as CRP [74] and IL-6 suggests 
that chronic inflammation of the coronary artery wall can play an important role in 
plaque rupture. This leads to a growing interest in the study of inflammatory biomarkers 
as markers of underlying atherosclerosis in apparently healthy individuals and the risk 
of recurrent events in patients with atherosclerotic vascular disease [75, 76]. Many 
studies have linked the metabolic syndrome to CRP since [77-79]. 
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Despite the lack of specificity of CRP to narrow inflammation aetiology, a significant 
association has been demonstrated between elevated serum CRP levels and the 
prevalence of underlying atherosclerosis. CRP has also been correlated to risk of 
recurrence of cardiovascular events among patients with established disease, 
incidence of early CVDs events [80, 81] and drugs used in the treatment of 
cardiovascular diseases reduce serum levels of CRP. Therefore, it is possible that 
inflammation contributes reducing the beneficial effects of these drugs. 
 As a direct pathogenic role, CRP has been found in atherosclerotic lesions, as well as 
linked to LDLc facilitating the action of macrophages, inducing the expression of 
adhesion molecules and the production of interleukin-6 and monocyte chemotactic 
protein-1 (MCP-1) in endothelial cells and recruitment of monocytes and lymphocytes 
[82]. As possible consequence the risk of ischemic heart disease was found 
significantly higher in individuals with higher serum CRP levels.  
The Centres for Disease Control and Prevention and the American Heart Association 
(CDC / AHA) (Pearson et al., 2004) define low, medium and high cardiovascular risk 
values as <1, 1 to 3, and> 3 mg / L of serum CRP respectively, these values 
correspond to the approximate tertiles in the general population. They also suggest that 
a value greater than 15 mg / L should initiate a search for a source of infection or 
inflammation. For patients with coronary heart disease> 3 mg / L would predict stable 
coronary disease and passing the threshold >10mg / L would be more predictive of 
acute coronary syndrome [83]. Among apparently healthy men, the plasma 
concentration of CRP predicted the long-term risk of a first myocardial infarction, 
ischemic stroke or peripheral vascular disease [84].  
Some studies associate CRP with the risk of future acute events in patients with stable 
angina and angiography [85] or the degree of calcification of the coronary arteries in 
the CT-scan. In patients with established coronary disease, a strong correlation 
between initial CRP and future acute coronary events has been demonstrated [86]. 
Several studies point to CRP as a predictor of the development of heart failure, new-
onset diabetes, a marker of rapid progression of coronary disease in revascularized 
patients correlation of serum levels of CRP with induction of ischemia in Stress tests 
[74, 87]. 
Previous studies have shown that MetS factors are individually associated with 
decreased endothelium-dependent vasodilatation, such as obesity, low HDL 
cholesterol, IGT, hypertriglyceridemia, and hypertension. Also, insulin resistance is 
associated with endothelial dysfunction. Subsequently several authors established the 
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link between CRP and endothelial dysfunction.  To demonstrate this theory, in-vivo 
studies [88] have shown that CRP impairs endothelial vasoreactivity and decreases 
eNOS activity. Knowing that patients with MetS are in a procoagulant state as 
evidenced by increased circulating plasminogen activator inhibitor-1 (PAI-1, some 
authors have shown that CRP induces PAI-1 and decreases tissue plasminogen 




2.5. Evolution of the metabolic syndrome to cardio-metabolic 
syndrome 
 
The metabolic syndrome (MetS) was defined for the first time by Reaven in 1988 as 
"syndrome X" or "insulin resistance syndrome" [91]. Since then, several studies and 
definitions have been conducted and copious pieces of literature have been produced 
as shown in the figure 2.4.   
The MetS concept has evolved to cardio-metabolic syndrome (CMS) by the addition of 
inflammation and reticular stress to the equation [92]. In fact, MetS and CMS are 
complementary pathophysiological concepts. If we include biomarkers of inflammation, 
oxidative stress, endothelial dysfunction and pro-thrombotic state, we refer to CMS, 
otherwise MetS.  
Metabolic syndrome represents a cluster of interrelated risk factors that promote the 
development of atherosclerotic vascular disease and are commonly associated with 
insulin resistance and type 2 diabetes. These include hyperglycaemia, dyslipidaemia, 
hypertension and abdominal obesity [93].  Dyslipidaemia involves elevated triglycerides 
(TGs) and low-density lipoprotein cholesterol (LDLc) and low high-density lipoprotein 
cholesterol (HDLc). 




Fig. 2.4: History evolution of the Metabolic Syndrome (MetS) concept. Modified from 
Anti-Obesity Drug Discovery and Development 2014 [94]. 
 
Cardio-metabolic syndrome (CMS) definition evolves one step further, adding the 
promotion of pro-inflammatory and pro-thrombotic states. The mayor mechanisms of 
the underlying forces of CMS are abdominal obesity, insulin resistance, obesity-
induced inflammation, reticulum and metabolic stress. It is also important to analyse 
the role of low-grade inflammation or meta-inflammation in fat tissue, as well as two 
new metabolic phenomena, metabolic Inflexibility and endoplasmic reticulum stress, 
and their interaction with the vascular triad: endothelial dysfunction, oxidative stress 
and vascular inflammation. 
Despite the MetS worldwide prevalence, there is still a lack of a uniformly accepted 
definition and great controversy with regard to the pathogenesis of MetS [35]. 
In our research team, we agreed with the most widely accepted definition, which was 
proposed by the National Cholesterol Education Program-Adult Treatment Panel-III 
(NCEP-ATPIII).  
Their criteria require three or more of the following parameters: waist circumference 
(WC) >102 cm in men and >88 cm in women, HDLc <40 mg/dl (<1.04 mmol/l) in men 
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and <50 mg/dl (< 1.29 mmol/l) in women, TG ≥150 mg/dl (≥1.7 mmol/l), blood pressure 
(BP) ≥130/85 mmHg and fasting glucose ≥100 mg/dl (≥6.1 mmol/l)[95].  
 
The clinical criteria for the metabolic syndrome diagnosis according to the ATP-III can 
be summarized into three or more of the following parameters: 
1. Variable waist circumference according to the different specifications related     
to populations, genders and location. 
2. Raised hypertriglyceridemic levels (or patient under specific treatment) > 
150 mg/dl. 
3. Reduced plasmatic C-HDLc levels (or patient under specific treatment)  < 40 
mg/dl (males) <50 mg/dl (females) 
4. Hypertension (or patient under specific treatment): 
i. Systolic blood pressure ≥130 mmHg 
ii. Diastolic blood pressure ≥ 85 mmHg 
5. Raised plasmatic fasting glucose ≥100 mg/dl 
 
Besides this definition, there are two other commonly used. The first one proposed by 
the International Diabetes Federation (IDF) [95], and a second one by the National 
Heart Lung and Blood Institute (NHLBI) and the American Heart Association (AHA). 
According to the IDF definition, MetS is diagnosed if an individual has abdominal 
obesity, that is waist size ≥94 cm in European men and ≥80 cm in European women 
and ≥2 of the remaining four criteria of the NCEP-ATP III definition. Cut-off points for 
hypertension, TG and HDLc levels are the same but glycaemia is considered abnormal 
at lower levels (FG≥100 mg/dl).  
The definition proposed by the AHA/NHLBI in 2005 retained most of the NCEP-ATPIII 
criteria but adopted the same waist thresholds for some ethnic groups (e.g., South 
Asians) but their cut-off points for fasting glucose levels [≥100 mg/dL (5.6 mmol/L)] are 
lower following the IDF definition [96]. 
Recently, the 2009 Joint Interim Societies (JIS) proposed a MetS definition to unify the 
aforementioned three definitions. This definition uses the same thresholds for TG, BP, 
and HDLc considers WC based on ethnicity (≥94 cm (males) or ≥80 cm (females) for a 
Mediterranean population, but this is not a mandatory criteria though) and finally 
glycaemia (FG≥100 mg/dl).  
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Three or more of these criteria are required for diagnosis. All these criteria are 
presented in table 2.1. 
 
 
Table2.1: listed MetS diagnosed criteria differentiated by each health organization 
standards, gender and personal characteristics. Modified from Indian Journal of 
Endocrinology and Metabolism, 2012. Abbreviations: as shown in list of acronyms.  
 
Summing up, obesity predisposes the individual to increased risk of developing 
diabetes mellitus (DM). It reflects our contemporary world‟s sedentary lifestyle, over-
nutrition, and resultant excess adiposity due to overweight. It seems to affect about 
one-fourth to one-fifth of the Mediterranean population, and its prevalence increases 
with age due to a reduction in energy requirements and consumption [97]. The “Look 
AHEAD Study” has shown that a body weight reduction of 7% improves glycemic 
control and cardiovascular risk factors in subjects with type 2 diabetes[98]. 
The physiopathological effects of adipose tissue are related to the specific site where 
fat is stored [99]. There is a clear functional distinction between visceral or 
intraperitoneal fat, extraperitoneal (peripancreatic and perirenal) and intrapelvic 
(gonadal/epididymal and urogenital) adipose tissues, all of them presenting a higher 
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metabolic activity than subcutaneous peripheral adipose tissue [100]. Moreover, 
abdominal obesity with low metabolic activity, android obesity, is strongly associated 
with MetS, cardiometabolic risk and cardiovascular disease, therefore the importance 
of the waist circumference measurements [101]. The term adiposopathy or sick fat, 
described by Dr Saban-Ruiz, refers to an excess of adipose tissue which results in 
pathogenic enlargement of fat cells and functional abnormalities, including endocrine 
and immune disorders.  
Obesity is already considered as a low-grade chronic inflammation disease or meta-
inflammation that comprises fat and vascular stroma [101]. This meta-inflammation 
involves adipocytes and the stroma (vascular endothelial cells) is infiltrated by 
macrophages, and leukocytes. As a result, the macrophages secrete pro-inflammatory 
cytokines and reactive oxygen species (ROS). The pro-inflammatory cytokines levels, 
such as IL-6, TNF-α, resistin and leptin are raised in obese patients along with reduced 
adiponectin. ROS activates stress pathways and disrupt metabolic processes as the 
insulin signalling cascade, energy homeostasis, lipid metabolism increasing the 
production of triglycerides and leading to MetS. 
 
Two concepts have been recently added to complete the MetS physiological picture:  
Metabolic Inflexibility (MI) and the Endoplasmic Reticulum Stress (ERS).  
The metabolic inflexibility is considered the ability to switch from fat to carbohydrate 
oxidation. Consequently, a healthy organism counts with a great adaptability to the fat 
from diet, so it is able to suitably metabolize this fat, while maintaining body weight. 
This process is mediated by genetic and hormonal factors [102, 103] .  
On the contrary, metabolically inflexible subjects present decreased adaptability to fat 
ingestion, which appears to usually be impaired in insulin-resistant subjects. In MI 
subjects, a fat accumulation occurs, fatty acids are stored in muscles and the liver and 
thus weight gain occurs as food intake increases. In addition, consumption of local 
glucose at muscular tissue is increased and consumption of postprandial glucose is 
decreased. MI individuals can lead to IR by interfering with the insulin-signalling 
cascade [104].  
MI is closely related to IR, and both processes are intimately linked Endoplasmic 
Reticulum Stress. ER is a cellular organelle that integrates the protein, lipid, and 
glucose metabolism. The secretion of inflammatory mediators increases as fat 
accumulation grows. The inflammatory mediators promote lipogenesis and impair 
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mitochondrial respiratory chain function and increases the generation of ROS, leading 
to mitochondrial calcium overload, and oxidative stress From chronic inflammation of 
adipose tissue and metabolic inflexibility, [105]. 
 Endoplasmic reticulum stress has been considered as the first step which leads to 
oxidative stress, vascular inflammation, endothelial dysfunction, T2DM and MetS. 
Because of the increased importance of obesity, waist circumference has been 
recommended as a screening tool to evaluate the risk of developing metabolic 
syndrome, diabetes and cardiovascular disease since 1995, though exact cut off points 
for maximum waist circumference have been debated [106].  The risk of developing 
diabetes (controlled for age, sex, race, and smoking) is 4.12 (2.72–6.24) times higher if 
waist is larger than International Diabetes Federation (IDF) recommendations [107]. 
 The risk of developing cardiovascular disease is greater for persons with intra-
abdominal obesity who have high levels of triglycerides. A recent study conducted in 
the United Kingdom proposes that screening for increased waist circumference and 
hypertriglyceridemia (the hypertriglyceridemic-waist phenotype) is an inexpensive 
approach for identifying patients with excess intra-abdominal adiposity and associated 
metabolic abnormalities[108]. This theory has been tested with confirmative results 
across the world, from China [42] to Brazil [109] and Puerto Rico [110].  
Several studies suggest that measuring triglycerides and waist circumference is 
particularly important in patients with normal traditional risk scores. Patients who have 
hypertension, diabetes or raised cholesterol will be identified with traditional methods. 
However, patients with hypertriglyceridemic waists and normal values on traditional risk 
scores had double or triple the risk of developing heart disease [111].  
There are several cut-off points of maximum waist circumference in relation to the 
different health organizations, ethnicity and gender. The European  Society of 
Cardiology (ESC) establish the cut-off point in 102 cm for men and 88 cm for women, 
while the International diabetes Federation (IDF) specify a cut-off point specifically for 
Mediterranean population lower than that, with 94 cm for men and 80 cm for women. 
Consensually, the WHO considers the IDF‟s cut off point as high risk and the ESC‟s cut 
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Population Organization Men waist circumference Women waist 
circ. 
Europeans IDF ≥94 cm ≥80 cm 
Europeans ECVs ≥102 cm ≥88 cm 
Caucasians OMS ≥94 cm high risk  
≥102 cm very high risk 
≥ 80 cm 
≥ 88cm 
Asians IDF ≥ 90 cm ≥ 80 cm 
Asians (excluiding 
Japanese) 
OMS ≥ 90 cm ≥88 cm 
Japanese Obesity Jap. Soc. ≥ 85 cm ≥80 cm 
Chinese Coop. Task 
Force 
≥85 cm ≥80 cm 
Mediterranean IDF ≥94 cm ≥80 cm 
Subsaharians IDF ≥94 cm ≥80 cm 
South Americans IDF ≥90 cm ≥80 cm 
USA AHA/ATP III ≥102 cm ≥88 cm 
Canadians Health Canada ≥102 cm ≥88 cm 
 




Beyond CVD and DM, the metabolic syndrome is also associated with higher urinary 
albumin excretion, lower glomerular filtration rate (GFR) and a greater prevalence of 
chronic kidney disease [46]. Other co-morbidities include non-alcoholic fatty liver 
disease [47-49], sleep-disordered breathing [112], and hypogonadism in males [113] .  
 
Furthermore, MetS has been associated with increased incidence of some types of 
cancer, such as pancreatic cancer, with DM being the key component for this 
correlation [52, 53], and breast cancer [54] One of the proposed mechanisms for this 
association may be related to increased insulin and insulin-like growth factor-I (IGF-I) 
activities observed in MetS. Elevated serum insulin concentrations observed in MetS 
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and IR states increase the level and bioavailability of IGF-I, which in turn plays a key 
role in the development and progression of several diseases. 
In nondiabetic, normotensive overweight individuals, serum triglyceride concentration, 
the ratio of triglyceride to high density lipoprotein HDLc concentrations, and fasting 
insulin concentration are useful markers. This makers identify those who may be insulin 
resistant, as measured by an insulin suppression test.  
Optimal cut-points were identified as 130 mg/dL for triglycerides, 3.0 (1.8 SI units) for 
triglyceride-to HDLc ratio and 15.7 µU/mL  for insulin, respectively [55]. The co-
segregation of overall obesity (increased BMI), abdominal obesity (raised waist 
circumference), raised blood pressure, increased fasting glucose levels, raised 
triglyceride levels, and low HDLc concentration suggest the existence of metabolic 
syndrome, which is closely related with the development of insulin resistance.  
 
 
2.6. The metabolic triad 
 
The association between T2DM and inflammation was noted in early 20th century when 
sodium salicylate therapy showed lower levels of glycosuria and further evidence 
emerged when aspirin treatment improved blood glucose control in T2DM [114]. 
Oxidative stress and increased ROS are associated with chronic hyperglycaemia and 
both play a role in endothelial dysfunction (ED) development. Chronic hyperglycaemia, 
as seen in diabetes, leads to ED and subsequently reduces the bioavailability of NO 
and increases the platelet activation, SMC and expression of adhesion molecules 
participating from the first step in the development of atherothrombosis.  
Thus, hyperglycaemia is likely to induce and perpetuate inflammation through 
increased mitochondrial reactive oxygen species (ROS) formation [115]. Furthermore, 
studies have shown that improving glycaemic control of T2DM can reduce plasma 
inflammatory proteins such as C3 complement [116]. T2DM may be implicated in the 
glycation of C3 and fibrinogen enhancing the incorporation of C3 in fibrin clots and 
promoting a prothrombotic estate [67]. The discovery in the 1990s that adipose cells 
were capable of secreting the pro-inflammatory cytokine, TNF-α, which subsequently 
able induced insulin resistance changed our approach [117]. 
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2.6.1. Insulin resistance as component of the metabolic triad 
The concept of a vasculo-metabolic theory interrelates two pathogenic bidirectional 
ways in the process of generating and maintaining low-grade fat inflammation and 
activation of adipose tissue stroma [94]. This theory of a meta-process combines the 
vascular triad, which includes endothelial dysfunction, oxidative stress and vascular 
inflammation, and the metabolic triad, which is composed by insulin resistance (IR), 
metabolic inflexibility (MI) and endoplasmic reticulum (ER) stress. 
Metabolic flexibility has been defined as the capacity for the organism to adapt fuel 
oxidation to fuel availability. In metabolic patients the inability to modify fuel oxidation in 
response to changes in nutrient availability has been implicated in the accumulation of 
intramyocellular lipid and insulin resistance. Insulin-resistant patient become 
metabolically inflexible (MI) and their ability to switch from fat to carbohydrate oxidation 
is usually impaired during a hyperinsulinemic clamp [104]. 
ER stress plays a role in the pathogenesis of diabetes, obesity, cardiovascular 
diseases [118] and myocardial damage by contributing to pancreatic beta-cell loss and 
insulin resistance. Components of the unfolded protein response (UPR) play a dual role 
in beta-cells, acting as beneficial regulators under physiological conditions or as 
triggers of beta-cell dysfunction and apoptosis under situations of chronic stress such 
as chronic high glucose and fatty acid exposure.  
High fat feeding and obesity induce ER stress in liver, which suppresses insulin 
signalling via kinase activation and contributes to cytokine-induced beta-cell death. The 
B-cell mediators, namely cytokines IL-1beta and interferon-gamma, induce severe ER 
stress and NO-mediated depletion of ER calcium and amplify the proapoptotic 
pathways [119]. Moreover, the endoplasmic reticulum stress induces autophagy 
response, a catabolic and degradation process for long-lived proteins and unnecessary 
or damaged organelles [120]. In healthy conditions starvation and cellular nutrient 
limitation triggers this stress, but also pathological conditions given in cardiometabolic 
subjects produce the autophagic response as prof. Y. Ohsumi, 2017 Medicine Nobel 
Prize, and other authors noted [121]. 
As a confirmation of this vasculo-metabolic theory hyperinsulinemia also comes along 
with raised levels of PAI-1 (Plasminogen-Activator Inhibitor-1), main inhibitor of tissue 
plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen and 
hence fibrinolysis, and it appears to be also associated with endothelial dysfunction, left 
ventricular hypertrophy and coronary disease. 
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2.6.2. Insulin resistance as single cardio-metabolic factor 
 
The insulin resistance (IR) is intimately associated with abdominal obesity and a 
variety of abnormalities that impact upon the cardiovascular system, such as T2DM, 
hypertension, an atherogenic lipid profile that includes hypertriglyceridemia and low 
serum HDL-cholesterol concentrations, and coronary disease. Adipose cells are 
metabolically active and lead to the hyperglycaemic hyperinsulinaemic state which 
characterised T2DM. Fatty hepatocytes and adipocytes increase the recruitment of 
inflammatory cells. These active inflammatory macrophages raise the cytokine 
production, which in conjunction with insulin resistance through impairment of 
adipocyte differentiation generate a positive feedback for hepatic and skeletal muscle 
lipid accumulation. 
Insulin resistance has been defined as a subnormal biological response to normal 
insulin concentrations. In clinical practice, insulin resistance refers to a state in which a 
given concentration of insulin is associated with a subnormal glucose response [122]. 
This abnormal response is to both, endogenous and exogenous insulin. Insulin 
resistance, instead of being a rare complication of the diabetes‟ treatment is now 
recognized as a component of several disorders, including the following: 
 Major causes of insulin resistance: Inherited states of target cell resistance, 
leprechaunism (insulin-receptor mutations), Rabson-Mendenhall syndrome 
(insulin-receptor mutations), type A syndrome of insulin resistance (insulin-
receptor mutations in some) and lipodystrophies. 
 Secondary insulin resistance: obesity (adipocytokines may contribute), excess 
counter regulatory hormones (glucocorticoids, catecholamines, growth 
hormone, placental lactogen), type 2 diabetes mellitus (secondary to obesity 
and other factors), inactivity, stress, infection (counter regulatory hormones), 
pregnancy (placental lactogen), immune mediated (anti-insulin antibodies), 
starvation, uraemia, cirrhosis and ketoacidosis. 
 Multifactorial aetiology of insulin resistance: HBP, polycystic ovary syndrome, 
MetS, T2DM. 
 
Insulin resistance contributes to the pathophysiology of diabetes and is a hallmark of 
obesity, metabolic syndrome, and many cardiovascular diseases. Therefore, 
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quantifying insulin sensitivity/resistance in patients was of great importance for 
epidemiological and clinical studies, and eventual use in clinical practice [123].   
In a research setting, the hyperinsulinemic euglycemic insulin clamp technique has 
been considered to be the gold standard, and intravenous glucose tolerance test 
(IVGTT) and/or the insulin tolerance test (ITT)/insulin suppression test are the tests 
most frequently used [124]. It is an invasive test and takes about two hours. The insulin 
is perfused through a peripheral vein and in order to balance the glycaemia a glucose 
20% is also infused.  
Low-dose insulin infusions are more useful for assessing the response of the liver, 
whereas high-dose insulin infusions are useful for assessing peripheral insulin action. 
Levels between 4.0 and 7.5 mg/min are not definitive and suggest "impaired glucose 
tolerance," an early sign of insulin resistance [123]. The main limitations of the glucose 
clamp approach are that it is an invasive technique, time consuming, expensive, and 
requires an experienced operator to manage the technical difficulties.  
The modified insulin suppression test is another measure of insulin resistance is 
developed by Gerald Reaven at Stanford University. The test suffers from less 
operator-dependent error than the clamp. Nonetheless, it is also requires a complicated 
methodology with infusion of octreotide, somatostatin, insulin and glucose. Subjects 
with  steady-state plasma glucose level greater than 150 mg/dl are considered to be 
insulin-resistant [125]. 
However, both techniques are impractical for routine clinical use, the methods to 
directly measure insulin resistance are invasive, complex, and costly. Given the 
complicated nature of the "clamp" technique (and the potential dangers 
of hypoglycemia in some patients) to directly measure the insulin sensitivity, 
alternatives have been sought to simplify the measurement of insulin resistance.  
Several authors developed simple surrogated indexes to calculate the relation in 
between insulin resistance and sensitivity. The first was the Homeostatic Model 
Assessment (HOMA), and a more recent method is the Quantitative insulin sensitivity 
check index (QUICKI). Both employ fasting insulin and glucose levels to calculate 
insulin resistance, and both correlate reasonably with the results of clamping studies. 
Simple surrogate indexes of insulin sensitivity/resistance are inexpensive quantitative 
tools that can be easily applied in almost every setting, including epidemiological 
studies, large clinical trials, clinical research investigations, and clinical practice.  
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To develop these indexes we have to assume that our patients accomplish a strictly 
fasting conduct along the previous night to reflect a primary hepatic insulin sensitivity 
versus resistance during a basal state of plasma glucose and Insulin levels. Both 
methods are widely used in our department of endothelial pathology, HOMA has been 
chosen for this study because of practicality. 
The homeostasis model assessment (HOMA) was developed in 1985 by Matthews 
and cols.[126]. At that time the steady-state basal plasma glucose and insulin 
concentrations were determined by their interaction in a feedback loop. A computer-
solved model was used to predict the homeostatic concentrations which arose from 
varying degrees beta-cell deficiency and insulin resistance.  
Matthews and cols. compared the patient's fasting values with the model's predictions 
and allowed a quantitative assessment of the contributions of insulin resistance and 
deficient beta-cell function to the fasting hyperglycaemia. The accuracy and precision 
of the estimation was determined by comparison with independent measures of insulin 
resistance and beta-cell function using hyperglycaemic and euglycaemic clamps and 
an intravenous glucose tolerance test. HOMA-IR had a reasonable linear correlation 
with glucose clamp and minimal model estimates of insulin sensitivity/resistance in 
several studies of distinct populations [127]. Both, the original HOMA and the updated 
HOMA2 assume a feedback loop between the liver and β-cell [128].  
The approximating equation for insulin resistance, in the early model, used a fasting 
plasma sample, and was derived by use of the insulin-glucose product, divided by a 
constant: (assuming normal-weight, normal subjects < 35 years, having 100% β-cell 
function an insulin resistance of 1).  In the table below referred to the primary HOMA 
model, IR is insulin resistance and  % β is the β-cell function. Insulin is given in mU/L. 
Glucose and insulin are both analyzed during fasting basal conditions. The HOMA 
model follows the formulas presented below: 
  
  
Fasting Glucose in Molar Units mmol/L Fasting Glucose in mass units mg/dL 
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In clinical practise, most studies using HOMA employ an approximation described by a 
simple equation to determine a surrogate index of insulin resistance. The denominator 
of 22.5 is a normalizing factor. This factor is determined by the normal individual 
results: the product of normal fasting plasma insulin of 5 μU/ml and normal fasting 
plasma glucose of 4.5 mmol/l typical of a “normal” healthy individual = 22.5. Therefore, 
for an individual with “normal” insulin sensitivity, HOMA-IR = 1. Even so, the coefficient 
of variation for HOMA-IR varies considerably depending upon the number of fasting 
samples obtained and the type of insulin assay used [63]. Hence, Log (HOMA-IR) is 
useful for evaluation of insulin resistance in individuals with glucose intolerance, mild to 
moderate diabetes, and other insulin-resistant conditions. However, in subjects with 
severely impaired or absent β-cell function, HOMA-IR may not give appropriate results. 
The updated HOMA2 adjusted the assessment of HOMA%S and HOMA%B in subjects 
with glucose levels ≤25 mM, accounts for renal glucose losses, assumes reduced 
suppression of HGP and increased insulin secretion in response to glucose levels >10 
mM, and allows for the use of total or specific insulin assays [128].  
The formula was based on the principle that assumes glucose concentrations are 
regulated by insulin-dependent hepatic glucose production, whereas insulin levels 
depend on the pancreatic β-cell response to glucose concentrations. Thus, deficient β-
cell function reflects a diminished response of β-cell to glucose-stimulated insulin 
secretion. Likewise, insulin resistance is reflected by diminished suppressive effect of 
insulin on hepatic glucose production. Decreases in [beta]-cell function were modeled 
by changing the [beta]-cell response to plasma glucose concentrations. Insulin 
sensitivity was modeled by proportionately decreasing the effect of plasma insulin 
concentrations at both the liver and the periphery [129]. In either situation, the glucose 
turnover in the model remains constant. In the HOMA model, no distinction has been 
made between hepatic insulin sensitivity and peripheral insulin sensitivity. The model 
predicts fasting basal levels of plasma glucose and insulin for any given combination of 
pancreatic β-cell function and insulin sensitivity.  
 
On the other hand, the quantitative insulin sensitivity check index (QUICKI) is 
derived using the inverse of the sum of the logarithms of the fasting insulin and 
fasting glucose: 
1 / (log(fasting insulin µU/mL) + log(fasting glucose mg/dL)) 
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This index correlates well with glucose clamp studies (r = 0.78), and is useful for 
measuring insulin sensitivity (IS), which is the inverse of insulin resistance (IR). It has 
the advantage of that it can be obtained from a fasting blood sample, and is the 
preferred method for certain types of clinical research [130]. During development of 
QUICKI, sensitivity analysis of data from the first 20 min of an FSIVGTT revealed that 
physiological fasting steady-state values of plasma insulin and glucose contain critical 
information about insulin sensitivity as determined by the reference standard glucose 
clamp [131] . Since fasting insulin levels have a non-normal skewed distribution, log 
transformation improves its linear correlation with insulin sensitivity.  
To accommodate some clinical circumstances such as where fasting glucose is 
inappropriately high and insulin is inappropriately low, addition of log (fasting glucose) 
to log (fasting insulin) provides a reasonable correction such that the linear correlation 
with insulin sensitivity, is maintained in both diabetic and non-diabetic subjects. Log 
(HOMA) is roughly comparable to QUICKI in this regard. Nevertheless, both indexes 
are mathematically related, QUICKI is proportional to 1/log (HOMA-IR).  
 
For selected patients, who have been brought under the oral glucose tolerance test, we 
can perform another test with dynamic properties. Obviously, dynamic testing requires 
more effort and cost than simple fasting blood sampling. Dynamic indexes that depend 
on dynamic testing take into account both fasting steady-state, dynamic postglucose 
load plasma glucose and insulin levels. Glucose disposal after an oral glucose load or 
a meal is mediated by a complex dynamic process that includes absorption, glucose 
effectiveness, neurohormonal actions, incretin actions, insulin secretion, and metabolic 
actions of insulin that primarily determine the balance between peripheral glucose 
utilization and hepatic glucose production. Logically, the oral glucose intake is more 
physiological than intravenous glucose infusion, taking into account the possible 
variability in the glucose absorption. For this specific patients spectrum in our unit we 
develop the Matsuda index.  
 
The oral glucose tolerance test is a simple test widely used in clinical practice to 
diagnose glucose intolerance and T2DM. After an overnight fast, blood samples for 
determinations of glycaemia and insulin concentrations are taken at 0, 30, 60, and 120 
min following a standard oral glucose load (75 g). The OGTT mimics the glucose and 
insulin dynamics of physiological conditions. more closely than conditions of the OGTT 
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is less invasive than the glucose clamp, IST, or FSIVGTT. Besides this, OGTT provides 
useful information about glucose tolerance but not insulin sensitivity/resistance per se.  
Because of this Matsuda and cols. proposed an insulin sensitivity index (ISI Matsuda) 
where the insulin secretion activity could be obtained at the same time as the insulin 
action was measured, where fasting glucose and insulin data are taken from time 0 of 
the OGTT, and the mean data represents the average values obtained during the 
whole process: 
 
 ISI(Matsuda) = 10,000/√[(Gfasting × Ifasting) × (GOGTTmean × IOGTTmean)] 
  
Nevertheless, HOMA or log(HOMA) are used widely in large epidemiological studies, 
prospective clinical trials, and clinical research studies. A big portion of them relate the 
insulin resistance measured by HOMA model to metabolic and hemodynamic 
alterations and higher cardio metabolic risk [67-70]. A cross-sectional and longitudinal 
research established relationships between C-reactive protein (CRP), a marker of low-
grade inflammation, and insulin resistance and whether the association was 
independent of obesity and oxidative stress [132]. Inflammation, measured by 
plasmatic CRP levels, showed a significant positive association with insulin resistance. 
During the last decade several authors have developed successful research which 
correlates C3 convertase, inflammation, metabolic syndrome, diabetes, hyperlipidemia, 
polycystic ovary syndrome, and new cardiovascular risk factors to HOMA and insulin 
resistance [72-77]. All of them seed a fruitful growing field to develop future studies 
which will connect a logical chain from C3 convertase, arterial chronic inflammation, 
metabolic risk factors, insulin resistance and cardiovascular events. 
Besides this, the criteria for metabolic syndrome are just a part of the cardiovascular 
risk factors. We have to remember that the classic risk factors also include smoking 
and a sedentary lifestyle. Into the bargain, during the last 3 decades the authors have 
included new interesting risk elements such as polycystic ovary syndrome, chronic liver 
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2.7. New components of metabolic syndrome 
 
2.7.1. Hyperuricemia  
 
Kyllin observed the role of hyperuricemia as a component of the metabolic syndrome. 
This observation was forgotten in the 20th century, but strong evidences during the last 
two decades reintroduced the hyperuricemia in the complex cocktail of cardiometabolic 
factors. Hence, large epidemiologic studies have shown that hyperuricemia is 
associated with an increased incidence of cardiovascular events, specifically coronary 
heart disease. Lately, hyperuricemia has been also correlated to metabolic syndrome 
[133], also in Mediterranean population [134]. It has been also demonstrated an 
increased mortality rate [135], mainly in patients with heart failure, due to a decrease in 
the tissue perfusion.  It is unclear if hyperuricemia has a causal effect, but it may 
develop HBP and oxidative stress, or is simply a marker for HBP, dyslipidaemia, and 
diabetes [136]. 
Lehninger described uric acid as the end product of purine degradation, nucleic acids 
and nucleoproteins [133, 137]. Hyperuricemia is a frequent metabolic disorder in 
general population [138]. The observed prevalence in studies of Tecumseh and 
Framinghan was about 5%. Uric acid overload is usually caused by an unhealthy 
lifestyle and the progression from asymptomatic hyperuricemia to urate deposition and 
advanced gout with organ damage varies among individuals.  
Body Mass Index (BMI) has been identified as the best predictor for levels of uric acid, 
showing a strong positive correlation [139]. Uric acid overload has been considered as 
a component of the called "insulin resistance syndrome " or "Syndrome X" or Metabolic 
Syndrome (MetS). Hyperuricemia is also associated with the consumption of drugs 
most frequently the use of diuretics and antihypertensives. Therefore, before 
considering hyperuricemia as a component of the syndrome, some authors 
recommend to rule it out as "secondary hyperuricemia". Hyperuricemia has been linked 
to cardiovascular pathology such as myocardial infarction, stroke, hypertension and 
heart failure [140, 141].  
Uric acid can change its chemical activity of antioxidant to prooxidant when entering 
the atherosclerotic plaque [142]. Within the plaque, the uric acid contributes to oxidize 
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lipoproteins in patients with metabolic syndrome and diabetes mellitus type 2. The 
association between uric acid and MetS promotes sinergically the renin angiotensin 
aldosterone system activation. Angiotensin II is a potent inducer of NADPH oxidase, 
which increases NADPH, this in turn increases the reactive oxygen species (ROS) in 
the arterial intima-media layers [143]. Meanwhile, hyperinsulinemia increases the renal 
reabsorption of urate. 
The association between MetS and increased uric acid levels was highlighted by 
Professor Reaven (Hayden, 2004), discoverer of the syndrome-X, then called 
metabolic syndrome. Lately uric acid levels have been correlated to Mets, insulin 
resistance and C3 complement in Japanese population [144]. In an experimental model 
of MS developed in rats an increase of uric acid in the plasma, concomitant with 
increased triglycerides, hyperinsulinemia and hypertension was observed [145]; as well 
as, increased reactivity of the left ventricular myocardium together with endothelial 
dysfunction expressed as attenuation vasodilator response to acetylcholine in aortic 
rings according to Rosa, et al. in 2005. 
The mechanisms that can raise uric acid in hypertensive are as follows: first, reduced 
blood flow, second, microvascular local ischaemia, third, increased lactate production 
by the aforementioned ischemia, which blocks the secretion of urate the proximal 
tubule, increased degradation of RNA and DNA which increases the uric acid synthesis 
by xantine-oxidase protein [146]. All this increases ROS production neutralizing 
endothelial nitric oxide and produce vascular endothelial dysfunction. Treatments to 
reduce uric acid concentrations, allopurinol and oxypurinol (inhibitors of xanthine 
oxidase), reverse the reduced synthesis of endothelial nitric oxide in patients with heart 
failure and T2DM. Despite controlling blood pressure with medication, hyperuricemia is 
significantly associated with increased incidence of cardiovascular events. The DASH 
diet (Dietary Approach to Stop Hypertension) not only reduces blood pressure but also 
the the plasma concentration of uric acid and its co-morbidities [147]. 
 
2.7.2. Hyperferritinemia  
 
Hyperferritinemia is associated with inflammatory processes such as metabolic 
syndrome [148], chronic rheumatological disorders, chronic anemia or 
hemochromatosis, iron overload after transfusions, chronic non-alcoholic liver disease, 
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hemochromatosis and other hereditary diseases. Therefore, it is undisputed its 
relationship with the inflammatory generation of atherosclerotic plaques and 
consequently with markers of the inflammatory cascade and acute phase reactants. 
Iron overload in vital organs, even in mild cases, increases the risk of atherosclerosis 
[149], dyslipidaemia [150], heart failure [151], metabolic syndrome[152], myocardial 
infarction [150], hypothyroidism [153], hypogonadism [153], osteoarthritis, 
osteoporosis, liver disease (cirrhosis), numerous symptoms and in some cases 
premature death. Mismanagement resulting in iron overload can accelerate 
neurodegenerative diseases such as Alzheimer's, early onset Parkinson's, 
Huntington's, epilepsy and multiple sclerosis [154]. 
The liver is the major reservoir of iron. Excess stored iron in the liver causes 
hyperinsulinemia via both decreased insulin extraction and impaired insulin signalling. 
On top of this hyperinsulinemia encourages and increase of iron deposition as a 
positive feedback [155]. Iron deposits within hemosiderin in different cells, including b-
cells, induce apoptosis and impaired response to insulin in the liver, muscle, and 
adipose tissue [156]. Subsequently, iron overload leads to diabetes by progressively 
reducing their β-cell function. Disruption of iron homeostasis, either in excess or in 
defect, results in impaired adipocyte differentiation and may affect insulin action by 
modulating the degree of adiposity. Iron-enriched diets reduce the adipocyte size and 
its insulin sensitivity [157]. 
The relationship between hyperferritinemia and various cardiovascular risk factors has 
been shown in multiple studies. A long list of metabolic risk factors has been correlated 
to iron overload such as diabetes mellitus [116], central obesity [158], metabolic 
syndrome [152], hypertriglyceridemia and dyslipidaemia [159], hepatic steatosis [160], 
insulin resistance [161], damage vascular [162], lipid metabolism disorders [163] 
among others. Increased transferrin saturation due to iron overload showed a dose-
dependent association with an increased total mortality [164]. Excess iron store 
contributes to the pathogenesis of MetS, T2DM, entothelial dysfunction and oxidative 
damage [165]. 
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2.7.3. New cardiovascular biomarkers 
 
Multiple cardiometabolic markers have been involved during the last two decades in 
the complex process of atheroma formation. Some of them were used in the daily 
clinical activity of the Endothelium and Cardiometabolic Medicine Unit (ECMU). These 
available data represented an excellent opportunity to compare the C3 complement 
activity with the new cardiometabolic markers participation in the cardiovascular 
pathology development. 
 
2.7.3.1. Inflammatory biomarkers: Adiponectin TNFα IL6 IL10 
 
Inflammation, already explained earlier on in this chapter, was widely known as to play 
a key role in the development and progression of cardiovascular diseases and obesity 
has been linked to many proinflammatory and cardiovascular conditions. It has also 
been observed that adipokines play an important role in systemic and local 
inflammation and adipose tissue have a more important role than previously thought in 
the pathogenesis of cardiometabolic syndromes.  Adipokines (such as leptin, TNF-α, 
PAI type 1, IL-1β, IL-6, and IL-8) are proinflammatory and increased in cardiometabolic 
pathologies. As Inflammatory markers and inmunomodulatory factors TNF-α and 
adiponectin intersect with the inflammation associated with both cardiovascular and 
metabolic pathologies. 
Tumour necrosis factor-α (TNF-α): 
TNF-α as part of the inflammatory cascade, plays a key role in the formation of 
atherosclerotic lesions [166]. Among many inflammatory markers TNF-α emerged as a 
pleiotropic cytokine that influences intermediary metabolism. TNF-α has 
proinflammatory properties, which play crucial roles in the innate and adaptive 
immunity, cell proliferation, and apoptotic processes. Tumour necrosis factor-α (TNF-α) 
has been correlated with chronic inflammatory conditions where a shift toward a 
proatherogenic lipid profile and impaired glucose tolerance occurs and worsen 
prognosis [167]. Adipose tissue secretes inflammatory cytokines, such as TNF-α, which 
in turn contribute to impaired glucose tolerance, insulin resistance, and T2DM. The 
TNF-α cytokine is produced by different kind of cells (macrophages, monocytes, T-
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cells, smooth muscle cells, adipocytes, and fibroblasts). In animal models, 
administration of TNF-α led to severe impairment of glucose tolerance and insulin 
sensitivity [168]. TNF-α has emerged as an important contributor to the development of 
atherosclerotic lesions, by promoting the expression of adhesion molecules on 
endothelial cells, recruitment and activation of inflammatory cells and initiation of the 
inflammatory cascade inside the arterial wall. Has been demonstrated that TNF-α 
directly interferes with the metabolic pathways of TGs and cholesterol and the 
development of dyslipidaemia, insulin resistance, metabolic syndrome and 
cardiovascular diseases [169].  
Secondly, TNF-α is able to induce proatherogenic changes in lipoproteins and 
influences the lipid metabolism. This action has been seen in patients with acute and 
chronic inflammatory disorders, such as sepsis and AIDS. Both pathologies, in which 
increased TNF-α concentrations occur, have been shown to have increased TG 
concentrations.  Also, the administration of TNF-α and endotoxin (LPS) to mice and 
humans resulted in an acute TNF-α induced hypertriglyceridemia in several studies. 
The effects of TNF-α on plasma triglycerides concentration occur through effects on 
both adipose tissue and liver triglycerides metabolic pathways. Besides increasing the 
concentration of TG-rich VLDL particles, TNF-α may also alter their composition, 
making them proatherogenic[170]. TNF-α is also involved in the cholesterol metabolism 
although the mechanisms are nor clear, high concentrations of TNF-α have been 
correlated to a reduction of HDLc concentrations and may decrease hepatic cholesterol 
catabolism and excretion [171]. 
Finally, TNF-α, by decreasing insulin sensitivity, interferes in the glucose 
metabolis[172]. Obesity has been proved as a state of low-grade chronic inflammation 
with increased concentrations of C-reactive protein, IL-6, and other inflammatory 
markers in plasma. Consequently other authors investigated the interaction between 
inflammation, TNF-α and diabetes. In 1993, TNF-α was the first inflammatory marker 
demonstrated to be involved in the pathogenesis of insulin resistance [173]. It was 
demonstrated that adipocytes became insulin-resistant when exposed to TNF-α by 
inhibiting the insulin-stimulated tyrosine kinase activity of the insulin receptor [174]. The 
TNF-α also stimulates lipolysis in the adipose tissue, thus increasing the plasma 
concentration of the free fatty acids that eventually contributes to the development of 
the insulin-resistant phenotype. All these factors contribute to the fact that TNF-α was 
also correlated to endothelial dysfunction [175]. 
 




Adiponectin is a cytokine, “adipokine”, produced almost exclusively in adipose tissue. 
Its concentrations are higher in healthy individuals and decline in pathological and 
inflammatory conditions such as diabetes, hypertension, obesity and cardiovascular 
pathologies inversely to TNF-α levels [176, 177]. Low adiponectin levels are inversely 
related to high levels of inflammatory markers, such as C-reactive protein (CRP), in 
patients with obesity, type 2 diabetes, and cardiovascular diseases [178].  
 
Fig. 2.5: In healthy individuals, adiponectin maintains anti-inflammatory properties. 
Cardiometabolic pathologies where adiponectin levels decrease result in pro-
inflammatory signalling and exacerbation of disease. 
Adiponectin inhibits the expression of TNF-α in adipocytes, and likewise, both TNF-α 
and IL-6 inhibit the production of adiponectin [173]. Negative regulation of adiponectin 
expression also results from hypoxia and oxidative stress . In cardiometabolic patients, 
adiponectin levels are decreased, and the ability of adiponectin to inhibit the 
inflammatory processes becomes limited. Hypoadiponectinemia also contributes to 
insulin resistance, impaired endothelium-dependent vasodilatation, impaired ischemia-
induced neovascularization, hypertension progression, and diastolic heart failure [70, 
174-176].  
Thus, adiponectin mediates protective effects cardio-metabolic and vascular disease 
presumably by its anti-inflammatory actions and protects the heart against ischemia-
reperfusion injury through its ability to suppress myocardial inflammation and apoptosis 
[177]. 




IL-6 is a multifunctional signalling cytokine which modulates responses to 
cardiovascular diseases and an independent indicator of vascular homeostasis. IL-6 is 
produced by a wide variety of vascular cells, including macrophages, lymphocytes, 
fibroblasts, endothelial cells and smooth muscle cells, and its secretion is up-regulated 
in response to inflammation, angiotensin II, oxidative stress, endothelial damage and 
vascular injury. IL-6 upregulates AT1R gene expression, it leads to increased 
angiotensin-mediated vasoconstriction and ROS production, and thereby plays an 
important role in mediating endothelial dysfunction. Consistent with this idea, it was 
observed that IL-6 deficiency protects against angiotensin-induced endothelial 
dysfunction [179, 180].  
As an inflammatory factor, IL-6 promotes macrophage differentiation, growth arrest and 
eventual apoptosis. IL-6 stimulation causes these cells to increase in size, develop 
irregularly shaped nuclei, larger vacuolar cytoplasm and become surface adherent 
inducing thrombosis. Through direct membrane receptor or trans-signaling modalities, 
IL-6 has diverse actions including modulating endothelial-dependent vasorelaxation, 
monocyte differentiation, platelet function, pro-coagulant state, myocardial hypertrophy, 
and effects on obesity and intermediary metabolism [181]. 
IL-6 levels are positively correlated to cardiovascular risk and myocardial re-infarction, 
obesity, diabetes, metabolic syndrome and inversely correlates with AHA functional 
classification, ejection fraction, and survival [182]. IL-6 has actions locally in the vessel 
wall in coronary atherosclerotic plaques interacting with angiotensin-stimulated vessels. 
Here, IL-6 is predominantly expressed by fibroblasts and activated macrophages in the 




. IL-10 has been considered the prototype of anti-inflammatory interleukins [184]. 
Contrarily to the previously mentioned pro-inflammatory cytokines, IL-10 acts as an 
endothelial protector. Its effector functions include a shift of T-cell cytokine expression, 
down-regulation of the production of pro-inflammatory cytokines by macrophages and 
represent the autocrine negative feed-back and cross-talk inhibition of cytokine 
signalling. IL-10 inhibits the induction of the pro-inflammatory cytokines such as TNFα 
and IL-6. IL-10 also enhances B cell survival, proliferation, and antibody production. 
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Moreover, IL-10 reduces vascular injury by its paracrine effect mediated by modulation 
of immune function by reduction in inflammatory gene expression [185].  
IL-10 is expressed in human atherosclerotic plaque reducing atherogenesis and 
improving the stability of plaques. Increased IL-10 serum levels are associated with 
improved systemic endothelial vasoreactivity in patients with coronary artery disease 
[186]. Besides this, IL-10 has been linked to myokines showing that exercise promotes 
an increase in circulating levels of IL-10 and fosters an environment of anti-
inflammatory cytokines. Therefore, IL-10 levels have been inversely associated to 




As cardiovascular risk marker, Lp(a) was a lipoprotein subclass discovered by Berg in 
1963. Genetic and epidemiologic studies have identified Lp(a) as a risk factor for 
cardiovascular diseases.  Lp(a) consists of an LDL-like particle and the specific 
apolipoprotein(a), which is covalently bound to the apoB of the LDL-like particle. The 
mechanism and sites of Lp(a) catabolism, but the kidney has been identified as playing 
a role in Lp(a) clearance from plasma and Apo(a) is expressed by hepatocytes [188]. 
Lp(a) as atherogenic carrier attracts inflammatory cells to vessel walls, reduces 
plasmin generation and leads to inflammation and smooth muscle cell proliferation. Its 
association with proteins of the acute phase response has been demonstrated [189]. 
Among its main functions, Lp(a) contributes to the process of atherogenesis. The 
macorphages low density lipoprotein receptor mediates de Lp(a) catabolism via 
endocytosis and lysosomic degradation leading to macrophagic accumulation of lipids. 
Lp(a) promotes endothelial dysfunction via selective impairment of vasodilation, binding 
extracellular matrix components and oxidizing LDLc [190]. Lp(a) also leads to 
thrombogenesis due its structural similarity to plasminogen stimulates PAI-1 secrection 
[191]. Moreover, Lp(a)‟s competitive inhibition with fibrinogen reduces fibrinolysis. Lp(a) 
also binds to macrophages via a high-affinity receptor that leads to foam cell formation 
and the deposition of cholesterol in atherosclerotic plaques. 
High Lp(a) has become a new modest independent predictor of atherosclerosis, 
especially myocardial infarction, and a coagulant risk of plaque thrombosis indicator 
after adjustment for traditional cardiovascular risk factors [192]. Lp(a) is also associated 
with unstable angina and complex coronary lesions, suggesting a possible role in 
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plaque rupture and coronary thrombosis. In patients with an acute coronary syndrome, 
Lp(a) concentrations predict increased risk of cardiac death [193]. The European 
Atherosclerosis Society recommended to measure Lp(a) levels in patients with 
moderate or high cardiovascular risk. 
 
 
2.7.3.2. Oxidative stress markers: TAP, homocysteine. 
 
Total antioxidant capacity of plasma (TAP): 
Oxidant factors, such as superoxide anion (O2-) and hydrogen peroxide, are produced 
in the body as a consequence of normal aerobic metabolism. These oxidant molecules 
interact with reactive oxygen species (ROS). Under normal physiologic conditions, the 
production of oxygen free radicals and peroxides is balanced by a system of 
antioxidants preventing oxidative damage [194]. The plasma capacity to scavenge 
ROS is measured by the TAP.  
At the cellular level, enzymatic antioxidants, such as superoxide dismutase and 
catalase, convert ROS to oxygen and water. Several non-enzymatic antioxidants, such 
as vitamins E and C, also tackle free radicals. In chronic inflammation, atherosclerosis, 
the free radicals are presented in excess leading to the pathologic condition of 
oxidative stress [195]. Measurement of the combined enzymatic plus non-enzymatic 
antioxidant capacity of plasma  provides an indication of the overall capability to 
counteract reactive oxygen species (ROS), resist endothelial oxidative damage and 
combat oxidative stress. 
TAC has been inversely related to the presence of obesity diabetes, metabolic 
syndrome insulin resistance, intima-media thickness and cardiovascular diseases [196-
198]. Antioxidants inhibit lipid peroxidation and therefore play a protective role in the 
development of cardiovascular disease by preventing the formation of early 
atherosclerotic lesions. Plasma concentrations of individual antioxidants could be 
measured separately in laboratory, but these measurements are time-consuming and 
costly. Therefore, since antioxidant effects of antioxidant components of plasma are 
additive, several methods have been developed to determine the total antioxidant 
plasma status [199].  




Hyperhomocysteinemia has been described as high levels of Hcy in blood. 
Etiologically, hyperhomocysteinemia is the consequence of a genetic disorder, certain 
drugs or related to nutritional deficiency in vitamins B6, B9 and B12. Hcy 
concentrations can be reduced by vitamins supplements.  
Hyperhomocysteinemia has been associated with cardiovascular pathology. Hcy has 
atherogenic and prothrombotic properties, promotes intimal thickening, elastic lamina 
disruption, smooth muscle hypertrophy, marked platelet accumulation, and the 
formation of platelet-enriched occlusive thrombi [200]. Supplements with folic acid 
lower Hcy concentrations and reduce endothelial dysfunction [201] and oxidative stress 
[202, 203]. Hyperhomocysteinemia screening has been recommended in Canada for 
people at moderate CVD risk. 
Hcy promotes vascular injury by recruiting leukocytes, up-regulating pro-inflammatory 
interleukines expression and secretion[204], interacting with LDLc and macrophages 
activation which release the lipids into atherosclerotic plaques  and increasing smooth 
muscle cell proliferation and enhances collagen production [205]. Hcy is also a pro-
thrombotic factor inhibiting plasminogen activation, heparin sulphate and endothelium-
mediated platelet-aggregation inhibition [206]. Evidence shows that 
hyperhomocysteinemia is a risk factor for venous thromboembolic disease (pulmonary 
embolism and deep vein thrombosis) [207, 208].  
 
Thiobarbituric acid reactive substances (TBARS)  
TBARS are formed as a byproduct of lipid peroxidation, which can be detected by the 
TBARS assay using thiobarbituric acid as a reagent. The TBARS assay has been 
assessed as an indicator of oxidative stress in a multiple cardiovascular disease 
models [209].  
In vivo, plasma TBARS concentration can be normalized through supplementation with 
various antioxidants [201]. TBARS were found to be elevated in the serum of cigarette 
smokers, patients with documented coronary artery disease and carotid atherosclerotic 
plaque progression. Serum levels of TBARS could predict major cardiovascular events 
and the need for a major vascular procedure independently of traditional risk factors. 
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Animal and human studies therefore support a potential role of lipid oxidation in 
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3. Hypothesis and objectives 
 
3.1 Hypothesis 
C3 complement levels are positively correlated to higher cardiovascular risk and 




1. Assess the parallelism between C3 complement levels and cardiovascular risk 
score amongst the Spanish population (REGICOR).  
 
Secondary  
1. Assess the role of C3 complement as a counterpart of the inflammatory 
cascade in correlation to other inflammatory markers. 
2. Study the correlation of C3 levels with insulin resistance as measured by the 
HOMA model. 
3. Evaluate the C3 levels‟ correspondence with metabolic syndrome criteria. 
4. Examine the C3 convertase measurement parallelism with classical 
cardiovascular factors in cardiovascular risk prognosis. 
5. Analyse the role of C3 complement as an oxidative stress marker and its 
interrelationship with other oxidative stress markers. 
6. Appraise the correspondence between C3 complement measurements with 
endothelial damage biomarkers. 
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4. Material and methods 
 
4.1. Study design  
An observational, cross-sectional, retrospective study was designed. For the initial 
database, we selected all participants who were referred to secondary cardiometabolic 
care at the ECMU during their first visit between December 2002 and September 2012 
and had their C3 complement levels measured. 
This research was designed to evaluate the aforementioned objectives. The study 
sample population was selected from an original cohort of n=776 according to the 
exclusion objectives (figure 5.2). 
Study design and population diagram: 
  
Figure 4.1: Study design inclusion and exclusion criteria’s flow chart obtaining the 
baseline population sample. 
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4.2. Study population 
 
Our cohort evaluated consisted of patients from the Endothelium and Cardiometabolic 
Medicine Unit (ECMU) at Ramon y Cajal University Hospital (Madrid, Spain). 
The random sample included Spanish individuals from the province of Madrid referred 
to cardiometabolic secondary care from primary care, plus voluntary healthy first-
degree family members of these cardiovascular pathology patients. The group of 
patients referred to secondary care comprises a heterogenic cluster of cardiometabolic 
pathologies and healthy individuals including the following: diabetes, dyslipidaemia, 
hypertension, obesity, MetS, first-degree family history of early coronary disease 
(parents or siblings), coronary, cerebral or peripheral established atherosclerosis, 
precocious menopause (<40 years), hyperferritinemia (exception: alcoholism in activity) 
and voluntary healthy family members.   
All the individuals studied were of Spanish and South American origin, both Caucasian.  
 
Exclusion criteria  
i) Subjects under age (younger than 18 years old).  
ii) Individuals having CRP values >15 mg/L, given that extreme CRP values are 
usually not associated with cardiometabolic disorders [211].  
iii) Patients with a history of current infection in the month preceding the study, such 
as acute hepatitis. 
iv) Chronic systemic inflammation or rheumatologic chronic diseases were not elicited, 
such as renal impairment with creatinine levels higher than 2 mg/dl, chronic 
rheumatologic disease, HIV, active cancer under treatment protocol, kidney, 
pulmonary or liver disease. 
v) Type 1 diabetes and LADA, because of their different genetic characteristics, 
metabolic and cardiovascular morbidity behaviour. 
vi) Participants with previous or current cardiovascular event such as history of 
myocardial infarction, angioplasty, coronary artery bypass or cerebrovascular 
ischemia/stroke, symptomatic congestive heart failure, atrial flutter or unstable 
angina, because the aim of this study is the primary prevention of cardiovascular 
events.  
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vii) Subjects with outlier C3  complement values, according to Reed‟s theory, 
establishing 1/3 ratio as a cut-off value, where observed values smaller than one-
third of the range R, to avoid bias from outlaying observations [212].  
viii) Additionally, any other condition that could interfere with study participation, such 
as pregnancy, alcohol or drug abuse and severe neurological or mental disorder. 
After the inclusion and exclusion criteria were applied, the resulting sample contained 
374 participants in primary cardiovascular prevention, free from cardiovascular events. 
 
4.3. Ethics 
The study conformed to the principles embodied in the Declaration of Helsinki 
(Appendix 10.2) and conducted in accordance to the research activity within the clinical 
routine of the ECMU. The researches at the unit follow the ethical guidelines of Good 
Clinical Practice (GCP) of the International Committee on Harmonization (ICH) and the 
law Biomedical Research (14/2007 of 3 July). Verbal informed consent was obtained 
from all study participants after having listened to an explanatory note about the 
ongoing scientific researching characteristics of the service before study enrolment.   
Following the 15/1999 Spanish Personal Data Protection Law, the patents included in 
the study were informed of their right of access, rectification and deletion of data. In 
case of publication of the study results, the identity of the participants would not be 
disclosed. 
Participants in this study did not receive any form of compensation for their 
participation. There are no declared conflicts of interest. 
 
4.4. Measurements of variables 
 
4.4.1. Demographic variables 
In both studies, the participants‟ age was measured in years and gender was divided 
between males and females.  
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4.4.2. Anthropometric parameters 
 
i) Weight was measured without shoes in light indoor clothes using a scale in 
kilograms (Kg).  
ii) Waist circumference was measured with a tape (Roche LI95 63B 00; Roche 
Diagnostics, Mannheim, Germany), with the subject standing and wearing only 
underwear, at the level midway between the lower rib margin and the iliac crest 
(centimetres).  Waist circumference high risk threshold for high risk population 
followed the Regicor and ATP-III recommendations >102 cm for male patients 
and >88 cm for female patients. 
iii) Height was measured in centimetres (cm) using an upright scale which 
consisted of a scale platform, a height scale, a height rod and a balance scale 
validated by the European Community standards. 
iv) Body mass index (BMI) was calculated as weight divided by height squared, in 
kilograms per square meter (kg/m2). BMI measurements were divided into 
normal weight (18-25), overweight (25-30) and obese (>30), according to the 
WHO recommendations. 
 
4.4.3. Haemodynamic parameters 
 
i) Blood pressure (BP) was measured in the sitting position on the right arm, and 
the mean of 2 recordings at least 3 minutes apart was recorded with OMRON 
705 CP device, after 5 min of rest in the seated position. Each measurement of 
BP included systolic and diastolic blood pressures (SBP and DBP), considering 
the threshold for high blood pressure measurements >135/85 mmHg according 
to the ATP-III recommendations.  
ii) Mean Arterial Pressure (MAP) describes the average blood pressure of an 
individual during a single cardiac cycle. It is determined from the following 
formula using the diastolic (DBP) and systolic (SBP) blood pressures previously 
measured: MAP=DBP + 1/3 (SBP-DBP). 
iii) Pulse pressure was calculated as the result from the difference between the 
systolic and diastolic pressure readings.  
iv) Heart rate (HR) was recorded with OMRON 705 CP device, after 5 min of rest 
in the seated position on the right arm. 
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4.5. Personal Medical History (PMH) 
 
 
PMH including age (years), gender, previous diseases and allergies, 1st-degree family 
history of CVD (parents or siblings before the age of 55 years for men and 65 years for 
women), as well as physical inactivity (< 90 min/week of walking), smoking status, 
treatments and surgeries were recorded at baseline examination by a doctor at the 
ECMU during the first visit. Self-reported cigarette smoking status was categorized into 




4.6. Laboratory measurements and formulas 
 
Overnight fasting blood samples were processed within 90 min of blood collection. 
Then, fasting serum concentrations of total cholesterol, triglycerides, HDL cholesterol, 
fasting glucose, creatinine and uric acid were measured (Hitachi Automatic Analyser).  
The table 4.1 lists the measured biochemical parameters, units and method of measure 
at the Ramon y Cajal hospital general laboratory. 
LDL-cholesterol was estimated indirectly with the Friedewald equation. The LDLc was 
analysed directly by the laboratory when chylomicrons were present and when plasma 
triglyceride concentration exceeded 400 mg/dL to avoid the limitations of the 
Friedewald equation. 
The homeostatic model assessment score was calculated following the given formula: 
HOMA score = Fasting insulin (µU/mL) x fasting plasma glucose (mmol/L)/22.5. 
The cardiovascular laboratory is located at the service of The Endothelium and 
Cardiometabolic Medicine Unit (ECMU). The ECMU, which is part of the Internal 
Medicine Service of the Ramón y Cajal Hospital, was conceived in 1998, the same 
year that the first researchers on endothelium pathology were awarded with the 
medicine Nobel Prize. The ECMU is a unit with clinical and research activity [213]. 
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Currently the unit is composed of a multidisciplinary group of professionals, doctors, 
nurses, nutritionists, geneticists, biologists, biochemists and engineers.  
General laboratory. Biochemistry parameters Units Measurement method 
CRP mg/L Behring nephelometer 
Albuminuria mg/24h Nephelometry 
Aldosterone ng/dL RIA Inmunotech 
Creatinine mg/dl HITACHI autoanalyser 
Complete Blood Count  
(polimorphonuclear leukocytes and monocytes) 
n x 103/µl GEN-S Coulter 
HDLc mg/dl HITACHI autoanalyser 
Triglycerides mg/dl HITACHI autoanalyser 
Fasting glucose mg/dl HITACHI autoanalyser 
Ferritin  µg/dl MSSA 
Fibrinogen mg/dl Behring System 






HPLC (High pressure 
liquid chromatography) 
LDLc mg/mL Friedewald formula 
Uric acid mg/dl HPLC 
Table 4.1: Biochemistry parameters measured at the hospital general laboratory, units 
and methodology.  
Vascular damage is assessed in daily clinical practice by: determining 22 
cardiometabolic risk biomarkers measurements at ECMU laboratory (inflammation, 
endothelial dysfunction, oxidative stress, chemokines and adhesion biomarkers), 
general blood indicators measured at the hospital general laboratory,  blood pressure 
and glycaemia ambulatory monitoring, five non-invasive hemodynamic examinations 
(SphygmoCor, EndoPat, DRT4, FMD-Celermajer, transcranial Doppler), indicators of 
atherosclerosis AAI (ankle arm index) and AIT (arterial intima thickness) and the 
evaluation of cardiorespiratory fitness. 
At the ECMU laboratory, focussed in cardiovascular and metabolic risk, whole blood 
was collected into anticoagulant-treated tubes (e.g., EDTA-treated or citrate-treated). 
Blood samples were clotted and centrifuged prior to testing. The cells where removed 
C3 convertase as a novel biomarker of cardiovascular pathology, insulin resistance and endothelial dysfunction  
81 
 
from plasma by centrifugation for 10 minutes at 1000 –2000 × g using a refrigerated 
centrifuge. The platelets were depleted by centrifugation for 15 minutes at 2000 × g.  
The supernatant plasma was transferred into 0.5mL aliquots using a Pasteur pipette. 
The aliquots were stored at -80ºC for assessment of biomarkers. Biomarkers were 
measured using commercial cytokine enzyme-linked immunosorbent assays.  
The complete list of biomarkers measured in daily practice in the ECMU laboratory and 
used in this research is displayed in more detail in the table 4.2. 
ECMU laboratory 
Biochemical parameters 
Units Measurement method 
Adiponectin µg/ml Elisa Thermofisher 
Antioxidant capacity of plasma(TAC) μM  Copper Reducing Equivalents. 
Colorimetry 
Complement C3 mg/dl Nephelometry 
Complement C4 mg/dl nephelometry 
Homocysteine (Hcy) µM/L IMX, Abott 
Interleukin-6 (IL-6) pg/ml Chemiluminescent /Immunometric 
Assay. Immulite.DCP Labs 
Interleukin-10 (IL-10) pg/ml Chemiluminescent /Immunometric 
Assay. Immulite.DCP Labs 
Insulin (in blood) µU/mL Inmunometric assay. Inmulite.DCP 
Lipoprotein-a (Lpa) mg/dL NLatex Lp(a) Reagent 
Plasminogen activator inhibitor-1 (PAI-
1) 
ng/ml ELISA Meranini 
Thiobarbituric acid reactive 
substances (TBARS) 
μM/L Cayman 
Tumoral necrosis factor (TNFα) pg/ml Chemiluminescent /Immunometric 
Assay. Immulite. DCP Labs 
Tissue Type Plasminogen Activator 
(tPA) 
pg/ml ELISA Eiboscience 
VCAM ng/ml ELISA Menarini 
 
Table 4.2: parameters measured at the ECMU laboratory on clinical routinely basis, 
units and used methods. 
 
C3 complement levels in plasma, main variable of this research, were measured from 
the stored aliquots by human competitive ELISA kit. A C3 complement specific 
antibody was pre-coated onto well plates and blocked. Standard plasma samples were 
added to the wells which included C3 complement detection proteins. The plates were 
washed with buffer solution. Streptavidin-Peroxidase Conjugate was added and 
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unbound conjugates were washed away with a second wash buffer. Chromogen 
solution was added and catalysed by Streptavidin-Peroxidase enzymatic reaction 
producing visible blue colour that changes into yellow after adding acidic stop solution. 
The density of yellow coloration was inversely proportional to the amount of C3 
complement captured in plate. The procedure is summarized in the figure 4.2. 
 
 
Figure 4.2: Summary of the nephelometry procedure to measure C3 complement 
concentrations by ELISA. Modified from Abcam ELISA kit manual. 
 
4.6.1. Inflammatory biomarkers measurement methods 
Inflammatory markers, such as PCR and fibrinogen, provide us with information about 
the degree of vascular inflammation. Beside the classical inflammatory markers, 
adipokines and cytokines (IL-6, adiponectin, IL-10hs and TNF-α) are released by the 
fat cells and / or vascular stroma in close contact with fat. These new inflammatory 
markers report the degree of inflammation of active adipose tissue (abdominal obesity). 
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Adiponectin and IL-10 are considered anti-inflammatory, anti-aggregant and anti-
hyperglycaemic markers. However, TNF-α and IL-6 are considered pro-inflammatory, 
pro-aggregative and hyperglycaemic markers. 
Adiponectin concentration in plasma aliquots is measured by enzyme-linked 
immunosorbent assay (Thermofisher® ELISA kit). The ELISA kit is based on solid 
phase sandwich Enzyme Linked-Immuno-Sorbent Assay.  
An antibody against the specific antigen is coated onto the wells of the microtiter strips. 
During the first incubation, samples are added to the coated wells to allow the antigen 
from the samples to bind to the immobilized (capture) antibody. After washing, an 
antigen-specific human antibody is added that binds to the immobilized antigen 
captured. After removal of excess detection antibody, a horseradish peroxidase 
enzyme is added. This binds to the detection antibody to complete the four-member 
sandwich. After a second incubation and washing to remove all the unbound enzyme, a 
stabilized substrate solution is added, which is acted upon by the bound enzyme to 
produce colour. The intensity of this coloured product is directly proportional to the 
concentration of antigen present in the original specimen. This process is illustrated in 
the figure 4.3.  
 
Figure 4.3: Pictogram of the adiponectin concentration measurement procedure by 
ELISA sandwich method. 
 
Interleukin-6 and interleukin-10 concentrations (IL-6, IL-10) were measured by an 
immunometric method. DPC IMMULITE immunoassay system uses enzyme-amplified 
chemiluminescence chemistry for the detection of IL-6. INMULITE device comprises 
several subsystems to process the assay tube minimizing human errors. After loading 
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a carousel with alkaline phosphatase-labelled reagents, followed in each case by an 
assay tube, the assay tubes are transferred to the incubation carousel. The alkaline 
reagent initiates the reaction and the tubes are intermittently agitated during incubation. 
After incubation, the assay tubes are shuttled to the wash station. A chemiluminescent 
substrate for alkaline phosphatase is added and the tubes are transferred to the 
luminometer. The light output is measured with a photomultiplier tube in the photon-
count. Counts are converted to analysed concentration by use of stored standard 
curves.  
Tumoral necrosis factor (TNF-α) concentration in plasma was measured by 
chemiluminescent-immunometric assay (Immulite® DCP Labs ELISA Kit) following the 




Figure 4.4: Summary of the laboratory technical procedure steps to measure TNF-α 
concentration, modified from DCP Labs manual. 
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4.6.2. Endothelial damage measurement methods 
Endothelial peptides values, such as PAI-1 and TPA, are related to endothelial damage 
by any of the classical cardiovascular risk factors (hypertension, smoking, 
dyslipidaemia, hyperglycaemia, etc). Chemokines and adhesion molecules, such as 
VCAM-1, were also activated in the early stages of endothelial dysfunction and 
responsible for the infiltration of the monocyte into the wall. Meanwhile, nitric oxide 
measurement was considered a controversial technique for this research because its 
concentrations were not reliable due to its instability in frozen samples. 
PAI-1 antigen (Imulyze) was assayed by ELISA using kits from Biopool-Menarini. PAI-1 
is synthesized and secreted by many tissue and cell types. Free PAI-1 is relatively 
unstable in its active form and readily converts into a latent, inactive form; however, 
binding of vitronectin to PAI-1 stabilizes the active form. The active form of PAI-1 binds 
tightly with tPA in a 1:1 ratio. After the formation of an initial docking complex, the 
proteases cleave the reactive central loop of PAI-1 to form a stable, covalent complex, 
resulting in the inactivation of the targeted serine protease. The ELISA protocol is 
similar to the ELISA kits for other variables explained above. 
Tissue Type Plasminogen Activator (TPA) in plasma was also measured by an 
ELISA kit. Specific antibodies were pre-coated onto the well plates and blocked. 
Streptavidin-peroxidase conjugate was added and unbound conjugates were washed 
away by buffer solution. TMB is catalysed by streptavidin peroxidase to produce a blue 
colour product that changes into yellow after adding acidic stop solution. The density of 
yellow coloration was directly proportional to the amount of TPA captured in plate. 
Vascular cell adhesion molecule-1 (VCAM-1) human solid-phase sandwich ELISA 
Kit quantified natural and recombinant soluble VCAM-1 in human serum. VCAM-1 is a 
member of the immunoglobulin gene superfamily. ELISA technical procedures were 
similar the ELISA techniques explained above. 
 
4.6.3. Oxidative stress measurement methods  
The increase of oxidative stress (OS) is one of the essential characteristics of 
endothelial damage. OS along with endothelial dysfunction and vascular inflammation 
form a triad in the initial phases of a prothrombotic status. OS can be measured by OS 
markers, such as total antioxidant capacity of plasma (TAP), thiobarbituric acid reactive 
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substances (TBARS) and homocysteine. The oxidative degradation, called lipid 
peroxidation, of lipids by reactive oxygen species (ROS) results in the formation of 
highly reactive lipid peroxides. Decomposition of lipid peroxides results in the formation 
of TBARS.   
The TBARS generated during oxidative stress were measured by a microplate-based 
TBARS Parameter Assay Kit which quantifies TBARS levels in plasma by setting up a 
reaction between MDA and two molecules of 2-thiobarbituric acid (TBA). In the 
presence of heat and acid, MDA reacts with TBA to produce a coloured end-product 
that can be measured. Intensity of the colour corresponds to the level of lipid 
peroxidation in the sample. This process is summarised in more detail in the figure 4.5. 
 
Figure 4.5: Summary of the TBARS measurement method by nephelometric assay. 
Step 1: Acid-treated samples and TBA reagent are added to the included well 
microplates. Step 2: The microplates are incubated at 45-50 °C for 2-3 hours to 
produce a coloured end product. Step 3: The microplates are read and the intensity of 
the colour corresponds to the level of lipid peroxidation in the sample (TBARS 
Parameter™ Kit for Measuring Oxidative Stress). 
 
Total Antioxidant Capacity (TAP) was measured by assessing the total copper 
antioxidant capacity of the combination of both small molecule antioxidants and 
proteins in plasma. Plasma samples are compared to a known concentration of uric 
acid standard within a 96-well microtiter plate.  Samples and standards are diluted with 
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a reaction reagent  upon the addition of copper.  Cu2+ ions are converted to Cu+ by 
both small molecules and proteins. The TAC Assay is based on the reduction of copper 
by antioxidants such as uric acid.  The reduced copper further reacts with a coupling 
chromogenic reagent that produces a color and gives a broad absorbance peak 
proportional to the total antioxidant capacity. The net absorbance values of antioxidants 
are compared with a known uric acid standard curve. Antioxidant capacity is 
determined by comparison with the uric acid standards.  
Homocysteine (Hcy) concentrations were measured by an automated latex-enhanced 
immunoassay for the quantitative determination of total L-homocysteine in human 
citrated plasma. Hcy levels in plasma were measured in three stages as explained in 
the figure below. The degree of agglutination is inversely proportional to the 
concentration of Hcy in the sample and is determined by measuring the decrease of 
transmitted light caused by the aggregates (figure 4.6) 
 
 
Figure 4.6: Stages of Homocystein measurement: 1. Reduction of mixed disulphides 
and protein-bound forms of Hcy present in the plasma samples to free Hcy. 2. 
Enzymatic conversion of free Hcy to S-adenosyl-L-homocysteine in the presence of 
adenosine. 3. SAH-antibodies conjugate allows competitive immunoprecipitation 
reaction between anti-SAH latex and free SAH/conjugate. Modified from HemosIL® 
Homocysteine manual. 
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4.7. Variables Definitions 
 
4.7.1. Metabolic syndrome 
Complete metabolic syndrome [214] diagnosis was met when at least three of five of 
the ATPIII criteria listed below were present.  
Incomplete metabolic syndrome diagnosis for this study was met when one or two 
ATPIII SM criteria were present.  
A healthy individual, metabolic syndrome-free, was defined when none of the ATPIII 
criteria were present. 
 
i) Abdominal obesity, recognized by increased waist circumference, was the first 
criterion listed when waist circumference was greater than 88cm (women) or 
102cm (men).  
ii) Patient with raised triglycerides (≥150 mg/dL) and/or treated with fibrates or 
nicotinic acid. 
iii) Individual with reduced HDL cholesterol (men <40 mg/dL, women <50 mg/dL) 
and/or under lipid lowering treatment. 
iv) Elevated blood pressure (≥130/85 mm Hg) and/or under antihypertensive 
treatment. 




4.7.2. Homeostasis model assessment of insulin resistance 
(HOMA-IR)  
Homeostatic Model Assessment (HOMA) is a method for assessing β-cell function and 
insulin resistance (IR) from basal (fasting) glucose and insulin or C-peptide 
concentrations. Insulin resistance was calculated with standard methods [215] HOMA-
IR using an approximation described by a simple equation to determine a surrogate 
index of insulin resistance: 
 




The denominator of 22.5 is a normalizing factor. This factor is determined by the 
normal individual results: the product of normal fasting plasma insulin of 5 μU/ml and 
normal fasting plasma glucose of 4.5 mmol/l typical of a “normal” healthy individual = 
22.5 (assuming normal-weight, normal subjects < 35 years, having 100% β-cell 
function an insulin resistance of 1). Therefore, for an individual with “normal” insulin 
sensitivity, HOMA-IR = 1.   
Glucose and insulin are both analyzed during fasting basal conditions. Log (HOMA-IR) 
is useful for evaluation of insulin resistance in individuals with glucose intolerance, mild 
to moderate diabetes, and other insulin-resistant conditions. However, in subjects with 
severely impaired or absent β-cell function, HOMA-IR may not give appropriate results. 
To avoid this eventuality we used the HOMA2 adjusted computer system. HOMA2 
adjusted the assessment of previous HOMA in subjects with glucose levels ≤25 mM, 
accounts for renal glucose losses, assumes reduced suppression of HGP and 
increased insulin secretion in response to glucose levels >10 mM, and allows for the 
use of total or specific insulin assays.   
Despite this improvement with HOMA2, for the secondary objectives studies, which 
imply insulin resistance calculation, patients under exogenous insulin treatment had to 
be excluded (n=54). The assumptions about hepatic extraction included in the model 
do not apply when a subject is being treated with exogenous insulin. The insulin-





The REGICOR model calibrates and adjusts the Framingham CHD functions for 
Spanish population in cardiovascular primary prevention by substituting the prevalence 
of CHD risk factors and incidence found in Framingham with the same values for 
Spain. The REGICOR model replaces the incidence of the Framingham equation with 
the data observed in the population of Gerona through the REGICOR population-based 
registry of cardiac disease in 1995.  
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The data observed in REGICOR were validated for the entire Spanish population 
through the VERIFICA study. Studies with REGICOR have enabled the variables 
included in the Framingham equation to be refined by including antihypertensive and 
lipid-lowering therapies. The REGICOR model estimates the 10-year probability of 
developing a CHD event according to the risk factor profile and HDL levels ranging 
from 35 to 59 mg/dl. Tables with the general model of all the Framingham coronary 
events were calculated using the equation published in 1998 by Wilson et al. that 
follows the described calibration method. The following ratio was used:  
 
H0(t)/FramAll / H0(t)/FramHard 
 
Where t is the follow-up time, 10 years in our case; H0(t)/FramAll is the coronary event 
rate including Framingham angina and silent AMI, and H0(t)/FramHard is the rate of 
symptomatic AMI, fatal or non-fatal. The heart event rate in males of Girona in the 
REGICOR registry (3.5%) is multiplied by 1.400 to obtain an estimated total coronary 
event rate (4.9%). This allows calculation of 95.1% male population without events 
(100-4.9%). In females the hard event rate (1.1%) is multiplied by its quotient (1.910) to 
obtain the estimated total coronary event rate (2.2%).  97.8% female population 
resulted without events (100-2.2%). 
 
 In this study the cardiovascular risk in 10 years thresholds have been assigned as 
being <5% low cardiovascular risk, 5-10% moderate risk and >5% high cardiovascular 
risk, as established by the REGICOR model. Due to an insufficient number of high 
cardiovascular risk patients in some statistical analyses moderate and high risk 
patients are grouped as high cardiovascular risk patients.  
 
Two examples of REGICOR function color-coded charts for hazard intensities in the 
risk factor combinations for diabetic and non-diabetic of overall CHD risk for the 
Spanish population according to the adapted equation are presented in the figure 4.7. 
These are separated for male/female and diabetic/non-diabetic population. The tables 
below are calculated for average HDL cholesterol (47.5 mg/dL) in 35 to 74 year old 
Spanish males.  





Figure 4.7: Example of REGICOR cardiovascular color-coded charts in non-diabetic 
and diabetic men divided into smokers and non-smokers, where low risk represents 
<5% possibilities of suffering a cardiac event in ten years, moderate risk is between 5% 
and <10% and high risk is ≥10%. 
 
 
4.8. Data collection and coding methodology 
Data collection process 
Data were obtained by a detailed personal medical history of the previous years via a 
questionnaire developed by a permitted doctor following the privacy policies of the 
Ramon y Cajal Hospital. The physical examination of the cardiovascular system, 
electrocardiogram test if required and the non-invasive endothelial function were 
performed by a permitted physician offering a chaperone if required. Blood samples 
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were taken by a permitted nurse following the phlebotomy Ramon y Cajal hospital 
policies.  
The results of the tests mentioned above were extracted from medical records codified 
into ECMU numbers to preserve patients‟ privacy. Data were collected manually from 
printed reports to an intranet electronic database electronically secured by a permitted 
laboratory biologist and a permitted doctor between August 2010 and August 2013. 
Three permitted professionals, a doctor, a laboratory technician and an IT engineer 
reviewed the data base three times to reduce personal bias.  
 
4.9. Statistical data analyses 
Statistical analyses were performed using SPSS 15 for Windows (SPSS, Inc., Chicago, 
IL, USA).  
 
4.9.1. Descriptive analysis 
Qualitative variables were described as percentages. Quantitative continuous variables 
were determined as mean ± standard deviation (SD).  The confident intervals were 
95%. 
 
4.9.2. Hypothesis testing  
Prior to hypothesis testing, variables were examined for normality by Kolmogorov-
Smirnov test. Differences at baseline in quantitative variables were assessed by 
student t-test for independent samples for a normal distribution or Mann-Whitney test 
for non-normal distribution. Anova test was performed for comparisons of independent 
sample means of more than two groups. Differences in qualitative variables were 
assessed by chi-square test. The significance level predetermined p-value for 
differences between groups was agreed at 0.05. 
The correlation between C3 levels and several continuous analytical variables was 
studied by linear Pearson coefficient agreeing statistical significance at p<0.05.  
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Serum complement C3 was used as a continuous variable and as quartiles for logistic 
regression analyses to ascertain whether a threshold effect existed. The quartiles were 
calculated from the median forming cut points. For correlations, a value of P ≤0.05 on 
the 2-sided test was considered statistically significant. 
 
4.9.3. Association of variables 
 
A multivariable linear regression analysis corresponding to the outcome measure 
(dependent variable) was developed to identify predictors. Backward variable selection 
was used for modelling, with the standard significance level for contrasts P≤0.05. 
Independent variables associated with an outcome of P≤0.20 in univariate analysis 
were included in the corresponding multivariate model.  
 
The collinearity of the maximum models was assessed with the criteria proposed by 
Belsley [217]. Normality and homocedasticity assumptions in each final model were 
assessed by analysing model residuals. Model validation was evaluated by bootstrap 
techniques and leave-one-out cross-validation.  
 
The maximum predictive model was determined by C3 levels as the continuous 
dependant variable. The independent selected variables, were: age, gender, CRP 
levels, presence or absence or MS, low or high cardiovascular risk according to 
REGICOR model for Spanish population (<5% or >5% risk in 10 years), insulin 
resistance measured by HOMA, hyperhomocysteinemia, Lpa levels, smoking status, 
smoking status adjusted by age, presence or absence of MS ATPIII criteria for 
hypertriglyceridemia, high blood pressure, hyperglycaemia, waist, low HDL and 
hypercholesterolemia. The selection of the independent variables was made in relation 
to the previous univariate analysis results and their interest in the study objectives. 
 
Smoking status was included twice in the regression model, as independent sole 
variable (dichotomised smoking status) and adjusted by age (smoking status multiplied 




UAH, PhD program: D234 Medicine  Rodriguez-Guerrero, A 
94 
 
4.10. Literature review  
 
i) English and Spanish language only: time limits made the translation from any 
other language impractical.  
 
ii) Synonyms were limited to Thesaurus 
 
iii) The information sources were limited to : 
o PubMed, Medline, LSE‟s library, Ramon y Cajal Hospital‟s library, 
Mostoles Hospital‟s library and Google databases. The first three are 
included in EndNote bibliographic software and facilitate the quick 
reading of abstracts and literature classification.  
o Documents and grey literature located in Endothelial Pathology Unit‟s 
intranet, professionals‟ personal files compilation and archives of hard 
copies. 
 
iv) Literature published between 1992, when Muscari et al. [70] performed a study 
to assess the possible involvement of humoral immunity in essential 
hypertension and cardiovascular pathology, and December 2016 only. Some 
previous references are limited to definitions of terms included in more recent 
publications. 
 
v) Keywords: C3 complement OR/AND C3 convertase OR/AND metabolic 
syndrome OR/AND insulin resistance OR/AND cardiovascular risk OR/AND C-
reactive protein OR/AND endothelial function OR/AND inflammatory cascade 
OR/AND atherosclerosis OR/AND complement pathways OR/AND 
inflammatory markers  OR/AND endothelial dysfunction OR/AND C-reactive 
protein OR/AND Lp(a) OR/AND homocystein OR/AND fibrinogen OR/AND 
oxidative stress OR/AND Regicor OR/AND HOMA OR/AND multi-regression 
analysis OR/AND hyperlipidaemia OR/AND nitric oxide OR/AND  ATPIII criteria 
OR/AND hypertension OR/AND T2DM 
 
vi) After basic searches in Cochrane and Google, in September 2016, a similar 
recent study of C3 convertase relation to cardiovascular risk and endothelial 
function in Spanish population was not identified. 




vii) Search strategy algorithm: 
 
. 






Financial and personnel constraints limited the availability of tests and reactives for a 
certain length of time and the number of performed tests for the study. 
The overlap of active clinical routine as a physician on top of the research activity 
reduces the available time to develop the research and extended the timeline. 
The lack of resources (human and financial) in research and development limited the 
number of available tests throughout the research and also affected by the availability 
of reactants for ECMU laboratory. 
The calculation of cardiovascular risk would be more precise in treatment-free patients, 
but the incremented risk of cardiovascular events by removing indicated treatments in 
cardiometabolic patients is ethically controversial. 
 
 




4.12 Study timeline 
 
The data collection process started in August 2010, during the development of my 
doctoral advanced studies project until August 2013. The thesis project was submitted 
in October 2012. The literature, references review and writing processes were on-going 
routine in parallel with the thesis development. The statistical analysis progressed from 
October 2015 until August 2016, the results analysis between April 2016 and October 
2016, and the discussion slightly overlapped from August until February 2016. 
Conclusions, text formatting, style review, printing and submission were performed 
from December 2016 until March 2017 when the final paper was submitted (figure 4.9). 
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5. Results  
 
5.1. Population description 
The study population included a total of n=374 subjects, where 168 were females 
(44.9%). At baseline examination, the mean age of the overall population was 
53.6±14.8 years.  
Study sample population (n=374) N Percentages 
Gender Males 206 55.1% 
Females 168 44.9% 
Table 5.1: Gender distribution of the study sample population. 
The majority of patients were overweight (BMI≥25), dyslipidaemic (altered lipid profile) 




Mean ±SD Minimum Maximum 
Demography             Age (years) 53.60  ±14.80 19.70 90.70 
Anthropometry BMI (kg/m2) 27.10  ±4.70 17.30 49.52 
Waist (cm) Males 95.70 ±9.70 70 139 
Females 87.70 ±13.80 59 128 
Waist/hip ratio Males 0.95 ±0.06 0.77 1.20 
Females 0.86 ±0.09 0.66 1.09 
Haemodynamic  
 
SBP (mmHg) 133.33 ±20.13 87 205 
DBP (mmHg) 82.11 ±10.56 55 116 
Pulse Presure (mmHg) 55.22 ±16.68 21 134 
MAP (mean arterial pressure) 99.18 ±12.14 69.67 142.67 
Heart rate (bpm) 71.86 ±12.40 55 116 
Metabolism 
 
Fasting Glucose (FG) (mg/dl) 107.36 ±40.02 64 421 
A1c (%) 5.81 ±1.21 4 11.70 
Total cholesterol (mg/dl) 201.99 ±46.45 83 407 
LDLc (mg/dl) 128.09 ±41.47 25 316 
TG (mg/dl) 118,39 ±63.33 34 381 
HDLc Males  (mg/dl) 44.66 ±8.27 25 76 
Females (mg/dl) 56.76 ±13.14 29 105 
Table 5.2: Summary of baseline characteristics of the study sample population. Means 
were calculated from their clinical examination and basic blood test data with special 
interest in metabolic profile. Abbreviations: body mass index, BMI; systolic blood 
pressure, SBP; diastolic blood pressure; A1c glycosylated haemoglobin; DBP; low-
density lipoprotein cholesterol; LDLc; high-density lipoprotein cholesterol, HDLc; 
triglycerides, TG.
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5.1.1 Personal Medical History (PMH)  
 
The metabolic profile of our sample population showed a high prevalence of 
hypertension (55.1%), hypercholesterolemia (46%) and T2DM (27.8%) in their personal 
medical history (PMH). The distinctive feature of our sample population was the high 
proportion of basally diagnosed metabolic pathologies.  
Furthermore, the population exhibited a tendency to obesity where 23.5% patients 
were obese (BMI≥30 kg/m
2
) and 42% overweight (BMI ≥25-<30 kg/m2). In particular, 
we highlighted the prevalence of central obesity. The average waist-hip ratio in both 
genders (0.95 in men, 0.86 in women) overcame the upper recommended limit 
established by the WHO. These particular PMH characteristics of our population are 
displayed in more detail in table 5.3.  
Regarding smoking habits, 27.8% were active smokers and 25.1% former smokers (>3 
months smoking-free period). The forthcoming analysis pointed out that smokers were 




Personal medical history population variables 
Population (n=374) 
N Percentages 
PMH  Hypertension  206 55.1% 
Hypercholesterolemia (LDLc>160 mg/dl) 173 46.3% 
Low HDL-c (<40mg/dl males, <50md/dl females) 78 20.95 
Hypertriglyceridemia (TG>150mg/dl) 86 23.0% 
Type-2 diabetes mellitus 95 25.4% 
Obesity Obese (BMI>30 Kg/m
2
) 88 23.5% 
Overweight (BMI 25-30 Kg/m
2
) 157 42.0% 
Smoking habit Smokers 104 27.8% 
Ex-smokers 94 25.1% 
 
Table 5.3: Summary of the proportions of metabolic conditions presented in the 
patients’ personal medical history (PMH). There is a high prevalence of hypertension, 
dyslipidaemia, obesity and diabetes in the main sample population. Obesity degrees 
were calculated from BMI data. Abbreviations: low-density lipoprotein cholesterol,LDLc; 
high-density lipoprotein cholesterol, HDLc; triglycerides, TG; body mass index, BMI. 
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5.2 Metabolic Syndrome (MetS) and C3 complement 
 
In order to classify the population sample we stratified the population into three groups 
according to the number of ATPIII criteria met per patient.   
MetS criteria diagnosis comprised patients with ciphers over each criterion threshold 
and/or already diagnosed in their PMH and under treatment for each metabolic 
pathology. 35.3% of the sample population presented MetS (≥3 MetS-criteria), 49.7% 
suffered from incomplete MetS (1-2 MetS-criteria) and 15% were metabolically healthy 
population (MetS-criteria free). As observed in the table 5.4 and graph 5.1 the majority 
of patients suffered from incomplete or complete metabolic MetS. 
 
In addition to this first finding, we distributed the population into groups, from zero to 
five fulfilled constitutive factors of metabolic syndrome per individual. The population 
were distributed among all the groups, with representatives in all the categories (graph 


















Figure 5.1: Bar graph shows the stratification of our population by number of ATP-III 
metabolic syndrome (MetS) criteria met per patient. Complete metabolic Syndrome is 
displayed in red, incomplete MetS in yellow and healthy metabolic patients in green. 
 
 











None 56 15.0% 15% 
Incomplete 
MetS 
One 80 21.4% 49.7% 
Two 106 28.3% 
Complete 
MetS  
Three 75 20.1%  
35.3% Four 40 10.7% 
Five 17 4.5% 
 
Table 5.4: Percentages of subjects classified in healthy, incomplete and complete MetS 
according to the number of MetS criteria met per patient. 
 
 
Hypertension (65%) and hyperglycaemia (42%) resulted the most prevalent criteria 
when we analysed individually the constitutive factors of the metabolic syndrome; albeit 
all ATP-III criteria were also presented in a significant percentagein the sample 
population (central obesity 36%, low HDLc 35%, hpertriglyceridemia 26%), as shown in 
the table 5.5.  
 
ATP-III Metabolic Syndrome criteria (n=374) N Percentages 
1. Hypertension (BP >135/85 mmHg or under treatment for HBP) 244 65.2% 
2. Hyperglycaemia (fasting glucose >100mg/dl or under treatment for 
hyperglycaemia) 
156 41.7% 
3. Central obesity (waist ≥88cm in women and  ≥102cm in men) 133 35.6% 
4. Low HDLc (HDLc <40mg/dl in males, <50mg/dl in females or 
treated with diet and exercise) 
132 35.3% 




Table 5.5:  Percentages distribution of ATP-III metabolic syndrome criteria in the study. 
Hypertension (65.2%) and hyperglycaemia (41.7%) were the most prevalent 
characteristics. TG: triglycerides. 
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5.2.1. C3 levels and ATPIII criteria 
 
The first step of our study was to assess the correlation between C3 concentrations 
measured in blood and the presence of MetS.  
C3 complement was measured in all the subjects of our population sample (n=374). 
The descriptive statistical values were mean 129.65 (±26.02) mg/dl, minimum 62.00 
mg/dl and maximum 216.00 mg/dl respectively. 
Patients who suffer from metabolic syndrome had statistically significant higher 
concentrations of C3 complement than metabolically healthy patients (142.10±25.47 
vs. 122.88±20.68; p<0.001). Furthermore, the mean levels of C3 complement 
increased proportionally to the number of MetS criteria met per patient (p<0.001), as 
shown in table 5.6.  
C3 levels (mg/dl) per number of Metabolic Syndrome criteria  
MetS criteria  N Mean ±SD p-value 
0 56 106.85 ±20.14 <0.001 
1 80 120.22 ±19.69 
2 106 133.36 ±24.22 
3 75 136.53 ±22.60 
4 40 148.67 ±26.78 
5 17 151.00(±23.49 
 
Table 5.6 Distribution of the population (n=374) per number of MetS criteria met per 
patient. The mean value of C3 complement measurements per group of number of 
MetS criteria met, standard deviation within each group and significant difference 
among groups (p<0.001) 
 
 
The association between C3 and MetS criteria was barely linear, showing a strong 
positive linear correlation (Pearson coefficient r=+0.49, p<0.001). Linear correlation is 
also graphically represented in figure 5.3. Moreover, the representation of C3 
complement concentrations is in correlation to the number of MetS criteria fulfilled by 
patient appeared almost linear as shown in the graph 5.3. 
 
The outcome of this C3 concentrations increment was proportional to the number of 
MetS criteria. As seen in figure 5.2 and 5.3 the difference between the two and three 
criteria groups was noticeably shorter though. 
  




Figures 5.2 and 5.3: median graphs. The first one shows the almost linear correlation 
between C3 complement level means and the number of C3 criteria met. In the graph 
on the right, the C3 complement plasma concentrations are expressed per number of 












C3 complement (mg/dl) 
 
Mean ±SD Mean 
difference 
95%-CI of the mean p-
value Upper b. Lower  
b.  
MetS No 242 122.88 ±24.20 19.20 24.38 14.01 <0.001 




HTG No 277 124.45 ±24.41 20.07 25.76 14.38 <0.001 
Yes 97 144.52 ±24.84 
HBP No 130 119.41 ±24.91 15.69 21.02 10.37 <0.001 
Yes 244 135.11 ±24.98 
Low 
HDLc 
No 242 125.33 ±25.70 12.25 17.65 6.84 <0.001 
Yes 132 137.58 ±24.80 
T2DM No 218 124.21 ±24.89 13.04 18.25 7.83 <0.001 
Yes 156 137.26 ±25.74 
Central 
obesity 
No 241 123,70 ±24.47 16.68 21.95 11.42 <0.001 
yes 133 140.41 ±25.38 
 
Table 5.7: C3 complement concentrations’ means per presence or absence of MetS 
criterion. The presence of each Mets criterion is associated with higher C3 levels than 
absence. The MetS criteria presence/absence were calculated according to MetS 
criteria definitions described in table 5.5. Abbreviations: hypertriglyceridemia, HTG; 
hypertension, HBP. 
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The MetS group (≥3 MetS criteria, mean=142.08±24.71 mg/dl) presented higher levels 
of C3 complement than Mets-free group (mean=122.88±24.20 mg/dl; p<0.001). In 
addition to this, the presence of the MetS constitutive factors individually was also 
significantly associated (p<0.001) with higher concentrations of C3 complement as 
shown in table 5.7.  
 
 
5.3. Association between C3 inflammation and coagulation 
In the first place, the correlation between inflammatory markers and C3 complement 
levels in plasma was tested with C-reactive protein (CRP) concentrations. CRP 
measurements were obtained in all the subjects of the study population (n=374). CRP 
descriptive values were 2.89±2.12 mg/L), ranged from a minimum of 0.14 mg/L to a 
maximum of 14.90 mg/L.  Subjects with CRP over 15 mg/l were excluded from the 
study (see methodology).  
The relationship between the C3 complement and the CRP showed a strong linear 
correlation in our population sample (r=0.271, p<0.001), as displayed in the figure 5.4.  
 
Figure 5.4: Scattered plot showing a strong statistical correlation (p<0.001) between 
CRP and C3 complement measurements. The vertical line of dots at 3mg/L represents 
the test sensitivity limit before a high sensitivity test was set up in the hospital general 
laboratory. 
 
Coagulation was analysed in this population by three pro-thrombotic factors such as 
fibrinogen and homocysteine. 
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As main representative of pro-thrombotic marker fibrinogen was measured in our 
sample population (297.63±64.32 mg/dl). There was strong association (r=0.254, 
p<0.001) between fibrinogen and C3 complement values. 
 
 
5.4. C3 complement and insulin resistance 
 
The correlation between C3 complement levels and insulin resistance was checked by 
the association with HOMA variable, as explained in the methodology. Hence, as 
disclosed in the methodology, the sample population was reduced to n=320 patients 
with basal insulin measured. The division of the original sample population resulted into 
two cohorts, the/a non-exogenous insulin replacement group (NEIR, n=320) and an/the 
exogenous insulin replacement group (EIR, n=54).  
Since EIR group required exogenous insulin and presented fictitious endogenous 
insulin levels, clinical metabolic differences were assumed between both groups. Even 
though this premise was assumed, both cohorts were tested for differences in their 
hydrocarbon metabolism. The (?) EIR group showed higher fasting glucose 
concentrations (130.65±66.17 mg/dl) and A1c (6.75±1.62 mmol/L) than the NEIR group 
(103.43±32.22 mg/dl and 5.66±1.05 mmol/L). Therefore, both groups showed 
significantly different glucose-metabolism characteristics as shown in table 5.8. . 
Independence tests for NEIR (n=320) vs. EIR (n=54) 
Variable N Mean ±SD Mean 
difference 
95%-CI p-value 
Lower b.  Upper b.  
C3 
(mg/dL) 
EIR 54 130.42 ±26.01 5.30 -2.22  12.81 
 
0.17 
 NEIR 320 125.12 ±25.87 
FG 
(mg/dl) 





 NEIR 320 103.43 ±32.22 
A1c 
(mmol/L) 
EIR 54 6.75 ±1.62 1.09 0.63 1.54  <0.001 
NEIR 320 5.66 ±1.05 
Age 
(years) 
EIR 54 55.69 ±15.20 2.49 -1.80 6.77 0.225 
NEIR 320 53.20 ±14.75 
Table 5.8: Independence assessment for several non-modifiable, age, and modifiable 
glucose-metabolism variables, such as C3 complement, fasting glucose (C3), glycated 
haemoglobin (A1c) and age was performed between exogenous insulin replacement 
group (EIR) and non-exogenous insulin replacement group (NEIR). 
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On the other hand, there was no difference in age distribution between the two groups 
(p=0.225). In addition to age, C3 mean concentrations showed no differences between 
both groups (p=0.17) either. Meanwhile, gender distribution between both groups 
differed with borderline significance (EIR group women=57%, p=0.046), as shown in 
the table 5.8 
For the population used in the insulin resistance sub-study, NEIR, where the basal 
insulin levels were measured, the calculated HOMA values (2.19±1.67%) were as 
shown in table 5.9. 
HOMA values distribution in NEIR group (n=320)  
Variable Mean SD Range 
minimum Maximum 
HOMA    (%)  2.19 1.67 0.32 10,18  
 
Table 5.9: Summary of HOMA variable descriptive statistics in non-exogenous insulin 
replacement (NEIR) group. 
 
 
The C3 complement concentrations showed a positive linear correlation with insulin 
resistance measured by HOMA (r=0.406 p<0.001). Therefore, higher levels of C3 
complement were strongly associated with increasing levels of insulin resistance as 
shown in figure 5.5.  
 
Figure 5.5: Scatter plot shows the relationship between HOMA, insulin resistance, and 
C3 complement plasma concentrations. A strong linear correlation was exhibited 
between both variables (r=0.406 p<0.001).    
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 Since insulin plasma levels were not available in the EIR group, the glucose-
metabolism was checked through the fasting glucose levels.  The fasting glycaemia in 
the EIR group did not show a significant correlation with C3 complement levels. Thus, 
the difference in the metabolic characteristics between both groups was corroborated 
again (r=0.164, p=0.241) as shown in the figure 5.6.  
 
 
Figure 5.6: Scatter plot did not show correlation between fasting glucose 
measurements and C3 complement levels in exogenous insulin replacement cohort 




5.5. Correlation of C3 with classical cardiovascular risk factors  
 
Non-modifiable classical cardiovascular factors, such as gender and age, did not show 
statistically significant association with C3 complement levels. Age was not linearly 
correlated to C3 complement levels (r=0.09, p=0.090). With regard to gender, there 
were no significant differences in C3 levels between males and females (p=0.210), as 
seen in table 5.10. 
 
There were no differences in age and gender distribution among the groups of subjects 
who presented each one of the modifiable risk factors and those who were factor-free, 
as seen in figure 5.7 and table 5.10. For instance, hypertensive and normotensive 
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patients had similar age and gender proportion. The exception was tobacco 
consumption, which was age dependant as explained in subsequent results.  
C3 complement (mg/dl) and gender 
Variable 
Gender 
N Mean SD Mean 
difference 
95%-Confidence interval p-value 
Lower bound Upper bound 
Male 206 131.18 24.31 3.39 -1.92  8.70 0.210 
Female 168 127.78 27.93 
 
Table 5.10: Distribution of C3 values according to gender.  
 
After confirming this independence, we studied the possible behavioural analogy 
between C3 convertase levels and the most frequent classical cardiovascular risk 
factors.  
 
Figure 5.7: Scatter diagram representing a certain tendency but no significant 
correlation between age and C3 complement concentrations in blood (r=0.088 p=0.09). 
 
As first analysed cardiometabolic risk factor, obesity, as defined by BMI, was 
measured according to BMI and showed a linear positive correlation with C3 levels. 
The sample population was divided into three groups: normal weight (BMI<25), 
overweight (BMI 25-30) and obesity (BMI>30). In both extremes, morbid obesity and 
anorexia, we assumed similar progressive distribution of weight values. C3 values were 
significantly different among the three groups (p<0.001), with higher values of C3 
complement associated to degree of obesity (table 5.11). Moreover, There was a 
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positive linear correlation betweenC3 levels and increasing obesity degrees (r=0.37, 
p<0.001)(Figure 5.8)  
 
C3 complement (mg/dl) and general obesity 
Variable N Mean SD P-value 
BMI 
 
Normal weight <25 129 118.31 2.23 <0.001 
Overweight 25-30 157 131.13 1.82 
Obesity  ≥30 88 143.66 2.66 
 
Table 5.11: Differences in C3 according to the degree of obesity. BMI cut-off points 
followed the obesity standards established by the WHO for Caucasians.  
 
 
Figure 5.8: Positive linear correlation between C3 levels and increasing obesity 
degrees (r=0.37, p<0.001). 
Following this study line, C3 concentrations were compared among subjects with and 
without the presence of classical risk factors other than obesity (Table 5.12). 
The strongest positive correlation bound high C3 concentrations to high levels of 
triglycerides (p<0.001).  
Hypertensive patients also showed higher levels of C3 complement than 
normotensive patients as displayed in table 5.12. 
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C3 complement (mg/dl) and classical cardiovascular risk factors 
Variable N Mean ± SD MD 95%-CI p-value 
Lower b. Upper b.  
Hypertension 
(>135/85mmHg) 
No 168 124.80±27.93 8.82 3.57 14.07 0.001 
Yes 206 133.62±23.70 
Hypercholesterolemia 
(LDLc >160mg/dl) 
No 201 125.52±25.84 8.93 3.69 14.16 0.001 
Yes 173 134.45±25.48 
Low HDLc  
(<40 mg/dL males, 
<50mg/dL females) 
No 296 127.58±26.14 9.94 3.50 16.38 0.003 
Yes 78 137.22±24.15 
Hypertriglyceridemia 
(TG> 150 mg/dl) 
No 288 124.89±24.25 20.71 14.78 26.64 <0.001 
Yes 86 145.60±25.52 
Hyperglicaemia 
(FG>100 mg/dl) 
No 279 127.54±26.41 8.30 2.28 14.33 0.007 
Yes 95 135.85±23.93 
 
Table 5.12: Summary of significant associations between presence of cardiovascular 
risk factors and   higher levels of C3 complement. 
We also analysed the association (p<0.001) of high concentrations of C3 with high 
levels of LDLc (>160mg/dl). In order to compare the LDLc levels in our population, a 
common cut-off value of >160mg/dl was established for hypercholesterolemia 
diagnosis in our sample population. The LDLc cut-off point for hypercholesterolemia 
differs from treatment threshold goal (general LDLc<130mg/dl) in the cardiovascular 
unit and is personalised per patient according to cardiometabolic PMH. 
Diabetic patients showed significantly higher C3 concentrations than those without 
T2DM (p=0.007), as shown in the table 5.9. To confirm this fact we also tested the 
relationship between C3 measurements and A1c determinations in our population.  
The T2DM ranges include pre-diabetes diagnosis for percentages of A1c of 5.7% or 
above until diabetes diagnosis from 6.5% or above. Both variables, C3 complement 
and A1c, reinforced a positive linear correlation (r=0.112, p=0.03) as shown in the 
figure 5.6.  




Figure 5.9: Scattered plot shows statistically significant correlation between A1c(%) 
measurements and C3 complement (mg/dl) concentrations (r=0.112 p=0.03). 
In relation to the tobacco consumption, the association between C3 complement and 
smoking habits showed a significant inverse correlation (p=0.001). Due to the 
questionable implications of a possible protective effect of tobacco against atheroma 
formation, we analysed closely the characteristics of the population of smokers.   
This examination showed that smokers (48.44±11.97 yr. old) were significantly younger 
than former smokers (53.34±12.72 yr. old) and non-smokers (55.64±11.97 yr. old. 
There was also a significant association between age and tobacco consumption 
(p<0.001) The association between age and smoking habit is also shown in the table 
5.13 and graphs 5.10 and 5.11. 
Figures 5.10, 5.11: Graphs displaying the means of C3 (first graph) and age (second 
graph) per tobacco consumption status. 
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Anova  C3 complement (mg/dl) (n=374) 
Variable N Mean ±SD P-value 
Tobacco Non-smoker 176 128.99 ±25.34 0.001 
 Ex-smoker 94 137.16 ±25.40 
 Smoker 104 123.99 ±26.02 
Age  Non-smoker 176 55.64 ±16.63 <0.001 
Ex-smoker 94 55.34 ±12.72 
Smoker 104 48.44 ±11.97 
 
Table 5.13: C3 complement means per smoking habit status which shows a negative 
correlation between smoking consumption and C3 complement concentrations. There 
is also a negative association between age and tobacco consumption, with the 
smokers group being the youngest and the non-smokers the oldest group (p<0.001).  
 
 
5.6. Association between C3 and new cardiovascular risk markers 
As a young component of the MetS, uric acid was measured in our population 
(5.81±1.59 mg/dl). The relationship between C3 complement and uric acid 
measurements exposed a strong linear correlation (r=0.224, p<0.001). Therefore, high 
levels of uric acid were associated with high levels of C3 complement as shown in the 
plot 5.12.  
 
Figure 5.12: Uric acid levels and C3 complement measurements regression graph. For 
these results r=0.224, showing strong linear correlation (p<0.001) 
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Since the values of uric acid could be compromised by treatment with allopurinol, the 
relationship between C3 complement and uric acid concentrations could be also 
compromised. In virtue of this assumption, the correlation of C3 levels with the absence 
or presence of diagnosed hyperuricemia (9.8% of the study population) was also 
tested. Although the correlation between both variables was not significant, a positive 
tendency was shown, as displayed in table 5.14.  
According to ferritin levels measured in our population sample (117.05±11.87µg/dl), 
there was strong linear association between ferritin blood concentrations and C3 
complement levels (r=0.142, p<0.006) as shown in figure 5.13. As we did with the 
previous variables, in order to check the possible effect of patients treated with 
phlebotomies, we also compared the presence or absence of diagnosed 
hyperferritinemia (9.9% of the sample population) with C3 measured values. The 
association between both variables did not reach statistical significance, as shown in 
the table 5.14. 
 
Figure 5.13: scattered plot with regression line of ferritin concentrations and C3 levels 
in 374 patients, both measurements are statistically positively associated (r=0.14, 
p=0.006). As seen in the graph outlier values have not been excluded here. 
Regression analysis has been done to fit a representative line of the set of data 
association between both variables. 
 
With regard to lipoprotein(a) (Lp(a)) (22.77±29.64 mg/dl), new cardiovascular 
biomarker also related to inflammation no significant linear correlation with C3 was 
shown, as seen in graph 5.14. Accordingly, the concentrations of C3 were not 
significantly different between patients with and without presence of 
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Figure 5.14: Graph showing Lp(a) and C3 complement values did not have a significant 
correlation (r=0.013, p=0.802). The vertical line drew by an accumulation of dots 
displays the Lp(a) test sensitivity limit before a second high sensitivity test, which 
included values close to 0, was set up in the Endothelium Pathology Unit. 
 
T-student  C3 complement (mg/dl)  Difference 







No 337 129.33 26.27 3.31 5.56 12.18 0.463 
Yes 37 132.63 23.80 
Hyper-Lpa  
(>30 mg/dl) 
No 330 129.10 26.47 4.69 -3.52 12.90 0.262 
Yes 44 133.79 22.17 
Hyperferritinemia 
(>180 µg/dl) 
No 337 128.99 26.13 4.50 2.15 15.54 0.137 
Yes 37 135.69 24.52 
 
Table 5.14: Differences in C3 complement concentrations according to the presence or 
absence of hyperuricemia, hyperferritinemia and high-Lp(a),none on them showed 
statistical significance. . 




5.7. C3 complement association with cardiovascular risk (REGICOR)   
 
 
The cardiovascular risk was calculated through the REGICOR model (Framingham 
model adapted for Spanish population) as the risk of suffering a cardiovascular event in 
10 years according to patient‟s age, gender and personal characteristics.  In our 
population, REGICOR mean was  3.65±2.91% 10-year cardiovascular risk of an 
individual, ranged from 0.01% as minimum value to 17.65% as maximum value. 
 
Testing the relationship between both variables, a positive linear correlation was 
observed between C3 concentrations and REGICOR values (Pearson r=0.196, 




Figure 5.15: scattered plot representing the linear correlation between C3 levels in 
plasma and cardiovascular risk percentages in 10 years calculated by REGICOR 
(r=0.196, p<0.001) 
 
As in routine clinical practice, we divided our population sample into three levels 
according to their cardiovascular risk. Following the REGICOR scales, as mentioned in 
the methodology, low risk was given to those individuals with less than a 5% possibility 
of suffering from a cardiovascular event in the next ten years, patients with 5-10% were 
considered moderate risk and those with >a 10% possibility were considered high risk 
as shown in table 5.15 and graphs 5.16 and 5.17. 
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C3 (mg/dl) and REGICOR N Mean SD P-value 
REGICOR  
Levels (CV risk) 
Low risk <5% 286 127.51 25.56 0.016 
Moderate risk 5-10% 72 136.32 27.08 
High risk >10% 16 129.65 24.08 
 
Table 5.15: Distribution of C3 concentrations according to cardiovascular risk 






Figures 5.16 and 5.17: representation of C3 mean concentrations per cardiovascular 
risk level (low, moderate, high) according to REGICOR formula. 
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The high risk cardiovascular group sample resulted too small (n=16) for statistical 
analyses and we decided to group moderate and high cardiovascular risk subjects into 
one moderate-high cardiovascular risk group for further calculations.  
 
Two population groups of low cardiovascular risk <5% (n=286) and moderate-high 
cardiovascular risk ≥5% (n=88) were created. The relationship between C3 
complement levels and REGICOR risk levels was tested again, showing that higher 
concentrations of C3 complement were significantly associated with higher 
cardiovascular risk (p=0.004), as displayed in graph 5.18 and table 5.16. 
 
 
Figure 5.18: representation of C3 mean concentrations per cardiovascular risk levels 
(low and moderate- high) calculated according to REGICOR formula. 
 
 
C3 complement (mg/dl) and REGICOR Difference 
 Coronary risk according 
to REGICOR model (%) 
N Mean ±SD MD 95%-CI p-value 
Lower b. Upper b. 
Low risk <5% 286 127.51 ±25.56 9.09 2.91 15.27 0.004 
High risk >5% 88 136.61 ±26.44 
 
Table 5.16: Statistically significant positive correlation (p=0.004) between C3 
concentrations and cardiovascular risk levels calculated by REGICOR formula, with the 
C3 levels being higher for high cardiovascular risk patients (136.61±35.56 mg/dl) than 
for low risk subjects (127.51±26.44 mg/dl). 
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5.8. Emerging cardiometabolic risk and endothelial damage biomarkers  
 
 
In random sub-groups of the population several detection tests were carried out, such 
as adiponectin, IL-10, IL6, TNF-α, VCAM-1, TAP, TAC or TBARS measurements. 
These tests were performed according to the availability of reactant‟s kits at the 
Endothelium and Cardiometabolic Unit‟s laboratory. These subgroups were selected 
randomly according to the accessibility to kits and reactants during their first visit. The 
characteristics of the multiple subgroups were not tested due to the limitations of the 
study and we assumed no differences with the original sample population.  
 
 
5.8.1. Metainflammatory biomarkers  
 
Adiponectin is considered an anti-inflammatory marker and recognised endothelial 
protector. The adiponectin levels (µg/ml) were arbitrarily measured in 254 subjects of 
the sample population. Adiponectin concentrations in plasma were negatively 
correlated to C3 complement values (r= -0.184, p= 0.003).  
 
The distribution of adiponectin values was different across the C3 complement 
quartiles, with lower adiponectin levels associated with upper quartiles. (p=0.025) as 
shown in table 5.17 and figure 5.19.  
 
Adiponectin levels (µg/ml) distribution between C3 quartiles 
C3 N Mean SD  ±S Error 
95% CI for Mean 
Min. Max. Lower B. Upper B. 
Q1 64 10.45 6.03 ±0.75 8.94 11.95 2.36 35.78 
Q2 67 9.85 5.71 ±0.69 8.46 11.24 3.80 31.54 
Q3 57 9.57 5.23 ±0.69 8.18 10.96 3.15 37.41 
Q4 66 7.74 3.99 ±0.49 6.76 8.72 2.38 21.70 
Total 254 9.39 5.36 ±0.33 8.73 10.05 2.36 37.41 
 
Table 5.17: Distribution of the adiponectin values across the C3 complement quartiles,. 




Figure 5.19: The graph represents the negative association between adiponectin 
leveles and C3 quartiles (p=0.025). 
 
 
Interleukin-6 levels were randomly quantified in 244 patients of the population sample. 
Higher levels of interleukin-6 were positively correlated to C3 complement 
concentrations in plasma (r=0.747, p=0.021). 
 
Interleukin-10 concentrations were randomly determined in 112 individuals of our study 
population. Il-10 showed an inverse correlation with C3 complement measurements, 
with borderline significance (r= -0.169, p=0.075). However, assessing the distribution of 
Il-10 between the C3 complement quadrants, a correlation was not shown (r= -0.134, 
p=0.262), as displayed in table 5.18 and figure 5.20 in further detail. 
Distribution of Interleukin-10 (pg/ml) between C3 quartiles 
C3 N Mean ±SD 
Std. 
Error 
95% CI for Mean 
Min. Max. Lower B. Upper B. 
1,00 25 1.73 ±1.19 0.24 1.24 2.23 0.16 5.23 
2,00 32 1.63 ±1.18 0.21 1.21 2.06 0.13 5.83 
3,00 27 1.32 ± 0.73 0.14 1.03 1.61 0.31 3.35 
4,00 28 1.25 ±1.02 0.19   .86 1.65 0.30 4.89 
Total 112 1.49 ±1.05 0.10 1.29 1.68 0.13 5.83 
 
Table 5.18: distribution of Interleukin-10 levels among across C3 quartiles (p=0.262). 




Figure 5.20: mean values of Il-10 according to C3 complement cuartiles.  
Tumoral necrosis factor (TNF-α) levels were quantified randomly in 90 subjects of our 
study population, a considerable smaller sample. TNF-α levels displayed a mild 
negative behaviour with respect to C3 complement values (r=-0.03, p=0.078,), albeit 
this negative association was not demonstrated. 
 
 
5.8.2. Endothelial damage biomarkers 
 
Plasminogen activator inhibitor-1 (PAI-1) was measured at random in 75 subjects of 
our sample population. The association with C3 complement was significant (r=0.335, 
p=0.003,), but the distribution between C3 complement quartiles exhibited borderline 
association (p=0.068) as shown in table 5.19 and figure 5.21. 
 
Figure 5.21: means of PAI-1 concentrations per quartile of C3. 
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PAI-1 mean values (ng/ml) per C3 quartiles 
C3 N Mean ±SD 
Std. 
Error 
95% CI for Mean 
Min. Max. Lower B. Upper B. 
Q1 25 28.90 ±25.98 5.19 18.17 39.62 1.76 109.03 
Q2 22 38.52 ±34.52 7.36 23.21 53.83 8.15 135.47 
Q3 13 34.85 ±14.81 4.11 25.90 43.81 7.02 64.24 
Q4 15 53.18 ±32.29 8.33 35.30 71.07 10.93 104.86 
Total 75 37.61 ±29.43 3.39 30.84 44.38 1.76 135.47 
 
Table 5.19: descriptive distribution of the PAI-1 means between C3 quartiles 
 
Tissue-type plasminogen activator (TPA) levels were determined in 265 patients 
selected randomly. These values were compared with C3 complement levels and a 
strong association between both variables resulted (r=0.263. p<0.001). The distribution 
of the means per C3 quartiles was also studied, but the association in the distribution 
was not shown as seen in figure 5.22 and table 5.20. 
 
 
Figure 5.22: Representation of the means of TPA and quartiles of C3. 
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Endothelial expression of vascular cell adhesion molecule-1 (VCAM-1) correlates with 
atheroma formation. We obtained the results from 208 subjects at random. There was 
also a significant correlation between both variables (r=0.19, p=0.019). 
 
Distribution of TPA means (pg/ml) 
C3 N Mean ±SD Std. Error 
95% CI for Mean 
Min. Max. Lower B. Upper B. 
Q1 71 2904.43 ±1507,50 178.91 2547.62 3261.26 730.3 8261.2 
Q2 70 3411.56 ±1717.37 205.26 3002.07 3821.05 966.9 9090.0 
Q3 57 3329.34 ±1467.73 194.45 2939.90 3718.78 1222.4 7746.0 
Q4 67 3981.37 ±1577.25 192.69 3596.64 4366.09 1562.7 8852.7 
Total 265 3402.07 ±1614.10 99.15 3206.84 3597.30 730.3 9090.0 
 





5.8.3. Oxidative stress biomarkers 
 
 
Finally the oxidative stress biomarkers were represented by total antioxidant capacity 
(TAC) and thiubarrbituric acid substances (TBARS).  
 
TAC levels (µM) were determined in 201 subjects of our sample population in an 
arbitrary way. The initial inverted direction of C3 convertase and TAC values, did not 
reach statistical significance (r=-0.50, p=0.485). 
 
TBARS (µM/L) values were measured in 232 patients of our study population chosen 
randomly. TBARS levels showed marginal linear correlation with C3 complement 
values (r=0.114, p=0.084). 










5.9. Variables distribution analysis between C3 complement quartiles  
 
To assess more exhaustively the correlation between all our variables with C3 
complement we performed an analysis per C3 quartiles. The distribution of the 
variables per quartiles also distributed their thresholds and pathological diagnosis per 
quartiles. 
Before proceeding with the analysis of the variables‟ behaviour, we assessed the 
distribution of the population across the C3 quartiles. The results of this analysis 
showed, that the number of subjects was homogenously distributed among quartiles 
with a similar number and percentage of subjects per quartile as shown in table 5.21. 
Complement C3 quartiles Frequency Percentage (%) Valid % Cumulative % 
Q1 93 24.9 24.9 24.9 
Q2 92 24.6 24.6 49.5 
Q3 93 24.9 24.9 74.3 
Q4 96 25.7 25.7 100 
Total 374 100 100  
Table 5.21: Homogenous distribution of the sample population among the quartiles of 
C3 complement concentrations. 
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5.9.1. Distribution of Sample population into C3 quartiles 
 
In order to assess the behaviour of different variables along the whole range of C3 
concentrations, we first assessed the distribution of the C3 complement variable, 
showing a histogram compatible with a normal distribution as shown in graph 5.24.  
 
Figure 5.24: histogram of C3 complement concentrations and normal distribution curve.  
 
Our study population (n=374) was divided into 4 quartiles based on the distribution of 
the C3 complement concentrations among the subjects. The division by quartiles was 
not affected by extreme values of non-normal distributions because the quartiles were 
calculated from non-parametric parameters (percentiles). In the study population the 
C3 complement variable (mean=129.65±26.02 mg/dl) had a median value of 127.00 
mg/dl (percentile 50). C3 complement quartiles cut-off values were as follows: Q1: 
C3<111.75; Q2: C3 ≥ 117.5 to <127; Q3: 3 ≥127 to <147; and Q4 C3 ≥147, as shown 
in table 5.22.  
 
Percentiles 25th  50th  75th  
C3 (mg/dl) 111.75 127.00 147.00 
 
Table 5.22: C3 distribution by percentiles, representing the quartiles cut-off points. 
Percentile 50 represents de median (127.00 mg/dl). 
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To check the independence of modifiable variables in our study the homogeneity of 
non-modifiable variables among the quartile‟s groups was assessed as follows.  
 
There was no significant association between the gender distribution and C3 quartiles‟ 
groups as seen in the table 5.23 (p= 0.175).  
C3 complement quartiles 
(N=374) 
Gender 
Total Females Males 
Q1 N 42 51 93 
Percentage 45.2 54.8 100 
Q2 N 52 40 92 
% 565 43.5 100 
Q3 N 54 39 93 
% 58.1 41.9 100 
Q4 N 58 38 96 
% 60.4 39.6 100 
Total N 206 168 374 
% 55.1 44.9 100 
 
Table 5.23: Homogenous gender distribution per quartile according to the number of 
subjects and percentages (p=0.175).  
 
There were not significant differences either in age among the C3 complement 
quartile‟s groups. The distribution of subjects per groups according to age was 
homogenous as seen in table 5.24. 
Age distribution among the C3 complement quartiles (years) 
C3 quartiles N Mean ±SD Std. Error 
95% CI for Mean 
Min. Max. Lower B. Upper B. 
Q1 93 51.08 ±15.18 1.57 47.95 54.20 24.79 90.70 
Q2 92 53.73 ±16.13 1.68 50.39 57.07 19.70 85.80 
Q3 93 56.26 ±14.56 1.50 53.26 59.26 19.92 82.31 
Q4 96 53.20 ±13.11 1.33 50.54 55.85 22.84 85.39 
Total 374 53.56 ±14.82 0.766 52.05 55.07 19.70 90.70 
Table 5.24: Display of the age distribution in the sample population across the C3 
quartiles. There was not a significant correlation of the mean ages among groups 
(p=0.12).  
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5.9.2. Distribution of Cardiometabolic continuous variables across the C3 
quartiles 
 
In order to assess the association between C3 complement concentrations and 
cardiovascular risk, the relationship between C3 values distributed by quartiles and 
several cardiometabolic continuous variables was evaluated. 
 






















SBP (mmHg) Q1 93 126.30 ±18.73 1.94 122.44 130.16 87 204 
Q2 92 134.72 ±23.20 2.41 129.91 139.52 91 205 
Q3 93 135.26 ±20.16 2.09 131.11 139.41 91 197 
Q4 96 136.94 ±16.61 1.69 133.57 140.30 101 183 
Total 374 133.33 ±20.13 1.04 131.28 135.38 87 205 
DBP (mmHg) Q1 93 78.00 ±10.57 1.09 75.82 80.18 55 112 
Q2 92 82.27 ±9.816 1.02 80.24 84.30 60 103 
Q3 93 82.59 ±9.83) 1.02 80.57 84.62 59 110 
Q4 96 85.46 ±10.74 1.09 83.28 87.64 65 116 
Total 374 82.11 ±10.55 0.54 81.03 83.18 55 116 
Waist/hip ratio Q1 93 0.87 ±0.09 0.01 0.85 0.89 0.70 1.05 
Q2 92 0.90 ±0.09 0.01 0.88 0.92 0.63 1.16 
Q3 93 0.93 ±0.07 0.01 0.92 0.95 0.70 1.09 
Q4 96 0.94 ±0.08 0.01 0.92 0.95 0.67 1.20 
Total 374 0.91 ±0.09 0.01 0.90 0.92 0.63 1.20 
Waist (cm) Q1 93 85.46 ±11.67 1.21 83.05 87.86 63 113 
Q2 92 90.43 ±12.42 1.29 87.86 93.01 59 128 
Q3 93 94.59 ±9.93 1.03 92.54 96.63 67 113 
Q4 96 97.75 ±12.05) 1.23 95.30 100.19 70 139 
Total 374 92.11 ±12.41 0.64 90.84 93.37 59 139 
BMI (Kg/m²) Q1 93 25.09 ±3.98 0.41 24.27 25.91 17.75 35.35 
Q2 92 25.91 ±4.32 0.45 25.01 26.80 18.31 47.54 
Q3 93 28.07 ±3.94 0.41 27.25 28.87 17.30 37.17 
Q4 96 29,40 ±5.24 0.53 28.33 30.45 21.14 49.52 
Total 374 27.13 ±4.71 0.24 26.65 27.61 17.30 49.52 
 
Table 5.25: Description of the haemodynamic and anthropometric variables distribution 
along the C3 complement levels quartiles.  
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All the anthropometric cardiometabolic variables‟ means increased in proportionally to 
the C3 complement quartiles. Furthermore, all the anthropometric means, such as BMI 
(p<0.001), SPB (p=0.001), DPB (p<0.001), waist/hip ratio (p<0.001) and waist size 
(p<0.001) showed positive linear correlations. The variables distribution among C3 
complement quartiles is displayed in table 5.25. 
 
The number of MetS factors per patient was associated with C3 quartiles (p<0.001). 
Thus, most of the MetS factors-free or metabolically healthy patients were situated in 
the first C3 complement and there were no patients presenting five MetS constitutive 
criteria. Additionally, the percentage of patients showing positive for all the factors 
increased accordingly to the quartiles increment as shown in table 5.26. Furthermore, 
the majority of the measured numerical metabolic variables also showed a positive 
correlation to the C3 complement concentration per quartiles. In particular, those 
related to MetS. 
 
 
Number of MetS criteria per C3 complement quartiles distribution 
C3 quartiles 
 




0 1 2 3 4 5 
Q1 N 31 27 23 11 1 0 93 
% within Q1 33.3 29.0 24.7 11.8 1.1 0.0 100 
% within no. of criteria 55.4 33.8 21.7 14.7 2.5 0.0 24.9 
Q2 N 17 23 26 16 8 2 92 
% within Q2 18.5 25.0 28.3 17.4 8.7 2.2 100 
% within no. of criteria 30.4 28.7 24.5 21.3 20.0 11.8 24.6 
Q3 N 6 20 23 24 10 10 93 
% within Q3 6.5 21.5 24.7 25.8 10.8 10.8 100 
% within no. of criteria 10.7 25.0 21.7 32.0 25.0 58.8 24.9 
Q4 N 2 10 34 24 21 5 96 
% within Q4 2.1 10.4 35.4 25.0 21.9 5.2 100 
% within no. of criteria 3.6 12.5 32.1 32.0 52.5 29.4 25.7 
Total N 56 80 106 75 40 17 374 
% by no. of criteria 15.0 21.4 28.3 20.1 10.7 4.5 100 
% within no. of criteria 100 100 100 100 100 100 100 
 
Table 5.26: Distribution of the percentage of number of metabolic criteria met per C3 
quartile. 
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 The cardiovascular risk calculated by the REGICOR model showed a sample 
population distribution with a mean risk in 10 years of 3.63 ±2.9 % cardiovascular, from 
a minimum of 0.01% to a maximum of 17.63%. The risk measured by REGICOR 
showed a statistically significant difference across the C3 complement quartiles 
(p=0.004), as displayed in table 5.27. 
REGICOR (%) distribution by C3 complement quartiles 
Q N Mean ±SD Std. error 95% CI for Mean Min Max 
Q1 93 2.70 ±2.43 0.25 2.20 3.20 0.03 11.90 
Q2 92 3.77 ±3.21 0.33 3.10 4.43 0.01 17.65 
Q3 93 3.90 ±2.99 0.31 3.28 4.52 0.03 14.94 
Q4 96 4.13 ±2.79 0.28 3.57 4.70 0.04 12.95 
Total 374 3.63 ±2.91 0.15 3.33 3.93 0.01 17.65 
 
Table 5.27: Differences in Cardiovascular risk measured by REGICOR formula among 
the C3 quartile groups (p=0.004). 
Fasting glucose, a metabolic marker of hyperglycaemia, showed a positive tendency 
towards the increment of C3 quartiles. The mean values of fasting glucose (p=0.119), 
had an increasing trend according to the C3 quartiles, but they did not reach a 
statistically significant difference as seen in figure 5.25. A similar non-significant trend 
was also observed in the glycosylate haemoglobin values (p=0.171). Both values were 
measured in the whole population without exclusions. 
 
Figure 5.25: Bar chart representing the tendency incrementing the mean fasting 
glucose levels per C3 complement quartiles (p=0.171). 
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Meanwhile, the insulin resistance representative variable, calculated through the 
HOMA formula, showed a strong positive correlation with the C3 quartiles. The different 
sample population used to calculate insulin resistance was noted again, which 
excluded exogenous insulin dependent subjects (n=320) as explained earlier in this 
paper.  
 
The Insulin resistance drew a clear positive correlation (p<0.001) with C3, HOMA 
incremented proportionally its percentages per quartile.  
 
All the variables related with the glycaemic metabolism, FG, A1c and HOMA showed 
strong association (p<0.001) with C3 quartiles, as the distribution of their means along 
the C3 quartiles show in more detail in table 5.28. 
 
The lipid metabolism of our population showed a more pathologic lipid profile in those 
patients with higher C3 quartiles as follows: Triglycerides levels were positively 
correlated (p<0.001) as showed in figure 5.26.  
 
Meanwhile HDLc concentrations were inversely correlated as low HDLc is correlated to 




Figure 5.26: Values of triglycerides concentrations means per C3 complement 
quartiles.Both variables showed a strong linear correlation (p<0.001). 
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 Description of population divided into C3 complement quartiles (n:374) 




Q1 93 102.03 ±48.09 4.98 92.13 111.94 64 421 
Q2 92 102.58 ±36.82 3.83 94.95 110.20 71 280 
Q3 93 112.44 ±33.60 3.48 105.52 119.36 71 241 
Q4 96 112.18 ±39.47 4.02 104.18 120.17 73 302 
Total 374 107.36 ±40.02 2.06 103.29 111.43 64 421 
A1c 
(%) 
Q1 93 5.76 ±1.29 .13 5.49 6.03 4.0 11.5 
Q2 92 5.61 ±1.08 .11 5.39 5.84 4.4 10.3 
Q3 93 5.99 ±1.17 .12 5.75 6.23 4.1 10.8 
Q4 96 5.88 ±1.24 .12 5.63 6.13 4.6 11.7 
Total 374 5.81 ±1.20 .06 5.69 5.93 4.0 11.7 
HOMA 
(score) 
Q1 73 1.31 ±1.01 .12 1.08 1.55 .32 6.16 
Q2 78 1.74 ±1.23 .14 1.46 2.02 .40 7.43 
Q3 84 2.45 ±1.58 .17 2.11 2.80 .39 10.19 
Q4 85 3.07 ±2.05 .22 2.62 3.51 .37 10.95 
Total 320 2.18 ±1.67 .09 2.00 2.37 .32 10.95 
 
Table 5.28: Distribution of the sample population values of fasting glucose, glycosylate 




On the other hand, other lipid profile parameters, such as LDLc and total cholesterol, 
did not show significant differences between LDLc (p=0.720) levels, total cholesterol 
concentrations (p=0.466) and the C3 complement quartiles as showed in table 5.29. 
None of these parameters are MetS criteria. Therefore, they are not directly involved in 
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Description of population divided into C3 complement quartiles (n:374) 




Q1 93 199.85 ±43.58 4.519 190.87 208.82 130 365 
Q2 92 203.99 ±45.63 4.757 194.54 213.44 83 407 
Q3 93 196.99 ±46.25 4.796 187.46 206.51 115 389 
Q4 96 207.00 ±50.07 5.110 196.85 217.15 122 367 
Total 374 201.99 ±46.45 2.402 197.27 206.71 83 407 
LDLc 
(mg/dl) 
Q1 93 127.86 ±39.19 4.064 119.79 135.93 55 274 
Q2 92 128.15 ±40.65 4.238 119.73 136.57 25 316 
Q3 93 124.61 ±40.46 4.195 116.28 132.94 61 315 
Q4 96 131.60 ±45.53 4.647 122.38 140.83 59 280 
Total 374 128.09 ±41.47 2.144 123.87 132.30 25 316 
Triglycerides 
(mg/dl) 
Q1 93 84.14 ±35.94 3.727 76.74 91.54 34 233 
Q2 92 120.92 ±65.79 6.859 107.30 134.55 41 354 
Q3 93 123.53 ±61.01 6.327 110.96 136.09 40 273 
Q4 96 144.16 ±69.95 7.140 129.98 158.33 44 381 
Total 374 118.39 ±63.33 3.275 111.95 124.83 34 381 
HDLc 
(mg/dl) 
Q1 93 54.62 ±13.56 1.406 51.83 57.42 32 101 
Q2 92 51.34 ±13.37 1.393 48.57 54.10 25 105 
Q3 93 48.16 ±11.32 1.174 45.83 50.49 29 80 
Q4 96 46.39 ±9.03 .922 44.56 48.21 29 71 
Total 374 50.09 ±12.30 .636 48.84 51.34 25 105 
 
Table 5.29: Distribution of the means lipid profile parameters among the C3 




5.9.3. C3 quartiles association with inflammation and coagulation. 
 
The inflammation biomarker, CRP, increased its values accordingly to increasing C3 
complement quartiles. High sensitivity CRP showed a statistically positive correlation 
with the C3 complement levels divided in quartiles (p<0.001).  Coagulation was 
represented in this analysis by three pro-thrombotic factors such as fibrinogen, 
homocysteine and lipoprotein(a).  
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Description of the sample population divided into C3 complement quartiles (n:374) 
Biomarkers  N Mean ±SD Std. Error 95% CI Mean Min Max 
CRPhs 
(mg/L) 
Q1 93 2.50 ±1.80 0.18 2.12 2.87 0.4 10.30 
Q2 92 2.45 ±1.92 0.20 2.05 2.85 0.16 14.90 
Q3 93 2.90 ±2.17 0.22 2.45 3.35 0.33 13.40 
Q4 96 3.6.5 ±2.32 0.23 3.18 4.12 0.29 12.70 
Total 374 2.88 ±2.17 0.10 2.67 3.10 0.14 14.90 
Fibrinogen* 
(mg/dl) 
Q1 62 275.42 ±56.20 7.13 261.15 289.69 181.7 464.0 
Q2 68 291.22 ±63.63 7.71 275.82 306.63 159.9 517.2 
Q3 79 299.48 ±59.76 6.72 286.10 312.87 161.0 448.2 
Q4 75 319.83 ±69.50 8.02 303.84 335.82 153.4 522.9 
Total 284 297.63 ±64.31 3.81 290.11 305.14 153.4 522.9 
Homocysteine 
(µmol/L) 
Q1 93 12.28 ±4.37 0.45 11.38 13.18 6.0 30.0 
Q2 92 11.96 ±3.36 0.35 11.27 12.66 4.5 21.6 
Q3 93 11.52 ±3.02 0.31 10.90 12.15 4.9 21.4 
Q4 96 11.69 ±2.79 0.28 11.12 12.26 5.9 21.8 




Q1 93 27.92 ±28.88 2.99 21.97 33.87 2.4 147.0 
Q2 92 27.90 ±30.56 3.18 21.58 34.23 2.3 164.4 
Q3 93 26.50 ±29.36 3.04 20.45 32.55 2.4 141.3 
Q4 96 28.71 ±30.17 3.08 22.60 34.83 2.3 170.9 
Total 374 27.77 ±29.64 1.53 24.75 30.78 2.3 170.9 
Ferritin 
(µg/dl) 
Q1 93 91.15 ±93.24 9.66 71.95 110.36 7.20 526.65 
Q2 92 109.13 ±92.33 9.62 90.05 128.29 2.42 514.06 
Q3 93 123.22 ±109.56 11.36 100.65 145.78 2.95 687.80 
Q4 96 143.70 ±134.22 13.69 116.50 170.89 4.43 829.14 
Total 374 117.04 ±110.22 5.69 105.84 128.25 2.42 829.14 
 
Table 5.30: Description of the distribution of levels of inflammation and coagulation 
markers in the sample population divided by C3 complement concentration 
levels.*p<0.05. 
As a first coagulation representative, fibrinogen was distributed in the sample 
population from a minimum of 153.4 mg/dl to a maximum of 522.9 mg/dl, with a mean 
of 2 97.63 ±69.50 mg/dl.  
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Second representative, homocysteine (Hcy) values ranged from 4.5 µmol/L to 30 
µmol/L, with a  mean of 11.86 ±2.79 µmol/L.  
Finally, Lpa measurements varied from 2.3 mg/dl to 170 mg/dl and the mean was 
29.64±27.77 mg/dl (table 5.30). Values of Lipoprotein-a (Lp(a)) over 30 mg/dl indicated 
Lp(a) overload. There was not a significant correlation shown between 
hyperlipoproteinemia(a) and higher quartiles of C3 complement (p=0.504).    
None of both variables, Lpa (p=0.966) nor Hcy (p=0.464), showed a correlation with C3 
complement quartiles.  Only fibrinogen values were significantly different among the C3 




5.9.4. Metabolic pathologies distribution between C3 quartiles 
 
The sample population was distributed according to the presence or absence of 
cardiometabolic pathologies into two dichotomous variables. The percentages 
allocated per yes/no diagnosis and differences per quartile were assessed by cross-
tabulation and chi squared.     
A uric acid level over 6µg/dl was defined as iron overload, hyperuricemia. The sample 
population was divided into hyperuricemic and non-hyperuricemic groups. There was 
not significant association between the presence of hyperuricemia and higher values 
of C3 complement in plasma divided into quartiles (p=0.812).  
 
On the other hand, Hyperferritinemia threshold was set at ferritin values in plasma 
over 180µg/L. The study population was split in two groups and correlated to C3 
complement quartiles. The population was also segmented into hyperferritinemic and 
normal values of ferritin patients. There was no significant association between both 










C3 quartiles cross-tabulation with uric acid and lipoprotein(a) overloads 
 





No Yes Total No Yes Total 
Q1 N 86 7 93 86 7 93 
% Q1 92.5 7.5 100 92.5 7.5 100 
% Variable 25.5 18.9 24.9 26.1 15.9 24.9 
Q2 N 82 10 92 81 11 92 
% Q2 89.1 10.9 100 88.0 12.0 100 
% Variable 24.3 27.0 24.6 24.5 25.0 24.6 
Q3 N 84 9 93 80 13 93 
% Q3 90.3 9.7 100 86.0 14.0 100 
% Variable 24.9 24.3 24.9 24.2 29.5 24.9 
Q4 N 85 11 96 83 13 96 
% Q4 88.5 11.5 100 86.5 13.5 100 
% Variable 25.2 29.7 25.7 25.2 29.5 25.7 
Total N 337 37 374 330 44 374 
% Total 90.1 9.9 100 88.2 11.8 100 
% Variable 100 100 100 100 100 100 
 




The same analysis was performed with CRP and homocysteine. A CRP level over 
2mg/L, according to Jupiter study, was defined as high CRP. Likewise, a correlation 
between both variables was not demonstrated (p=0.622).  Homocystein overload 
hyperhomocyteinemia, was conventionally described as above 15 µmol/L. A statistical 
association was demonstrated between high C3 complement quartiles and a diagnosis 









C3 quartiles cross-tabulation with: 
C3 complement  
Quartiles 
Iron excess High C-reactive protein Hyperhomocysteinemia 
No Yes Total No Yes Total No Yes Total 
Q1 N 88 5 93 92 1 93 81 12 93 
% Q1 94.6 5.4 100 98.9 1.1 100 87.1 12.9 100 
% Variable 26.1 13.5 24,9 24.9 20.0% 24.9 28.2 13.8 24.9 
Q2 N 82 10 92 91 1 92 72 20 92 
% Q2 89.1 10.9 100 98.9 1.1 100 78.3 21.7 100 
% Variable 24.3 27.0 24,6 24.7 20.0 24.6 25.1 23.0 24.6 
Q3 N 83 10 93 91 2 93 66 27 93 
% Q3 89.2 10.8 100 97.8 2.2 100 71.0 29.0 100 
% Variable 24.6 27.0 24,9 24.7 40.0 24.9 23.0 31.0 24.9 
Q4 N 84 12 96 95 1 96 68 28 96 
% Q4 87.5 12.5 100 99.0 1.0 100 70.8 29.2 100 
% Variable 24.9 32.4 25,7 25.7 20.0 25.7 23.7 32.2 25.7 
Total N 337 37 374 369 5 374 287 87 374 
% Total 90.1 9.9 100 98.7 1.3 100 76.7 23.3 100 
% Variable 100 100 100 100 100 100 100 100 100 
 
Table 5.32: Cross-tabulation between C3 complement quartiles and iron excess, CRP 
overload and Hyperhomocysteinemia.  
 
 
Because of their particular relevance, the classical cardiovascular factors were studied 
with more attention. The association of C3 complement quartiles with hypertension 
was doubly examined. First, we analysed the association with previous clinical 
diagnoses of hypertension  (BP>135/85), second, with HBP MetS criterion (BP >135/85 
mmHg or under treatment for HBP).  
 
This double analysis showed significant association between the prevalence of 
hypertension and its incremental distribution per higher C3 complement quartiles. 
However, the association was stronger with HBP MetS criterion (p<0.001) than with 
hypertension diagnosis (p=0.011), as shown in table 5.33.     
 




Cross tabulation between  
C3 complement 
Quartiles 
Hypertension HBP MetS criterion 
No Yes Total No Yes Total 
Q1 N 55 38 93 52 41 93 
% Q1 59.1 40.9 100 55.9 44.1 100 
% Variable 32.7 18.4 24.9 40.0 16.8 24.9 
Q2 N 41 51 92 33 59 92 
% Q2 44.6 55.4 100 35.9 64.1 100 
% Variable 24.4 24.8 24.6 25.4 24.2 24.6 
Q3 N 36 57 93 22 71 93 
% Q3 38.7 61.3 100 23.7 76.3 100 
% Variable 21.4 27.7 24.9 16.9 29.1 24.9 
Q4 N 36 60 96 23 73 96 
% Q4 37.5 62.5 100 24.0 76.0 100 
% Vatriable 21.4 29.1 25.7 17.7 29.9 25.7 
Tot
al 
N 168 206 374 130 244 374 
% Total 44.9 55.1 100 34.8 65.2 100 
% Variable 100 100 100 100 100 100 
 
Table 5.33: Cross-tabulation between hypertension, HBP MetS criteria and C3 
complement quartiles. 
 
The distribution of hypercholesterolemia (LDLc>160mg/dl) per C3 complement 
quartiles also showed a significant association (p=0.006). A closer examination of the 
patients with a presence of low HDLc (men<40mg/dl, women<50mg/dl) also showed a 
significant association between both variables (p=0.007).  
 
This association was even stronger when C3 complement quartiles were crossed with 
low HDLc MetS criteria (low cyphers or under treatment, p=0.001) as displayed in more 
detail in table 5.34. 




 Cross tabulation between  
Quartiles 
Low HDLc Low HDLc MetS criterion 
No Yes Total No Yes Total 
Q1 N No Yes Total 75 18 93 
% Q1 85 8 93 80.6 19.4 100 
% Variable 91.4 8.6 100 31.0 13.6 24.9 
Q2 N 28.7 10.3 24.9 60 32 92 
% Q2 70 22 92 65.2 34.8 100 
% Variable 76.1 23.9 100 24.8 24.2 24.6 
Q3 N 23.6 28.2 24.6 57 36 93 
% Q3 72 21 93 61.3 38.7 100 
% Variable 77.4 22.6 100 23.6 27.3 24.9 
Q4 N 24.3 26.9 24.9 50 46 96 
% Q4 69 27 96 52.1 47.9 100 
% Variable 71.9 28.1 100 20.7 34.8 25.7 
Total N 23.3 34.6 25.7 242 132 374 
% Total 296 78 374 64.7 35.3 100 
% Variable 79.1 20.9 100 100 100 100 
 
Table 5.34: The distribution of population with low HDLc diagnosed by plasma 




The allocation of patients diagnosed with hyperglycaemia per C3 complement quartile 
showed a positive association. Again the diagnosis of hyperglycaemia MetS criterion 
(p<0.001) was stronger than the single fasting glucose levels measurement 
(FG>100mg/dl, p=0.01) as is shown in table 5.35. 
 
Assuring the aforementioned statistical analysis, the distribution of hypertriglyceridemic 
patients among the C3 complement quartiles showed the strongest association. The 
majority of the hypertriglyceridemic subjects was allocated in the higher quartiles, 
inversely to the non-hyperglyceridemic individuals. Both the diagnosis of 
hypertriglyceridemia according to triglycerides plasma levels (TG>150mg/dl, p 
<0.001) and hypertriglyceridemia MetS criterion (p<0.001) showed a significant 
association with C3 quartiles, as displayed in more detail in table 5.36. 




Cross tabulation between  
Quartiles 
Hyperglycaemia Hyperglycaemia MetS criteria 
No Yes Total No Yes Total 
Q1 N 75 18 93 66 27 93 
% Q1 80.6 19.4 100 71.0 29.0 100 
% Variable 26.9 18.9 24.9 30.3 17.3 24.9 
Q2 N 76 16 92 62 30 92 
% Q2 82.6 17.4 100 67.4 32.6 100 
% Variable 27.2 16.8 24.6 28.4 19.2 24.6 
Q3 N 59 34 93 44 49 93 
% Q3 63.4 36.6 100 47.3 52.7 100 
% Variable 21.1 35.8 24.9 20.2 31.4 24.9 
Q4 N 69 27 96 46 50 96 
% Q4 719 28.1 100 47.9 52.1 100 
% Variable 24.7 28.4 25.7 21.1 32.1 25.7 
Total N 279 95 374 218 156 374 
% Total 74.6 25.4 100 58.3 41.7 100 
% Variable 100 100 100 100 100 100 
Table 5.35: distribution of the sample population classified by presence/absence of 
hyperglycaemia and C3 complement quartiles.  
  
Cross tabulation between 
Quartiles 
HTG HTG MetS Criterion 
No Yes Total No Yes Total 
Q1 N 89 4 93 89 4 93 
% Q1 95.7 4.3 100 95.7 4.3 100 
% Variable 30.9 4.7 24.9 32.1 4.1 24.9 
Q2 N 73 19 92 71 21 92 
% Q2 79.3 20.7 100 77.2 22.8 100 
% Variable 25.3 22.1 24.6 25.6 21.6 24.6 
Q3 N 71 22 93 61 32 93 
% Q3 76.3 23.7 100 65.6 34.4 100 
% Variable 24.7 25.6 24.9 22.0 33.0 24.9 
Q4 N 55 41 96 56 40 96 
% Q4 57.3 42.7 100 58.3 41 100 
% Variable 19.1 47.7 25.7 20.2 41.2 25.7 
Tot
al 
N 288 86 374 277 97 374 
% Total 77.0 23.0 100 74.1 25.9 100 
% Variable 100 100 100 100 100 100 
 
Table 5.36: The distribution of the hypertrygliceridemic and non-hypertrigliceridemic 
populations by C3 quartiles showed a statistical correlation (p<0.001). 
UAH, PhD program: D234 Medicine  Rodriguez-Guerrero, A. 
140 
 
As described in the methodology, the sample population was stratified by degrees of 
obesity as follows, normal healthy weight (BMI=18-25), overweight (BMI>25-30), obese 
(BMI>30). The distribution of these three groups among the C3 complement quartiles 
was positively associated (p<0.001).  The obese and overweight groups were more 
prevalent in the upper quartiles. Abdominal obesity (waist >102 cm in males, >88 cm in 
females) was also significantly associated with increased C3 complement levels, and 
more prevalent in superior quartiles (p<0.001) as shown in table 5.37. 
 





waist Total Normal Overweight Obese Total 
Q1 N 73 20 93 49 34 10 93 
% Q1 78.5 21.5 100 52.7 36.6 10.8 100 
% Variable 30.3 15 24.9 38.0 21.7 11.4 24.9 
Q2 N 69 23 92 42 38 12 92 
% Q2 75 25 100 45.7 41.3 13 100 
% Variable 28.6 17.3 24.6 32.6 24.2 13.6 24.6 
Q3 N 53 40 93 19 44 30 93 
% Q3 57 43 100 20.4 47.3 32.3 100 
% Variable 22 30.1 24.9 14.7 28 34.1 24.9 
Q4 N 46 50 96 19 41 36 96 
% Q4 47.9 52.1 100 19.8 42.7 37.5 100 
% Variable 19.1 37.6 25.7 14.7 26.1 40.9 25.7 
Total N 241 133 374 129 157 88 374 
% Total 64.4 35.6 100 34.5 42 23.5 100 
% Variable 100 100 100 100 100 100 100 
 
Table 5.37: Cross-tabulation distribution of BMI and central obesity across the C3 
complement quartiles.  
 
However, there was not a demonstrated association between gender and distribution 
by C3 complement quartiles either, showing that C3 levels were independent of 
gender(p=0.157). 
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As explained further above, due to the scarce number of high cardiovascular risk 
subjects, the sample population was stratified in low (<5%) and moderate-high (≥5%) 
cardiovascular risk. Moderate-high CV risk showed a trend of association with C3 
complement quartiles (p=0.092). Meanwhile, C3 complement quartiles exhibited a 
positive association with diagnosis of MetS (≥3 MetS criteria), as the number of 
metabolic patients increased proportionally to the C3 quartiles (p<0.001), as can be 
seen in table 5.38 in more detail. 
 
Cross tabulation between  
Quartiles 
Gender MetS REGICOR CV risk 
Male Female Total No Yes Total <5% >5% Total 
Q1 N 42 51 93 81 12 93 80 13 93 
% Q1 45.2 54.8 100 87.1 12.9 100 86 14.0 100 
% Variable 20.4 30.4 24,9 33.5 9.1 24.9 28 14.8 24.9 
Q2 N 52 40 92 66 26 92 68 24 92 
% Q2 56.5 43.5 100 71.7 28.3 100 73.9 26.1 100 
% Variable 25.2 23.8 24,6 27.3 19.7 24.6 23.8 27.3 24.6 
Q3 N 54 39 93 49 44 93 69 24 93 
% Q3 58.1 41.9 100 52.7 47.3 100 74.2 25.8 100 
% Variable 26.2 23.2 24,9 20.2 33.3 24.9 24.1 27.3 24.9 
Q4 N 58 38 96 46 50 96 69 27 96 
% Q4 60.4 39.6 100 47.9 52.1 100 71.9 28.1 100 
% Variable 28.2 22.6 25,7 19 37.9 25.7 24.1 30.7 25.7 
Total N 206 168 374 242 132 374 286 88 374 
% Total 55.1 44.9 100 64.7 35.3 100 76.5 23.5 100 
% Variable 100 100 100 100 100 100 100 100 100 
 
Table 5.38: Cross-tabulation distribution of gender, presence of MetS and 
cardiovascular risk among C3 quartiles. C3 complement quartiles were independent of 
gender (0.157). Reversely, moderate-high cardiovascular risk was correlated (p=0.092) 
and metabolic syndrome was strongly associated (p<0.001) to C3 complement 
quartiles’ distribution.  
 
Finally, the presence of active smokers was higher in the lower quartiles and inversely 
distributed. A smoking habit was not statistically associated with C3 complement 
quartiles (p=0.59). When we separated non-smokers into ex-smokers and never-
smokers the inverse correlation was not statistically significant either (p=0.10), table 
5.39.  
UAH, PhD program: D234 Medicine  Rodriguez-Guerrero, A. 
142 
 
Cross tabulation between smoking habit and C3 
Quartiles 
Smoking Smoking 
No Yes Total No Former Yes Total 
Q1 N 61 32 93 50 11 32 93 
% Q1 65.6 34.4 100 53.8 11.8 34.4 100 
% Variable 22.6 30.8 24.9 28.4 11.7 30.8 24.9 
Q2 N 62 30 92 38 24 30 92 
% Q2 67.4 32.6 100 41.3 26.1 32.6 100 
% Variable 23.0 28.8 24.6 21.6 25.5 28.8 24.6 
Q3 N 76 17 93 47 29 17 93 
% Q3 81.7 18.3 100 50.5 31.2 18.3 100 
% Variable 28.1 16.3 24.9 26.7 30.9 16.3 24.9 
Q4 N 71 25 96 41 30 25 96 
% Q4 74 26 100 42.7 31.3 26 100 
% Variable 26.3 24 25.7 23.3 31.9 24 25.7 
Total N 270 104 374 176 94 104 374 
% Total 72.2 27.8 100 47.1 25.1 27.8 100 
% Variable 100 100 100 100 100 100 100 
Table 5.39: Association between smoking status classifications (smoker/non-smoker 
vs. smoker/ex-smoker/non-smoker) and C3 levels. 
 
 




The multivariate model of lineal regression was performed as described in the 
methodology. With this model, we analysed the constitutive factors of MetS and certain 
laboratory variables as possible predictors of C3 complement levels.  
 
Our maximum model initially comprised 17 variables, which explain the 34% of the C3 
complement values variability (co-linearity coefficient=34), as described in the table 
5.40.  
The non-modifiable variables, age and gender, remained in the model to adjust 
interaction of the modifiable variables, although none of them had statistical 
significance in the initial model. Co-linearity between age and gender was associated. 
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Tobacco consumption variable was adjusted to age. To avoid co-linearity problems, 
quantitative variables were centred at their mean before including them in the 
multivariate models. 
We initially suspected interaction between age and smoking habit variables in our 
sample population. Therefore, the association between C3 and smoking habit would 
have been influenced by the patient‟s age. Consequently, we introduced a variable to 
model the interaction, age per smoking habit. By doing so, the relation of smokers and 
C3 levels was differentiated from non-smokers. 
Descriptive Statistics C3 multivariate model population 





C3  130.42 ±26.01 320 1.000 . 
Age 53.21 ±14.75 320 0.07 0.120 
Gender 0.43 ±.50 320 -.104 0.032 
CPR 2.72 ±1.90 320 0.277 <0.001 
MetS 0.33 ±.47 320 0.362 <0.001 
REGICOR high risk 0.23 ±.42 320 0.161 0.002 
Hypertriglyceridaemia 0.26 ±.44 320 0.379 <0.001 
Hypertension 0.64 ±.48 320 0.282 <0.001 
Low HDLc 0.34 ±.47 320 0.209 <0.001 
Hyperglycaemia 0.40 ±.49 320 0.252 <0.001 
Waist 0.32 ±.47 320 0.310 <0.001 
HOMA 2.19 ±1.68 320 0.406 <0.001 
Hypercholesrerolemia 0.47 ±.50 320 0.187 <0.001 
Hyperhomocysteinemia 11.63 ±3.36 320 -0.069 0.110 
Lipoprotein(a) 27.51 ±29.79 320 -0.016 0.385 
Smoking 0.28 ±.45 320 -0.131 0.010 
Smoking-age 13.24 ±22.44 320 -0.115 0.020 
  
Table 5.40: Multivariate model for C3 complement population description. N=320, 
Patients under exogenous insulin treatment were excluded as explained in insulin 
resistance analysis.  
 
Gender, hyperhomocysteinemia and lipoprotein(a) diagnosis variables according to 
cut-off points were not significantly associated to C3 complement conforming to the 
multivariate analysis (p>0.050). Gender was inversely correlated to C3 levels (males 
have higher C3 values). Smoking habit negatively correlated to C3 concentrations and, 
as mentioned earlier, was associated to age. 
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According to beta coefficient‟s significance the first less significant variables removed 
from the maximum model were smoking and interaction of smoking habit and age. 
When we adjusted tobacco to age there was not significant association any longer. At 
the same moment or directly after removing smoking habit, the next less influential 
variables Table 5.41 presents data of the multivariable model.  
 
 







95% CI for B 
B Std. Error Beta Lower B Upper B 
C3 121.67 7.44  16.36 .000 107.04 136.31 
Age -0.19 011 -0.11 -1.66 0.10 -0.41 0.04 
Gender -3.76 2.89 -0.07 -1.30 0.19 -9.44 1.93 
CPR 2.10 .65 0.15 3.23 0.00 0.82 3.39 
MetS -7.78 4.62 -0.14 -1.69 0.09 -16.87 1.31 
REGICOR -2.72 3.45 -0.04 -.79 0.43 -9.51 4.06 
Hypertriglicerida
emia 
15.73 3.31 0.26 4.75 0.00 9.21 22.25 
HBP 10.85 3.05 0.20 3.56 0.00 4.84 16.86 
Low HDLc 5.74 3.10 0.11 1.85 0.07 -0.36 11.83 
Hyperglycaemia 8.59 3.33 0.16 2.58 0.01 2.03 15.14 
Waist 12.10 3.30 0.22 3.65 0.00 5.57 18.63 
HOMA 2.06 0.90 0.13 2.29 0.02 0.29 3.83 
Hypercholesterol
emia 
6.21 2.53 0.12 2.46 0.02 1.23 11.18 
Hyperhomocyste
inemia 
-0.59 0.40 -0.08 -1.50 0.14 -1.37 0.19 
Lipoprotein(a) -0.02 0.04 -0.03 -0.53 0.59 -0.10 0.06 
Smoking -4.56 10.95 -0.08 -0.48 0.68 -26.10 16.99 
Smoking-age -0.07 0.21 -0.06 -0.34 0.73 -0.49 0.35 
Table 5.41: initial analysis of the maximum model variables. The less significant 
variables and first to be removed were smoking (p=0.677) and smoking adjusted to age 
(smoking-age, p=0.733) 
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The remaining variables after regression analysis were considered predictors of C3 
complement concentrations. The regression analysis finished when all the variables 
included in the maximum model reached statistical significance (p≤0.05), excluding age 
and gender as fixed variables (table 5.42).  
 
Predictive factors of C3 complement concentrations by co-linearity diagnosis 







95.0% CI Interval for B 
B Std. Error Beta Lower B. Upper B. 
Age -0.19 0.1 -0.11 -1.94 0.05 -0.39 0.00 
Gender -1.95 2.62 -0.04 -0.74 0.46 -7.12 3.20 
CRP 2.06 0.66 0.15 3.12 0.00 0.76 3.36 
HTG 14.34 3.01 0.24 4.76 0.00 8.41 20.27 
HTA 8.70 2.81 0.16 3.10 0.00 3.18 14.22 
Hyperglycaemia 6.35 3.02 0.12 2.10 0.04 0.41 12.29 
Waist 9.14 2.86 0.16 3.20 0.00 3.51 14.76 
HOMA 2.39 0.90 0.15 2.67 0.01 0.63 4.15 
High LDLc 4.90 2.49 0.09 1.97 0.05 0.01 9.79 
  
Table 5.42: Final results of the multivariate linear correlation model. Inflammation 
(CRP), MetS criteria (HTG, HBP, FG and waist) and IR (HOMA) were the predictor 
variables of the 32% variance of the C3 complement. 
 
Some confounding factors, such as hyperglycaemia, and HOMA, were predictive of the 
C3 levels. However, the most significant covariates for C3 were hypertriglyceridemia 
(p<0.001), waist, hypertension, and CRP (p=0.002) in our multivariate linear model.  
 
The predictive value of hypercholesterolemia in the C3 model turned out to be 
borderline significance (p=0.050). Age (p=0.52) and gender (p=0.456) remained not 
statistically significant to predict C3 values in the final outcome measure model. 
Together, those variables could explain more than 32% of the variance of C3 levels 
(R2=0.316).  
 
Patients with vascular inflammation (higher CRP levels), insulin resistance (higher 
HOMA results) and/or fulfilling MetS criteria, such as central obesity (waist), HBP or 
hypertriglyceridemia will have higher C3 complement levels with equal age and gender. 
 
 






























In this observational cross-sectional study, representative of population from Madrid 
referred to secondary cardiometabolic care, the majority of our population was 
metabolically unhealthy, as expected for a cardiometabolic unit, where 49.7% suffered 
from incomplete MetS and 35% from MetS, while the prevalence of the MetS in Spain 
for adults was 31% according to DARIOS study [218]. Furthermore, hypertension 
(65%) and hyperglycaemia (42%) resulted as the most prevalent pathologies when we 
analysed individually the constitutive factors of MetS. This finding was contrary to 
expectations in literature where central obesity plays the main role [219]. 
 
Our study demonstrated that circulating C3 strongly predicts the cluster of MetS (Adult 
Treatment Panel III–defined) independently of the MetS components. In previous 
research in South Asians but not in Caucasians, C3 levels were found to be 
independently associated with MetS [220]. In preceding studies that did not fully adjust 
for the MetS components, C3 was found to be a predictor of complete MetS [68, 221, 
222]. 
 
The presence of each MetS criteria was strongly associated to higher concentrations of 
C3 complement individually in our population. So, the degree of obesity, high levels of 
triglycerides, low HDL, hypertensive and hyperglycaemic status, were foreseen by C3 
level variations.  These findings were not previously known and we considered them 
particularly relevant. Thus, these new insights indicate that complement cascade 
activation would be within the first physiologic alterations leading to MetS 
independently of its aetiology as pre-diabetic and cardiovascular condition.  
 
Besides this, the C3 complement values increased proportionally to the number of 
MetS criteria. This is the first documented study in which C3 complement predicted the 
number of MetS criteria. Even more reassuringly, the association between C3 levels 
and ATP-III criteria was almost linear. Adding extra evidence, the percentage of 
patients positive for all the factors increased in parallel to increment of the quartiles and 
there were no patients presenting five MetS constitutive criteria in the first C3 quartile 
and most of the MetS factors-free or metabolically healthy patients were situated in the 
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first C3 complement quartiles. Thus, C3 concentrations would be able to be considered 
a predictor of MetS and stratification by number of MetS criteria. 
 
Even more interesting, there was a change in the slope inclination between two and 
three criteria met.  Levels of C3 complement, although higher for three criteria, were 
similar. This fact made us consider the possible arbitrary threshold of three criteria for 
MetS diagnosis, not sustained in clinical evidence.  This fact has already been 
described by Lemieux in relation to the hypertriglyceridaemic waist [223]. However this 
slope has not been described for other combination of MetS components and it should 
call expert‟s attention for further MetS actualisations. Moreover, the graph correlating 
C3 complement means and cardiovascular risk also changed the inclination of the 
slope between moderate and high risk, as explained later in the text. If we can simplify 
MetS diagnosis, through equal risk, we will be able to benefit a larger number of 
patients with preventive strategies.  
 
The association between obesity, general obesity and central obesity with C3 values 
was confirmed in this study by four ways: firstly quantitatively, correlating values of BMI 
and waist size with C3 high concentrations; secondly qualitatively, associating 
diagnosis of overweight and obesity by BMI thresholds and central obesity by WHO 
cut-off points for Caucasians with high levels of C3 complement; thirdly, there was 
statistical correlation between BMI and central obesity with C3 complement quartiles; 
fourthly, waist as one of the variables remaining as predictor of C3 values variability by 
multivariate analysis as will be shown below. The central role of C3 in obesity-induce 
inflammation has been described in the literature according to general obesity [224, 
225] but not stratified by central obesity and C3 quartiles. 
 
Carrying on with the firm association between C3 levels and MetS, hyperglycaemic 
diagnosis showed a significant correlation with high C3 concentrations. To confirm this 
fact we also tested the relationship between C3 measurements and glycated 
haemoglobin (A1c) determinations in our population. Both variables reinforced a 
positive linear correlation. This positive association was emphasised when C3 
complement quartiles were crossed with the diagnosis of hyperglycaemia MetS 
criterion that showed a linear distribution.   
 
Low HDLc MetS criterion was also associated with C3 complement levels and this 
distribution was even more significant when C3 complement quartiles were crossed. As 
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expected due to its inverse correlation to cardiovascular risk broadly accepted, HDLc 
were also negatively correlated to C3 concentrations. With this correlation we 
confirmed the negative association between HDLc, cardiovascular protector, and C3 
complement levels already described in the literature [222, 226]. 
 
The readings of diastolic and systolic blood pressure also counterpartyed C3 
concentrations in plasma as seen previously in the literature [227]. Besides this, the 
diagnosis of hypertension as a qualitative variable demonstrated parallel correlation 
with the C3 quartiles, with high C3 complement concentrations being a predictor of 
hypertension in our study. When C3 complement quartiles were crossed the correlation 
was stronger with hypertension MetS criterion than with single hypertension readings, 
but both were statistically significant. We preferred the qualitative than the quantitative 
hypertension variable because the blood pressure values could be distorted in treated 
patients and removing treatments is considered an ethical limitation in our study. 
 
 Qualitatively, hypertriglyceridemia diagnosis represented the most robust interrelation 
with C3 values in our study. Moreover, both diagnosis of hypertriglyceridemia, 
triglycerides plasma levels and hypertriglyceridemia MetS criterion, showed an 
increasing parallel correlation when C3 complement quartiles were crossed. Ultimately, 
hypertriglyceridemia was the most influential factor determining C3 complement values 
according to multivariate analysis as explained below. Along these lines, C3 
complement would be a predictor of hypertriglyceridemia [228, 229].  
 
Following the thread, we mention the two often forgotten important companions of the 
MetS. Firstly hyperuricemia [19], which has been a long term accompanist of obesity 
and secondly hyperglycaemia. Hyperuricemia has been found to predict the 
development of both obesity and T2DM [230]. Furthermore, it has been described 
hyperuricemia association with MetS in multiple papers [231, 232], but the association 
between C3 complement and uric acid has not been further investigated. The results of 
this study showed an intense association between both variables, linear distribution by 
numbers, strong association with hyperuricemia diagnosis and reinforcing proportional 
distributions along quartiles, an association not previously demonstrated in the 
literature.  
On the other hand, raised levels of ferritin have been found relevant to central obesity 
and metabolically obese normal weight individuals, hypertension, dyslipidaemia and 
MetS in several studies of Western populations [233].  In our study, high values of 
UAH, PhD program: D234 Medicine  Rodriguez-Guerrero, A. 
152 
 
ferritin were strongly associated with high values of C3 complement. Meanwhile the 
correlation of hyperferritinemia diagnosis and C3 complement was not significant 
because of the inference effect of phlebotomies in our population.  
 
One of the key features of our study was represented by the fact that levels of 
complement C3 were independent of non-modifiable factors, such as age and gender 
when we correlated quantitatively and by C3 quartiles. Therefore, none of the previous 
findings analysed above in this discussion can be attributed to these factors. This 
correlation was checked with C3 concentrations and with the population distributed per 
quartile. However, a slight influence between age factor and C3 levels showed as a 
tendency but not significant association in the scatter diagram between the values of 
both variables. This impact of age in the C3 concentrations behaviour was definitely 
discarded in the multivariate analysis mentioned below.  
 
Finally within the MetS entity, the association with Insulin Resistance (IR) was proven 
with a strong positive correlation of C3 plasma levels and C3 quartiles with HOMA 
values, influencing all of the above unlike age and gender [144, 224, 234]. This strong 
link between HOMA and C3 convertase activity independent of non-modifiable factors 
has been fully supported by statistical evidence in our study by association between 
HOMA and C3 concentrations, C3 quartiles, diagnosis of insulin resistance and as 
bidirectional predictive factor of C3 concentrations with multiple regression analysis at 
the end of our statistical analysis, this original finding was not found in the literature 
 
Cardiovascular risk factors not included among the MetS components and their 
association with C3 will be considered below prior to analysing the cardiovascular risk, 
named LDLc, smoking habit, Lp(a) and Hcy. 
 
In our study, LDLc levels were also strongly correlated with C3 complement levels, a 
finding not demonstrated for the general population in the literature [8], which has been 
only previously demonstrated in familiar hypercholesterolemia [9, 10].  As with the 
obesity-LDLc relationship [235],  the possible correlation of LDLc with C3 via VLDLc, 
which belongs to MetS as a broadly accepted component [236], and 
hypertriglyceridemia,  is not excluded. Only small dense LDLc, instead of total LDLc, 
are considered as part of the MetS and were not measured in this study which also 
comprised treated patients [237, 238].  




With respect to smoking habit and C3, the inverse association represented an 
unexpected finding, as also happened previously in the literature in the negative 
association between tobacco and Alzheimer‟s and other examples [239, 240], but can 
be explained because  the smokers group was significantly younger than that of non-
smokers and ex-smokers. We proved in this study that in our population tobacco 
consumption was influenced by age. When adjusted to age, smoking habit did not 
show a correlation with C3 complement.  Despite this, we can not obviate that tobacco 
consumption can activate the complement alternative pathway in vitro by modifying the 
third component of complement [241]. 
 
As a mention of the cardiovascular risk factors not associated to MetS but emerging 
factors, lipoprotein(a) and homocystein have been related to cardiovascular pathology 
[193, 242]. None of them showed association with C3 concentrations in our study 
population. Therefore our study confirmed in humans the correlation findings previously 
found in rabbits, where crossed inmuno-electrophoresis analysis indicated that Lp(a) 
apo(a) portion retarded the migration of C3b in complement activated serum, but had 
no effects on complement C3 activation[243, 244]. 
 
  
With the above results at hand, regarding the correlation of C3 with MetS and LDLc, a 
statistically significant correspondence between C3 concentrations and cardiovascular 
risk levels calculated by REGICOR formula did not surprise us, with the C3 levels being 
higher for high cardiovascular risk patients than for low risk subjects.  Moreover, 
reinforcing this close association, a robust interrelationship was found between C3 
concentrations and cardiovascular risk scales, C3 levels and REGICOR treated as a 
numerical variable and C3 complement quartiles and REGICOR values. 
 
The relationship between cardiovascular risk measure by Framingham score was 
previously described in the literature [245-247] and C3 was established as a 
cardiovascular risk associate in both cross-sectional and in longitudinal studies in the 
CODAM study [248],  but there are no previous publications correlating C3 complement 
levels with REGICOR, just suggested in a medical conference abstract written by 
ourselves [249]. With this research we confirm our previous suspicion and the 
hypothesis of this paper associating C3 levels with REGICOR CV score.  
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The Framingham risk and REGICOR cardiovascular risk scores predict development 
only of cardiovascular disease whereas the presence of the MetS, which has been also 
correlated to C3 complement, predicts both diabetes and cardiovascular disease. 
Subsequently, C3 convertase can become a cardiometabolic biomarker of both 
pathologies. 
 
A step further, C3 convertase was also associated with the more complex idea of 
cardiometabolic syndrome (CMS), an amplified version of MetS, as explained in the 
knowledge review chapter. Thus, active components like inflammation (CRP, 
fibrinogen) and metaflammation (adipokines), oxidative stress and endothelial 
dysfunction are included in the complex CMS equation.  
 
Inflammation in the cardiometabolic syndrome (CMS), where its low-grade 
inflammation is led by the CRP and followed by Lysosomal phospholipase A2 (LPLA2) 
[250], amyloid protein a (SAA: serum amiloide A) [251] and fibrinogen [252] 
participated, is continued by metaflammation (in Greek: μετά, along with), that should 
also be added to this process. This metabolic triggered inflammation has been 
described as a process of neighbourhood (highly vascularised abdominal fat) and a 
process of distance (intestinal dysbacteriosis, periodontal disease) [253]. 
Metaflammation would amplify the basic inflammation which characterises the 
atherothrombotic disease [254]. 
 
As a first finding, we showed a close relationship between C3 and C-reactive protein 
levels in our population sample. The cardiovascular chronic inflammatory status was 
established according to the threshold of CRP resulting from the JUPITER study [255, 
256]. Both, inflammatory status diagnosis and CRP numerical values were heavily 
correlated to C3 complement levels. Moreover, CRPhs increased its values in parallel 
with the C3 complement levels according to the behaviour of its means along the C3 
complement quartiles. Thus, high sensitivity CRP showed a firm correlation to the C3 
complement levels divided in segments and C3 convertase activity became a solid 
predictor of inflammatory status in our population. This strong association confirms the 
central role of C3 convertase in the inflammation process as seen in the literature [257, 
258].  
 
The intense relationship between fibrinogen, the other evaluated inflammatory marker, 
and C3 complement levels and quartiles has been demonstrated in our population. 
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Fibrinogen has proaggregant properties besides its role as an inflammatory marker, 
thence, C3 convertase activity may represent a barometer of the pro-coagulant state 
degree in our population plasma, not previously found in the literature. 
 
A step further, we looked for the links of C3 with metaflammation related to highly 
vascularised abdominal fat tissue actively participating in the low-grade inflammation 
involving the vascular endothelium [94, 259].  Consequently, adipose tissue is now 
considered a dynamic endocrine organ that releases adipokines. Multiple adipokines 
are involved in this complex process [89, 253, 260-263], from all of them we measured 
two pairs, pro-inflammatory adopokines (TNF-α and IL-6) and anti-inflammatory 
adipokines (adiponectin and IL-10). In our study it was mandatory to further examine 
the possible interrelation between both activities, pro and anti-inflammatory, and C3 
levels. As an expected result of its recognised protective role, adiponectin was clearly 
inversely correlated with C3 complement concentrations in our population by direct 
correlation and distributed into quartiles. Adiponectin is considered a protective 
cytokine produced in healthy adipose tissue and its levels decline in inflammation and 
oxidative stress. There are a scarce number of publications correlating C3 convertase 
with adiponectin in population subgroups [235, 264, 265]. Together, these results may 
partly contribute to explain the role of adiponectin linking obesity with atherosclerosis, 
as a dependent dose-response of this hormone and C3 complement concentration. 
Likewise, IL-10 concentrations, another protective adipokine,  resulted borderline 
inversely correlated to C3 plasmatic levels. Although this marginal correlation could not 
be confirmed by quartiles distribution, it represents a new input in the cardiometabolic 
literature where the correlation between IL-10 and C3 levels only has been confirmed 
in vitro studies in acute inflammation [266-268] 
 
On the opposite side, IL-6 y la TNF-alpha behaved in the expected direction. Both 
cytokines values grew in parallel with C3 values, contrarily to the protective adipokines 
previously observed, although only IL-6 reached statistical signification. Thus, IL-6 pro-
inflammatory marker levels were correlated positively with C3 convertase values in our 
study. Recently, it was demonstrated that complement C3 (C3) synthesis can be up-
regulated by pro-inflammatory cytokines, such as IL-6, but the authors were not able to 
relate C3 levels with IL-6 [245]. IL-6/C3 association was demonstrated in burned 
patients with classical acute inflammation, correlating both variables levels with the 
severity of injury and development of infection [269]. In the same manner, these 
parameters could be used in metaflammation to measure the severity of vascular injury 
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and prediction of CV risk. Unfortunately, tumoral necrosis factor (TNF-α) levels were 
only quantified in a small random subgroup of 90 subjects following the same direction 
although the scarce number of results did not demonstrate a correlation with C3 
values. Platel and al. suggested in vitro the possible action of TNF-α as u-regulator of 
C3 production in a dose-dependent manner but it has been not confirmed in vivo [270]. 
 
On the grounds of the aforementioned low-grade inflammation, our results showed that 
C3 complement circulatory concentration levels were a useful inflammatory and 
metaflammatory measurer. This finding alone would deserve further studies, in vivo 
and in vitro, specifically designed to clarify if there is also a physiologic interaction on 
top of its biomarker action. This physiologic interaction should be understood as active 
participation and interaction in the low-grade inflammation which characterises the 
atherothrombotic vascular disease from early stages.   
 
Inflammation and metaflammation form along with endothelial dysfunction and 
oxidative stress a pathogenic triad of great vascular impact [94]. After the analysis of 
the results obtained with pro and anti-inflammatory adipokines and with CRP, we 
continued evaluating the C3 interaction with biomarkers of endothelial dysfunction and 
oxidative stress. 
 
Within the endothelial markers, we have chosen the most liable ones, which are 
represented by VCAM, tPA and PAI-1. VCAM-1 ligand is expressed in endothelial cells 
after cytokines stimulation and plays an important role in the recruitment of 
mononuclear leukocytes to inflammatory sites in vivo [271]. Endothelial dysfunction 
leads to rapid induction of VCAM-1 expression and increased monocyte adhesion. The 
significant association between both variables in our research, VCAM-1 and C3, 
reaffirms our initial hypothesis of C3 convertase as a marker of endothelial damage. 
Even more interesting, C3a activates the phosphorylation of protein kinases (MAPK) 
and induces the up-regulation of vascular cell adhesion molecule 1 (VCAM-1) and 
intercellular cell adhesion molecule 1 (ICAM-1) [272]. Therefore, as a destructive 
endothelial cascade C3 convertase up-regulates VCAM-1, which promotes cellular 
adhesion, endothelial and vascular damage. In contempt of this logical thinking, the 
correlation of these two proteins with endothelial damage is in short supply in the 
literature. This finding about the VCAM-1 is considered of enormous interest by us 
because of contrary findings in the literature about its relationship with the C3 as 
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endothelial dysfunction marker and also causative entity, with potential to amplify all 
the CMS cascade. 
 
In our study, despite of the small number of subjects tested the correlation between 
plasminogen activator inhibitor-1 (PAI-1), not only as an adipokine but as an excellent 
endothelial marker [19], and C3 complement was strongly significant. Raised PAI-1 is 
responsible for hypofibrinolysis in specific diseases, and it has been specifically 
described in MetS and diabetes [273]. This down-regulation of fibrinolysis and pro-
aggregating factors, such as raised Von Willebrand factor (fvW) in endothelial 
dysfunction, leads to a prothrombotic state responsible of a high percentage of 
cardiovascular events. Even more interesting, today we know that PAI-1 also promotes 
formation of endothelial microparticles and reduces transmembrane asymmetry of 
phospholipids increasing in vitro thrombin generation [274]. 
 
As the PAI-1, tPA levels were also strongly correlated with C3 complement values. tPA 
is a serine protease secreted by the endothelial cell and considered the quintessential 
fibrinolytic factor,  which binds to fibrin and converts the inactive plasminogen into 
plasmin, widely considered standard of care in acute ischemic stroke [275]. Recently it 
has been demonstrated that tPA activates the classic complement pathway from C3 to 
terminal components [144]. Moreover, tPA is produced and released from endothelial 
cells and is responsible for the removal of intravascular fibrin deposits coordinated with 
the complement cascade [276]. tPA and PAI-1 activate the complement cascade but 
only the tPA activates the kinin system in plasma [268].  
 
C3 can represent a marker of both factors, tPA and PAI-1, and the final balance 
between both of them will decide the resulting status whether anti-thrombotic or pro-
thrombotic in relation to haemostasis. Because of the dual association of C3 with both 
of them, C3 would assume a neutral role.  
 
Entering more into detail of the analysed markers, the association between tPA and 
VCAM- 1 with C3 quartiles showed a significant association, meanwhile C3 quartiles 
and PAI-1values showed a borderline positive correlation. 
 
As the third axis of the vascular triad, inflammation, endothelial dysfunction and 
oxidative stress, oxidative stress joined the party, although in our study it appeared as 
borderline signification. So, oxidative stress is a key feature in atherogenesis, involved 
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in the whole process from endothelial dysfunction to atheromatic plaque formation and 
rupture. In this direction, disturbances in the normal redox state of cells can cause toxic 
effects through the production of peroxides and free radicals that damage all 
components of the endothelial cell and represent the earliest stage of the endothelial 
dysfunction [277, 278]. As a byproduct of lipid peroxidation, TBARS (Thiobarbituric acid 
reactive substance) has been considered a marker of oxidative stress and the TBARS 
assay has been applied in clinical studies linking oxidative stress response with 
cardiovascular risk. Although TBARS levels showed marginal association with C3 
complement values, the small sample analysed indicated that we pointed in the right 
direction [279]. There is no available literature correlating both variables and further 
studies should be designed to establish the specific role of C3 in oxidative stress as 
predictor, marker or participant factor. 
 
Total antioxidant capacity in human plasma (TAC) is a useful technique to evaluate 
individual responses to antioxidant treatment, but with low liability within a population 
context [280, 281], as occurred in our study that then explained our no statistically 
significant result.  
 
As a final statistical test in this research, in order to distinguish between the relations of 
C3 complement (dependant variable) with others independent variables, we used the 
multivariable analysis technique. This tool evaluated the strength of associations 
between age, gender, various components of the MetS, inflammation, insulin 
resistance, cardiovascular risk and C3 complement.  With the final multivariate analysis 
we initially explained the 35% of the variability of the C3 complement dependant 
variable in our sample population. With this statistical tool we simultaneously analysed 
multiple independent variables, those previously found significantly associated with C3 
and measured in all the non-exogenous insulin dependent subjects in the study, with 
our dependent variable, C3 complement quartiles, using matrix correlational algebra. 
Although C3 complement was previously defined in our study independent from the 
non-modifiable factors age and gender, they both remained in our multivariable model 
of regression analysis on purpose to dismiss any possible cofounding in the 
association assessment with other modifiable variables in this study [218].  
 
The resulted cluster of most influential variables in their multivariable interrelationship 
with C3 complement was hypertriglyceridemia in first place followed by hypertension, 
CRP, waist, insulin resistance (HOMA) and hyperglycaemia in descending order 
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according to signification, independently of age and gender. The factor analysis yielded 
this cluster of six variables that alone accounted for almost 34% of the total C3 
complement variance. Thus, HOMA can have an influence but does not explain all the 
findings related to MetS, CMS and C3. 
 
Our study provided to triglycerides the leading role as factor with the biggest impact 
over C3 levels and deserves an additional comment. The role of triglycerides in 
cardiometabolic pathology grew in the last two decades since the overexpression 
receptors for VLDL (VLDLr) by unhealthy endothelium is known [19]. These receptors 
are present in small amounts in the healthy endothelium to play a key role in three 
actions: a) LPL stimulation, an enzyme of endothelial origin that is essential in the 
metabolism of triglycerides [282]. b) PAI-1 expression, as endothelial synthesis 
product, that in physiological amounts plays a determining role in haemostatic control 
but which excess leads to hypofibrinolytic status [283].  c) VLDLr, besides its action 
recognising VLDL, is intrinsically a potent endogenous inhibitor that negatively 
regulates the angiogenic properties of RVECs (retinal vascular endothelial cells). 
Therefore, the VLDLR activates RVECs and significantly enhances angiogenesis in 
vivo and in vitro [284]. Its three beneficial actions at endothelium are achieved with low 
degrees of expression. Ideally, the organism, in the presence of hypertriglyceridemia, 
would be able to overexpress VLDLr at the liver level to improve the plasma clearance 
of VLDL. Thus, VLDLr overexpression would indirectly reduce the rate of plasma LDLc 
(formed in the bloodstream itself from VLDL by the CEPT, cholesterol ester transfer 
protein) [285]. Unfortunately, this overexpression at hepatic level is only possible 
through genetic therapies [286]. Contrarily, the overexpression of VLDLr in MetS and 
diabetes occurs at vascular level and participates in endothelial dysfunction as Saban-
Ruiz et al. described. From all the above in respect to VLDLr, there is an association 
described in the literature between overexpressed VLDLr in presence on high 
triglycerides and PAI levels, because of the main role of hypretrygliceridemina in our 
study this relationship acquires a bigger dimension.  
 
As a final comment related to hypertriglyceridaemia, I would like to stress the 
importance of its association with C3 complement that should be a factor taken into 
account for treatment purposes. Hypertryglyceridaemia has recently been forgotten in 
clinical practice guidelines and in daily practice by doctors in general. These results 
made us recommended to measure C3 plasma concentrations in Hypertriglyceridemic 
patients. Doing so we would be aware of the importance of the high levels of 
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triglycerides effects and treat in consequence. The treatment of hypertriglyceridemia 
seems more justified when taking into account its relation with VLDLr and PAI-1 as 
described above. 
 
Summarising our research, C convertase value goes beyond its role as cardiovascular 
risk predictor and our most interesting results described C3 complement as predictor of 
classical MetS, insulin resistance and newer Cardiometabolic Syndrome (CMS) with 
insulin resistance swinging between both syndromes.  
 
In relation to MetS the robust relation with each of the criteria and the proportional 
relation to the number of criteria called our attention and made us to consider the 
presence two MetS criteria enough to initiate preventive treatment strategies. In this 
direction, based on these findings, subgroups of incomplete MetS patients with higher 
C3 complement values may be identified that are at a disproportionally high risk of 
developing insulin resistance and cardiovascular disease, with possibly therapeutic 
consequences. Therefore, C3 convertase down-regulation may become the target for 
new biological treatments to reduce cardiovascular events directly and indirectly, but 
this final question will be answered in future specific studies designed to target C3 
convertase activity.  According to Cardiomentabolic Syndrome, C3 has demonstrated 
its role as witness of the vascular triad which comprises inflammation, endothelial 
dysfunction and possibly oxidative stress, and its role as a somehow active factor 
interacting with all of them. Future studies will provide us with the degree and 
importance of our findings. 
  
Finally, The C3 complement seems to go beyond CRP in several aspects, moreover in 
relation to MetS/CMS. None of the multiple studies performed in relation to CPR 
obtained as many relevant findings as our study. Besides this, C3 seems to have 
higher specificity than CRP, which is raised in multiple situations where C3 
complement is not.  We suggest determining both variables in Cardiometabolic Units 
until specifically designed studies compare specificity and cost-effectiveness between 
both variables.  
 
While awaiting definitive results, the simultaneous evaluation of C3 and CRP would 
provide the intrinsic value of CRP more liability and both variables, jointly analysed, 
would result in a high predictive tool as contemporary precise Cardiometabolic 





























1. The studied population was characterised by high prevalence of Metabolic 
Syndrome (MetS). Besides this, hypertension and hyperglycaemia were the most 
prevalent MetS criteria contrary to expectations in the literature, where central obesity 
plays the main role. These findings matched the characteristics of a population referred 
to a Cardiometabolic Risk Unit.  
2. The MetS was strongly correlated to high concentrations of C3 complement, 
meanwhile low C3 levels were associated with metabolically healthy patients free of 
MetS criteria. Furthermore, C3 complement levels in plasma increased proportionally to 
the number of diagnosed MetS criteria per subject, a finding not previously known. 
There was also a change in the slope inclination between two and three criteria, so 
levels of three criteria were similar for two and three criteria.  This fact made us to 
consider the possible arbitrary threshold of three criteria for MetS diagnosis. Besides 
this, the graph representing the relation between C3 complement and cardiovascular 
risk also changed the inclination of the slope between moderate and high risk. Both 
findings could be correlated and MetS diagnosis could be simplified to two criteria 
through equal risk. 
3. The presence of each single MetS criterion was also strongly associated with C3 
complement values and quartiles, named hypertriglyceridemia, central obesity, 
hyperglycaemia (measured by A1c), hypertension and Low-HDLc criteria individually. 
The strongest association between C3 values and MetS criteria was displayed by 
triglycerides. High levels of C3 complement were significantly correlated with high 
levels of triglycerides, hypertriglyceridemia diagnosed by cut-off point, 
hypertriglyceridemia MetS criterion and linear association between hypertriglyceridemia 
and C3 quartiles. Our study provides to hyperthiglyceridemia great impact on the 
association C3/MetS. 
4. Besides the aforementioned Metabolic Syndrome classical components, C3 
complement levels were also associated with uric acid and ferritin usually forgotten in 
the literature. 
5. Age and gender were not associated with C3 in our sample population and none of 
the previous findings in this paper can be explained by them. Any impact of age in the 
C3 concentrations behaviour was definitely discarded in the multivariate analysis. 
6. Strong positive correlation between C3 plasma levels and C3 quartiles with HOMA 
values was proven. Insulin resistance can influence but not explain all the previous 
findings. 
7. Even the LDLc (not a MetS criterion) was also correlated with C3 levels. As with the 
obesity-LDLc relationship, the possible correlation of LDLc with C3 via VLDLc is not 
excluded. 
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8. The correlation between high C3 concentrations and high cardiovascular risk 
diagnosed by REGICOR formula was statistically demonstrated between both 
variables, between numerical variables and quartiles. Therefore, C3 represented a 
cardiovascular biomarker for our population. 
 
9. Our interest went beyond C3 complement as a cardiovascular biomarker to the 
amplified version of MetS, named Cardiometabolic Syndrome (CMS). CMS sums up to 
the classic MetS criteria these three axis: inflammation and metaflammation, 
endothelial dysfunction and oxidative stress. We obtained a positive result of C3 
correlation with each one of the three interconnected axes:  
 CRP and fibrinogen values, representatives of acute inflammation, increased in 
parallel with C3 complement levels. With regard to metaflammation, the 
adipokines, behaved as expected in respect to the C3 complement: positively 
associated IL-6 and TNF-α and inversely associated IL-10 and adiponectine. 
 From the endothelial point of view, VCAM showed significant association with 
C3, a finding of important interest due to contrary results in the literature about 
the C3-VCAM association. Therefore, in our study C3 acts as endothelial 
dysfunction marker and causal agent, with potential to amplify the entire CMS 
lesional cascade. Two additional endothelial markers, tPA and PAI-1, were 
correlated in the limit of the statistical signification with C3 concentrations. On 
the other hand, a relation between overexpressed VLDLr in the CMS and the 
PAI levels has been described in the literature, but in our study reached a 
higher dimension because of the main role of hypertriglyceridemia.  
 With respect to oxidative stress, a marginal association between TBARS and 
C3 was shown. The small sample analysed showed us that we are on the right 
track. 
10. In this order, hypertriglyceridemia, CRP, HTA, waist, HOMA and hyperglycaemia 
resulted predictors of the 34% of C3 complement variability by multivariate analysis. 
HOMA, with less significance than the four cited elements, reached the end of the 
multivariate analysis to stay as an influential factor.  
11. C3 seems to go beyond CRP because none of the multiples studies performed with 
CRP in relation to MetS/CMS obtained as many relevant findings as shown in this 
study. Specifically designed studies should compare C3 and CRP cost-
effectiveness/specificity in the future. Meanwhile, we suggest the simultaneous 
evaluation of CRP and C3 determination in plasma to increase the intrinsic value 
liability of CRP as required in Cardiometabolic Medicine.  This new medicine is 
predictive, personalised and anticipative, being an integral part of the Precision 
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Resumen en Español  
 
Introducción: La enfermedad aterotrombótica es la primera causa de muerte en el 
mundo occidental y su principal causa no es la hipercolesterolemia sino el Síndrome 
Metabólico. Éste ha pasado en las tres últimas décadas de ser un quinteto 
(hiperglucemia, hipertensión, hipertrigliceridemia, HDL bajo, aumento de la cintura)  a 
ser un octeto (Síndrome Cardiometabólico) donde la triada formada por la 
inflamación/metainflamación, estrés oxidativo y disfunción endotelial es esencial para 
comprender su impacto a nivel vascular. La resistencia a la insulina está en el eje de 
ambos síndromes. Desde el punto de vista inflamatorio el marcador más utilizado  ha 
sido la PCR con el inconveniente de ser altamente inespecífico y se ha puesto en 
marcha desde hace años una búsqueda de nuevos marcadores. El presente trabajo 
confirma que la C3 convertasa en sangre puede ser útil como marcador y 
posiblemente como factor patogénico, lo que, de confirmarse  lo postularía como diana 
de futuras estrategias preventivas. 
 
Objetivos: Este estudio está dirigido a analizar el comportamiento de la C3 
convertasa, enzima clave y central de la cascada de complemento, en relación con el 
riesgo cardiovascular incluyendo la disfunción endotelial, resistencia a la insulina y 
riesgo cardiovascular en pacientes derivados a medicina cardiovascular especializada.  
 
Metodologia: Fue realizado un estudio retrospectivo transversal sobre una muestra 
aleatoria de población adulta de Madrid derivada a medicina cardiometabólica 
especializada para prevención primaria de riesgo cardiovascular. La analítica 
convencional fue realizada en el laboratorio central del hospital mientras que los 
factores específicos cardiometabólicos fueron medidos en el laboratorio de la Unidad 
de Medicina Cardiometabólica y Daño Endotelial como parte de su rutina clínica. El 
riesgo cardiovascular fue calculado por la fórmula de REGICOR para población 
española. La resistencia a la  insulina fue estimada según la fórmula de HOMA en un 
grupo de pacientes no dependientes de insulina exógena. La población a estudio fue 
estratificada en cuartiles de complemento C3 y se analizó la distribución de las 
variables cardiometabólicas entre los cuartiles. El análisis de regresión multivariable 
fue utilizado para identificar predictores de la variabilidad de las concentraciones  de  
complemento C3. 
 
Resultados: Fueron seleccionados un total de n=374 sujetos (53.60±14.80 años, 
44.9% mujeres), donde el 65% fueron hipertensos, 42% hiperglucémicos y 35% 
padecían Síndrome Metabólico. Los niveles de complemento C3 fueron asociados 
con: 1. Síndrome Metabólico: diagnóstico de Síndrome Metabólico, cada uno de sus 
criterios, proporcional al número de sus criterios por paciente y con los nuevos criterios 
de síndrome metabolico (p<0.001), 2. Síndrome Cardiometabólico: inflamación (CPR y 
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fibrinógeno, p<0.001) y metainflamación (adiponectina e IL-6, p≤0.001), disfunción 
endotelial (TPA, PAI-1, p≤0.050) y el estrés oxidativo mostro tendencia (TBARS, 
p=0.084). 3. Resistencia a la insulina: el HOMA (p<0.001). 4. Factores de riesgo 
cardiovascular clásicos y con el riesgo cardiovascular calculado por REGICOR 
(p<0.001).Todas estas correlaciones fueron independientes de sexo y edad. La 
mayoría de las variables anteriores también mostraron asociación con los cuartiles de 
complemento C3. Hipertrigliceridemia ostentó el mayor impacto sobre el 
comportamiento de las concentraciones de complemento C3 según los resultados del 
análisis multivariable (p<0.001). 
 
Conclusiones: En relación con el quinteto de criterios del Síndrome Metabólico, el 
complemento C3 resultó ser predictor del diagnóstico de Síndrome Metabólico, de 
cada uno de sus criterios por separado y fue proporcional al número de criterios 
diagnosticados por paciente, describiendo un posible umbral arbitrario entre dos y tres 
criterios y sugiriendo una más temprana intervención para la prevención 
cardiovascular ante una posible igualdad de riesgo.  En relación con el octeto de 
Síndrome Cardiometabólico, el complemento C3 tambien se mostró predictor de 
inflamación, metainflamación, daño endotelial y mostró tendencia con estrés oxidativo. 
En el siguiente orden: hipertrigliceridemia, PCR, HTA, cintura, HOMA e hiperglucemia 
resultaron predictores del 34% de la variabilidad de las concentraciones de 
complemento. La asociación significativa de C3 con HOMA puede influir en los 
resultados anteriores, pero difícilmente explicaría todas las correlaciones encontradas 
en este trabajo. Este estudio sugirió que la evaluación simultanea de C3 y PCR podría 
aumentar la validez intrínseca de la PCR, como es requerido en Medicina 
Cardiometabólica precisa. 
 
Palabras clave: C3 convertasa, complemento C3, aterotrombosis, aterosclerosis, 
Síndrome Metabólico, Síndrome Cardiometabólico, resistencia a la insulina, riesgo 
cardiovascular, PCR, disfunción endotelial, inflamación, metainflamación, estrés 
oxidativo, REGICOR, HOMA, análisis multivariable. 
 
Áreas de Clasificación de la UNESCO  
 Áreas Clasificación de la UNESCO UNESCO International Nomenclature 
3207.04 Patología Cardiovascular Cardio-vascular pathology 
3207.02 Aterosclerosis Atherosclerosis 
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